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SUMÁRIO  
 
Xenobióticos são compostos estranhos aos organismos e de difícil degradação no ambiente. Entre 
estes compostos incluem-se os princípios activos de compostos farmacêuticos (PACF) e fragrâncias. A 
ocorrência e comportamento destes compostos nas estações de tratamento de águas residuais (ETARs) 
em Portugal era pouco conhecida, quer ao nível da detecção à entrada, quer na eficiência de remoção 
da própria estação. Este trabalho teve como objectivos: 1) seleccionar princípios activos de compostos 
farmacêuticos e fragrâncias e optimizar a sua detecção em matrizes reais; 2) estudar a sua ocorrência e 
comportamento em ETARs; 3) estudar em ambiente controlado à escala de laboratório, os processos 
de remoção biológica e de oxidação avançada, usando a radiação UV. 
Numa primeira fase foram desenvolvidas e validadas metodologias analíticas para a detecção dos 
compostos farmacêuticos e fragrâncias nas amostras de águas residuais e nas lamas secundárias de 5 
ETARs, durante diferentes períodos do ano. Com este estudo, foi possível priorizar as famílias mais 
importantes de PACFs e concluir que a ocorrência era independente da estação do ano. O PACF mais 
abundante foi o ibuprofeno, embora o enalapril, cafeína e o ácido clofibrico também estivessem 
presentes em concentrações relativamente elevadas no afluente e efluente. Com base na informação 
recolhida, foi efectuado um estudo detalhado da estação de tratamento de Fernão Ferro (Seixal), onde 
foram colhidas amostras de água residual e de lamas com o objectivo de estudar a variabilidade e 
reprodutibilidade de ocorrência dos compostos farmacêuticos e fragrâncias, bem como os mecanismos 
de remoção. As concentrações dos PACFs no afluente apresentaram maior variabilidade do que as das 
fragrâncias, que foram mais reprodutíveis. O mecanismo de remoção mais importante na ETAR para 
os PACFs foi principalmente a biodegradação e enquanto para as fragrâncias foi a adsorção. A 
radiação UV teve um efeito importante sobre a remoção de alguns PACFs (por exemplo, o 
diclofenaco), devido à baixa remoção biológica encontrada para este composto e elevada concentração 
detectada nas lamas.  
Numa segunda fase, foi estudada a biodegradação e biotransformação de ácido clofibrico em reactor 
descontínuo sequencial com um consórcio de microrganismos adaptados à biodegradação do propanil. 
Neste estudo, observou-se a remoção de cerca de 51% de ácido clofibrico após 3 dias. Foi provado que 
as bactérias heterotróficas tiveram um papel mais importante na biodegradação do que as bactérias 
autotróficas nitrificantes. Os principais metabolitos gerados (ácido α-hidroxiisobutirico, 4-clorofenol e 
ácido láctico) foram identificados e quantificados. Com base nesta identificação, foi proposto um 
mecanismo de remoção biológica do ácido clofibrico.  
Finalmente, foram realizados estudos de cinética de oxidação do atenolol, diclofenaco e cetoprofeno 
através de lâmpadas UV de baixa e média pressão. O efeito da matriz, água pura e efluentes (filtrada e 
não filtrada) também foi estudado. O coeficiente de absorção molar e os valores de rendimento  
quântico de fotodegradação foram mais elevados para o cetoprofeno, seguido pelo diclofenaco. O 
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efeito da fotólise na oxidação do atenolol provou-se ser baixo. A presença de matéria orgânica 
particulada no efluente teve um impacto negativo na fotodegradação de PACFs. Os produtos de 
transformação mais persistentes da MP/fotólise UV do cetoprofeno, diclofenaco e atenolol foram 
identificados e monitorizados ao longo do tempo de irradiação. 
 
 
Palavras – chave: Princípios activos de compostos farmacêuticos, fragrâncias, estações tratamento 
águas residuais, reactores biológicos, radiação UV 
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SUMMARY 
 
 
Xenobiotics are compounds foreign to living organisms and difficult to biodegrade in the environment. 
This group of compounds includes the pharmaceutical active compounds (PhACs) and musk 
fragrances. Prior to this work, the occurrence and fate of these compounds in Portuguese wastewater 
treatment plants (WWTP) was still unknown, not only regarding the influent to WWTPs, but the 
removal efficiencies of the different biological, physical and chemical processes occurring in the 
plants had never been studied together. This thesis aimed at the identification of the most relevant 
PhACs and musks for studying their occurrence and fate in WWTPs, as well as the implementation of 
biological removal and photolysis processes for a select group of compounds at the laboratory scale. In 
the first phase, analytical methodologies were developed and validated for the detection of these 
PhACs and musks in wastewater and sludge samples in five WWTPs during different periods of the 
year. With this study, it was possible to prioritize the most important families of PhACs independently 
of the season. The most abundant PhACs were the NSAIDs (e.g. ibuprofen), while enalapril, caffeine, 
and clofibric acid were also present in relatively high concentrations in the influent and effluent. Based 
on this information, an intensive survey was carried out in the WWTP of Fernão Ferro, where samples 
of wastewater and sludge were collected to study the variability and repeatability of the occurrence in 
the influent and the removal mechanisms in the WWTP. PhAC concentrations in the influent were 
subject to a higher variability than the musks, which were more repeatable. The most important 
removal mechanism in the WWTP for PhAC was mainly biodegradation, while adsorption was most 
important for the musks and the UV radiation had an important effect on some PhAC (e.g diclofenac) 
due to the low biological removal found for these compounds. In the second phase, the biodegradation 
of the recalcitrant clofibric acid was studied in a sequential batch reactor with a consortium of 
microorganisms adapted to transform propanil, a structurally similar compound. In this study, we 
observed the removal of about 51% of clofibric acid after 3 days. It was proved that mainly the 
heterotrophic bacteria were responsible for the biodegradation when compared to autotrophic nitrifier 
bacteria. The main metabolites (e.g. α-hydroxyisobutiric acid, 4-chlorophenol and lactic acid) were 
also identified and quantified, forming the basis for a proposed metabolic pathway for clofibric acid 
biodegradation. Finally, photolysis studies of the kinetics of atenolol, diclofenac and ketoprofen 
degradation were performed through low and medium pressure UV lamps. The matrix effects in pure 
water and wastewater effluent (filtered and unfiltered) was also studied. The decadic molar absorption 
coefficient and quantum yield values indicated high photodegradation for ketoprofen, followed by 
diclofenac, and low photolysis for atenolol. The presence of particulate organic matter in the 
wastewater had a negative impact on the photodegradation of PhACs. The most persistent 
transformation products from MP/UV photolysis of ketoprofen, diclofenac and atenolol were 
identified and monitored throughout irradiation time. 
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1. Motivation and Thesis Outline 
 
1.1 Background 
 
Over the last decade, xenobiotic compounds have become a big concern to the 
environment. The development of more sensitive analytical techniques was responsible 
for the possibility of detection of a very large number of substances (organic and 
inorganic) in very small concentrations in the ranges of ng L
-1
 and µg L
-1
. Since that time, 
many compounds have been identified as xenobiotics. These chemicals are often called 
micro pollutants (because their concentrations are very low) or emerging contaminants 
(since the concern about them is only recent) or xenobiotics (since most of them are 
synthetic, i.e. xenon to bios which means foreign to life). Xenobiotic compound can be 
defined as a chemical which is found in an organism, but is not normally produced or 
expected to be present. It can also cover substances which are present in higher 
concentrations than are usual (Fatta-Kassinos et al., 2010). 
 
For a long time the production of chemicals and pharmaceuticals, their usage and 
application was connected with the heavy pollution of the environment and serious health 
effects. At the end of the last century, it was realized that the products of chemical and 
pharmaceutical industries are presenting a new type of environmental pollution that may 
cause a health risk to the consumer. Most chemicals are used in excessive amounts e.g. 
for personal care, hygiene, health care products and pharmaceutical active compounds. 
Some other compounds are of natural biological origin such as mycotoxins, aflatoxins, 
some hormones and others. They can also be included in the group of xenobiotics, since 
they are foreign to the organisms in which they are found, due to uptake and 
bioconcentration processes, after their release in the environment. 
The xenobiotics often spread within the water cycle, however, the knowledge on their fate 
and effects and on opportunities for their removal and input prevention is scarce. In 
particular in Portugal there was no information available about their presence in the 
wastewater  until 2005. The presence of xenobiotics in the aquatic environment seems to 
be a big challenge for sustainable water in future when the reuse of the wastewater treated 
from the wastewater treatment plants will became important. In countries with no water 
reuse, the wastewater discharges in the environment can be responsible for groundwater 
infiltration and possible contamination of the drinking water supply aquifers. Hazardous 
chemicals, like many of the xenobiotic organic compounds, are of rising concern in urban 
water management since water supply, urban drainage and wastewater treatment systems 
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were originally designed only to solve other problems (supply of potable water, flooding 
prevention and sanitation). There is need to understand, in an integrated manner, the 
sources, flow paths, fate and effects of hazardous chemicals on both humans and 
ecosystems.  
Most of them are released into the environment according to their use, like for example, 
personal care products and pharmaceuticals. These types of chemicals enter the 
environment continuously via domestic and industrial sewage systems and via wet 
weather or raining run-off (e.g. from animal farms). Many of the chemicals of emerging 
interest, including pharmaceuticals, have not been fully examined yet for their negative 
environmental and health effects. The pharmaceuticals, for example, are designed to 
modulate immune and endocrine systems and cellular signal transduction and have a 
potential to interfere with organisms in the environment. Many of these chemicals are 
designed to have profound physiological effects, so it would not be surprising if they 
were found to affect fish, insects and other forms of life. Relatively short-living chemicals 
can cause chronic exposures because they are continuously infused into the environment. 
Even if the individual concentrations of such chemicals are low, the combined 
concentrations from those sharing a common mechanism of action could have a 
substantial effect on the living organisms. The transformation of the parent compounds 
may be incomplete in the environment and in treated effluents. These recalcitrant or 
persistent chemical entities may also add to the already huge number of potentially toxic, 
suspicious, unsafe chemicals present in the environment. Less is known about these 
transformed chemicals compared to their parent compounds, in particular in relation to 
their possible effects on environmental organisms and humans (easily reachable e.g. via 
drinking water). 
Illicit drugs constitute a new class of chemicals with potent psychoactive properties and 
unknown effects to the aquatic environment. The occurrence of such drugs in water 
resources in various countries such as the U.S. (Bartelt-Hunt et al., 2009), Italy (Zuccato 
et al., 2006), Germany (Wick et al., 2009) and Croatia (Terzic et al., 2010) is an example 
of the importance of studying micro pollutants and PPCP in wastewater treatment system 
and combined with the effect with the urban water cycle.  
Some of the studies reported the occurrence and fate, effects and risks associated with the 
presence of xenobiotics in urban waters such as: 
 Occurrence and fate in water and wastewater by the application of different 
technologies  
 Co-metabolism removal of different organic compounds in pilot and laboratory 
studies 
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 Photochemical transformation of pharmaceutical active compounds when present 
in the aquatic environment and/or during the application of photo induced 
treatment processes 
 Analytical identification and quantification of the transformation products of 
selected pollutants  
Storm water is also another major pathway for the introduction of xenobiotics into the 
water cycle. The treatment of storm water should of course constitute an integral part of 
precipitation water management. This could also contribute to the current demands 
concerning water quality including this group of compounds called xenobiotics. In this 
respect, the requirements of the Water Framework Directive (2000/60/EU, WFD) 
continue to play a central role and provide a basis for discussion leading to further 
innovative solutions for the persistent compounds not quite well studied. In order to 
assess these requirements, major investments are necessary in water and wastewater 
treatment in future, to extent and nature of the xenobiotics released from these different 
sources that will certainly differ and each can have different potential and cause different 
environmental pollution effects, and consequently will became a potential challenge for 
environmental management. 
The inherent properties (e.g. solubility, volatility, biodegradability, etc.) of xenobiotics 
are varied, as well as their potential sources and uses, and the behavior of different 
xenobiotic substances released to the environment is not equal between the different 
classes of compounds. The ecotoxicity and environmental persistence of a substance have 
a large range of variability to the environmental hazard, and it is clear that an emission 
level for one compound may be orders of magnitude higher or lower than that specified 
for another. Some sources and uses of xenobiotics may release a single harmful 
substance, and others release a mixture which difficult how to deal with this problem. The 
spatial distribution and scale of that source and use in the area of interest (e.g. a city, 
country, etc.) and the type of regulatory and/or voluntary controls imposed, play a major 
role in determining its importance in relation to the overall emission of hazardous 
substances into the environment and to the overall risk posed by the particular substance 
emitted. This knowledge also forms an important basis for pollution monitoring, exposure 
assessment, and source control strategies for emission prevention and/or reduction. It is 
important to know which sources are the most important in terms of the quantity released, 
which sources are relatively easy to control using on-site treatment technologies, which 
sources are mobile, which sources are continually emitting. This knowledge is vital for 
building a picture of the patterns and pathways of substance flow throughout the 
environment and for supporting the calculation of mass balances and the evaluation of 
different pollution control strategies. The pharmaceutical active compounds (PhACs) and 
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musks are included and have been detected in many sources, such as urban, industrial and 
hospital wastewaters, sludges and even in the surface and ground water, sources for 
drinking water system. Marine sediments are also characterized as to have memory of the 
pollution constituting a sink source for the more hydrophobic compounds that can cause 
risks to aquatic biota, in which these compounds can, bioaccumulate, and affect the 
human health through the ingestion of contaminated fish and shellfish. Due to the 
importance of the detection of these pharmaceutical active compounds and musks in 
many parts of the urban water cycle, many studies are being carried out to understand the 
mobility of these compounds in the water cycle and the potential toxicity effect on 
wildlife, human beings, animals and plants.  
The changes and interferences in endocrine function may lead to altered growth, 
development, or reproduction in exposed animals and these changes may be expressed 
later in the life cycle or even in future generations. The presence of estrogenic substances 
in municipal effluents has been linked to a number of biological responses, such as 
induction of plasma vitellogenin and intersex in fish exposed in the environment 
immediately adjacent to the outfalls (Servos et al., 2005). The exposure during critical 
life stages may result in a variety of biological impacts mediated through endocrine 
systems affecting the female and male ratio, mainly on fish. The impact of 17 -
ethinylestradiol (EE2) on fish reproduction under laboratory conditions have been 
performed by Liebig et al., (2006) and  PhACs by Grung et al., (2008) and Sanderson et 
al., (2009). 
Numerous potential endocrine disrupting compounds (EDC) have been reported in 
municipal effluents including natural and synthetic estrogens (Liniert et al., 2007). Many 
of these compounds can be detected in surface waters and sediment that receive 
wastewater discharges ( Kolpin et al., 2002, Servos et al., 2005). The major contribution 
to the estrogenicity in effluents has been shown in previous studies to be related to the 
presence of natural and synthetic estrogens in several municipal effluents. The presence 
of industrial chemicals, such as alkylphenols  and natural estrogens such as -estradiol 
(E2) and estrone (E1) (Servos et al., 2005) as well as the active ingredient of most birth 
control drugs, 17 -ethinylestradiol (EE2) (Ternes et al., 1999, Andersen et al., 2003), has 
also been shown to contribute to the estrogenicity of effluents, depending if there are 
important contributions of the industrial or other sources to the effluent. This potential 
effect of the other similar micro pollutants such as PhACs and musks in the 
environmental organisms was also a source of motivation to proceed with further studies 
on this area and also because of a lack in information about the most important 
compounds that should be prioritized. 
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It is important to prioritize the most harmful and the less harmful compounds to the 
organisms and environment. This is the main reason why so much research is carried out 
nowadays on the different sources of PhACs and musks, especially in wastewater 
treatment plants, one of the main receptors of these compounds. Biodegradation, 
adsorption and oxidation studies with different technologies are being tested for 
evaluation of the efficiency of removal, and to suggest potential changes in the design of 
the treatment plants in order to remove this kind of compounds. 
 
 
1.2 Research Objectives   
 
This work aims at contributing to the development of methods for measuring xenobiotic 
compounds in real wastewater systems, and to assess their abundance in various 
wastewater treatment plants (WWTPs) in the south region of Lisbon. The same analytical 
procedures are employed throughout the study to monitor the oxidation and/or 
biotransformation extent of the studied compounds. The xenobiotic screening in the 
selected WWTP indicates which compounds are present in higher amounts in this socio-
economic context (an urban, densely populated region of Portugal). The pharmaceutical 
and personal care product (PCP) selection is done according to those that are known to be 
more toxic to human health and aquatic life or more resistant to biodegradation for the 
subsequent treatment studies. 
The level of xenobiotic removal currently achieved by WWTPs is assessed through 
analysis of influent and effluent samples and sludge samples. Single and composite liquid 
samples reveal those compounds that appear in high peak concentrations (e.g. in the 
morning), and those present in significant levels on a 24 h basis. The xenobiotic removal 
efficiency in the existing treatment systems are assessed by comparing the concentrations 
in the influent and effluent of the WWTP. While some biological degradation of the 
xenobiotics is expected, removal may also take place by adsorption to biomass cells, 
which must be accounted for through analysis of the sludge. This process is particularly 
important for hydrophobic compounds, such as the musks.  
The metabolic transformations that the target xenobiotic compounds undergo in 
conventional biological wastewater treatment plants (WWTPs) was assessed through 
laboratory bioreactor tests. The biodegradation/adsorption of each compound was studied 
and compared with the screening of real WWTP carried out, and the metabolic by-
products that are generated were monitored by the analytical procedures. 
Accurate assessment of the by-products produced by the sludge can only be done when 
each xenobiotic was fed individually to a bioreactor. This assessment is critical since 
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some of the by-products are potentially more harmful than their parent compounds. Most 
previous studies focusing on xenobiotic removal from wastewater have not investigated 
this potential problem, thus this work aims to provide a more comprehensive outlook on 
the capacity of biological treatment systems to prevent toxic xenobiotics from entering 
into waterways. The chemical structure of each compound provide an indication of the 
operational conditions (aerobic/anaerobic, reactor pH, sludge age, etc.) that are likely to 
be more efficient for the biodegradation of each compound. The extent of biodegradation 
was followed by kinetic reaction rates and stoichiometric yields that calculated for each 
set of reactor operational conditions. 
After the identification and quantification of the target xenobiotics, bench scale reactors 
were operated under specific conditions to study their removal. One important feature of 
this work is the identification of metabolic products formed by the microbial cultures as 
well as the intermediate oxidation step. The isolation and identification of these by-
products were conducted by chromatographic separation techniques: gas chromatography 
coupled to mass spectrometry (GC-MS); high pressure gas chromatography coupled 
diode array detector and to mass spectrometry (HPLC-DAD-MS) and liquid 
chromatography tandem mass spectrometry (LC-MS/MS).  
Additional degradation steps are provided by advanced oxidation processes (AOP) (e.g. 
ultraviolet (UV) radiation). AOP are expected to be more efficient in degrading the 
selected compounds than direct photolysis due to the production of the highly reactive 
and unselective
 •
OH radicals. The efficiency of direct photolysis depends on the selected 
compound‘s absorbance, since for a compound to be photo liable it needs to have the 
capacity to absorb light. Therefore, the absorbance of each target xenobiotic has to be 
measured to be able to predict how efficient UV radiation degrades it. The presence of 
suspended matter can also interfere with the efficiency of the UV treatment and should be 
monitored by using real wastewater supernatant as matrix. The oxidation processes are 
expected to produce more by-products than the photolysis processes and the compounds 
formed more toxic since they will be more oxidized than the parent compound.  
The chemical structures of the by-products give information about the possible (bio-) 
chemical transformations of the parent compound, suggesting potential (metabolic) 
degradation pathways. Based on this information, we also aim at developing metabolic 
pathways for the biodegradation of some of the studied xenobiotic compounds and/or 
their by-products. Of special interest was whether or not the compounds are completely 
mineralized, or if other, potentially harmful, by-products are formed.  
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This work is an important contribution for: 
i) the study of the occurrence and fate of the PhACs and musks in the WWTPs in 
Portugal as well as the analytical methodological techniques applied  
ii) assessing the variability of the PhACs and musks in the influent of a WWTP and 
how repeatable are the samples obtained 
iii) assessing the removal mechanisms by the sequence of treatment in a WWTP by 
establishing mass balances for the PhACs and musks, including the effects of 
the secondary biological treatment as well as UV radiation  
iv) the study of the biological removal of a recalcitrant PhAC such as clofibric acid 
with a specific consortium and identification of  the metabolites produced 
v) the study of the kinetic oxidation and sub-product identification of the reaction in 
UV irradiation with low and medium pressure lamps of 3 PhACs (atenolol, 
diclofenac and ketoprofen) in different matrices.  
 
1.3 Research Strategy 
 
The starting point for the project was the lack of information about the presence or 
absence of PhACs and musks in our WWTP in Portugal. One of the main objective of this 
work was to identify and quantify pharmaceutical active compounds (PhACs) and musk 
fragrances present in wastewater treatment plants (WWTP) in the south region of Lisbon 
(Almada, Seixal and Setúbal). The analytical techniques for the detection of xenobiotics 
and their by-products have been developed. A preliminary screening, based on 
consumption statistics for Portugal (INFARMED, INE) was carried out. Among the 
PhACs selected, it was included antidepressives (e.g. carbamazepine, hydroxyzine); anti-
inflammatory drugs: non-steroidal (e.g. diclofenac) or steroidal (e.g. tramadol); drugs for 
asthma and allergic diseases (e.g. salbutamol); antibiotics (e.g. amoxicillin); 
contraceptives – steroid hormones (e.g. progesterone, 17β-estradiol, 17α-ethinylestradiol) 
and musks (e.g. galaxolide, cashmeran), among others. 
The concentration in the influent, effluent and sludge was measured in order to determine 
the removal efficiency of the target compounds by different existing treatment processes 
(activated sludge (WWTP of Valdeão, Setúbal and Parque Industrial do Seixal) and 
trickling filters (Quinta da Bomba and Fernão Ferro)). These WWTP are managed by 
Águas do Sado, SMAS Almada and SIMARSUL. A partnership agreement was signed 
with these companies in order to ensure the continuous transfer of materials and 
knowledge throughout the study. Single and composite liquid samples (influent and 
effluent) and grab sludge samples were collected. The sludge samples were treated by 
9 
 
solid phase microextraction (SPME) for the musks and/or solid phase extraction (SPE) 
methods for PhACs. Different techniques were used to extract the PhACs, depending on 
their nature: the acidic compounds were extracted using OASIS HLB as extracting 
medium and the neutral compounds, with RP-C18. The analysis of the liquid samples was 
also depending on the compound‘s properties. The collected samples were treated with 
headspace extraction techniques using SPME fibers, PDMS/DVB 
(polydimethylsiloxane/divinylbenzene) to selectively isolate the musks. The analysis of 
the non-polar compounds (e.g. musks) was done by gas-liquid chromatography (GC) 
and/or gas-liquid - mass spectrometry (GC-MS) and the polar compounds (i.e. most 
PhACs), by liquid chromatography-diode array detector-mass spectrometry (LC-DAD-
MS). With the results of detection of the PhACs and musks in the influent, effluent 
(before and after UV) and sludge samples, it was possible to study not only the influent 
variability of these compounds but also to establish mass balances to the plant to get an 
understanding of the removal mechanisms of biodegradation and/or biotransformation, 
adsorption and the effect of the UV radiation of low pressure lamps on the degradation of 
the PhACs and musks in full scale WWTP.  
 
The second phase of the study was to investigate the biological removal and effect of UV 
of specific xenobiotics found to be relevant in the first phase. Bioreactors were inoculated 
with sludge collected at WWTPs known to receive the xenobiotic. The fate of selected 
organic compounds was assessed in a bench scale reactor operated under similar 
conditions as the WWTP. The aim was to investigate the adsorption and 
biotransformations occurring for each target compound as well as to monitor the resulting 
by-products associated with each compound, using the optimized analytical methods. The 
bioreactor was operated under aerobic conditions for the degradation of clofibric acid. 
The microbial diversity and activity of these consortia was also investigated in this thesis. 
Initially, the xenobiotic were the sole carbon and energy source, to determine the sludge 
capacity for direct metabolism. Since the biotransformation of the xenobiotic compound 
was not observed, an easily biodegradable carbon source (i.e. propanil) was supplied in 
combination with the xenobiotic to test the potential for co-metabolism and enhanced 
degradation.  
The efficiency in degradation of some target xenobiotics (atenolol, diclofenac, 
ketoprofen) using ultraviolet (UV) radiation was also tested. Batch experiments were 
conducted to evaluate the xenobiotic degradation kinetics and to determine the main 
parameters that influence their degradation (such as decadic molar extinction coefficient, 
quantum yield and source water quality) and also identifying the by-products formed. The 
photodegradation experiments were performed in a bench scale collimated low pressure 
10 
 
lamp and medium pressure UV reactor. The selected oxidation technique was finally 
tested with real wastewater to verify its efficiency in the presence of suspended particles 
and of the other components of the effluent.  
 
1.4 Thesis Structure 
 
This thesis is composed of eight chapters, including the current introductory chapter 
describing the motivation and outline of the work developed (Chapter 1). The remaining 
chapters include an overview of the state of art in xenobiotics, in particular the 
pharmaceutical active compounds and musks (Chapter 2), five chapters (Chapters 3 to 7) 
describing the work developed according with the specific objectives laid out above, and 
a final chapter summarizing the conclusions draw from this study (Chapter 8).   
Chapter 1, Motivation and thesis outline: This chapter contains a short description of the 
motivation to get involved in the research of the effect of PhACs and musks in 
wastewater treatment plants. The aim is to describe the main activities developed during 
the PhD and a brief description of the project. This chapter also contains a short 
description of the main objectives of this thesis.  
Chapter 2 State of art and introduction: This chapter contains a short description of the 
xenobiotic problem in wastewater treatment plants and the environment. The chapter also 
contains an introduction to the specific pharmaceutical active compounds and musks 
studied in the wastewater treatment processes and their removal processes in the WWTP, 
which is extensively discussed in the thesis. An overview of the literature on the subjects 
of occurrence and fate of PhACs and musks in WWTPs, the analytical techniques for the 
detection of these kind of compounds and lab scale reactors for biological and oxidation 
studies is presented. 
Chapter 3 Analysis of 65 Pharmaceuticals and Personal Care Products in 5 Wastewater 
Treatment Plants in Portugal Using a Simplified Analytical Methodology: This chapter 
consists of a survey of PhACs and musk fragrances in different WWTPs. In this study, 
the abundance of 65 PPCPs was analysed in 5 Portuguese WWTPs during the spring and 
autumn. The analytical methods were described in detail for the wastewater and sludge 
samples for the determination of PhACs and musks and also the validation of the method 
was performed using influent wastewater matrices, showing comparable limits of 
detection and quantification as literature values for most PPCPs. 
Chapter 4 Assessing the Diurnal Variability of Pharmaceutical and Personal Care 
Products in a Full-Scale Activated Sludge Plant: In this chapter, an intensive sampling 
campaign has been carried out in a municipal wastewater treatment plant (WWTP) to 
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assess the dynamics of the influent pharmaceutical active compounds (PhACs) and 
musks. The mass loadings of these compounds in wastewater influents displayed 
contrasting diurnal variations depending on the compound. The range of PhACs loadings 
in the influent to WWTPs can vary several orders of magnitude from one day or week to 
the next, representing a challenge in obtaining data for steady-state modelling purposes.  
Chapter 5 Assessing the Removal of Pharmaceutical and Personal Care Products in a 
Full-Scale Activated Sludge Plant: In this chapter, was investigated the different removal 
mechanisms of PhACs and musks in a WWTP. Biological removal and adsorption in the 
activated sludge tank was studied as well as the effect of UV radiation used for 
disinfection purposes. By establishing a mass balance for the WWTP, the main removal 
mechanism (biological, adsorption and UV radiation) of PhACs and musks in the WWTP 
was possible to obtain, as well as its variability over different sampling days.   
Chapter 6 Biodegradation of clofibric acid and identification of its metabolites: In this 
chapter, the environmentally persistent and refractory clofibric acid, the 
pharmacologically active metabolite of the lipid regulator family of pharmaceuticals, was 
subjected to biological transformation by a microbial consortium. The goal of this study 
was to evaluate the biotransformation of this compound and the production of 
metabolites. Kinetic studies of the carbon source consumption and also ammonium, 
nitrite and nitrate have been performed in order to investigate the effect that nitrifiers and 
heterotrophic bacteria have in the biotransformation of clofibric acid. For the detection 
and identification of clofibric acid metabolites, GC-MS combined with HPLC-DAD-MS 
was employed.  
Chapter 7 Photodegradation kinetics and intermediates of ketoprofen, diclofenac and 
atenolol in pure water and treated wastewater: In this chapter, kinetic studies were 
performed with UV radiation using low and medium pressure lamps with atenolol, 
diclofenac and ketoprofen as PhACs. The matrix effect is compared in pure water as well 
as filtered and unfiltered treated wastewater, where pseudo-first order UV kinetic 
constants are determined. Metabolites of the transformations are also identified using GC-
MS and UPLC-MS/MS.  
Chapter 8 Conclusion: This chapter provides an aggregated discussion of the results 
obtained in the thesis as well as a summary of the main conclusions.  Main achievements, 
contributions to the advancement of PPCP monitoring and removal studies in WWTPs 
and future work are also listed in this chapter. 
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2. State of art  
 
2.1 Xenobiotic definition and occurrence in the environment 
 
The term xenobiotic is derived from the Greek words (xenos) = foreigner, stranger and 
(bios) = life. Specifically, drugs such as pharmaceutical active compounds (PhACs) and 
their metabolites are xenobiotics in humans because the human body does not produce 
them itself, nor are they part of a normal diet (Fatta-Kassinos et al., 2010). The 
pharmaceutical active compounds (PhACs) are considered xenobiotic, man-made 
chemical compounds, foreign to living organisms that are discharged in municipal 
wastewater treatment plants (WWTP). The term xenobiotics is often used in the context 
of pollutants such as musk fragrances, pharmaceutical active compounds and other 
persistent personal care products (PPCP) and their effect on the biota.  
Natural compounds can also become xenobiotics if they are taken up by another 
organism, such as the uptake of natural human hormones by fish found downstream of 
sewage treatment plants (Fatta-Kassinos et al., 2010). The exposure to these xenobiotic 
compounds can alter the oxidative state of cells and thereby increase oxidative stress. The 
induction of oxidative metabolism by the hemoprotein family of cytochrome P450s is 
well known to release oxygen radicals that can lead to oxidative stress. Aquatic biota 
exposed to these pharmaceutical compounds can be adversely affected, as they are not 
possibly as efficient as mammals in eliminating lipophilic drugs and oxygen radicals. The 
persistent personal care products (PPCP) act at various tissues and most of them are 
metabolized in the liver (hepatocytes). These metabolize drugs differently attempt to 
eliminate them and prevent toxic accumulation in tissues. This is of particular importance 
because municipal wastewaters from major urban areas are considered to emit these 
substances into the aquatic environment on a continuous basis, where they can persist for 
days (Gagné et al., 2006).  
These substances are problematic for the sewage treatment systems, since they are 
relatively new substances without defined regulations and are very difficult to categorize. 
There is a lack in the European Community regulation for these compounds (PhACs and 
musks) in sewage wastewater and sludges, only other groups of organic compounds are 
considered as for example polycyclic aromatic hydrocarbons (PAHs) and 
polychorobiphenyls (PCBs). 
Many tons of drugs are produced every year, because of its application in human and 
veterinary medicine. The exact production figures are difficult to obtain in INFARMED 
statistics. The INFARMED is national authority of medicines and health products, a 
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governmental agency accountable to the health ministry with the objective monitoring, 
assessing and regulate all activities related with human medicines and health products for 
the protection of public health.  The amount of pharmaceuticals prescribed by physicians 
can be evaluated by multiplying the amount of daily dose with the amount of prescribed 
daily doses per year. This amount can increase dramatically when drugs that can be 
purchased without prescription in the pharmacy are considered. These concentrations are 
dependent of the pharmacokinetical behavior (half life, urinary and fecal excretion, 
metabolism, etc.) or the application mode as injection, pill, where the human body 
metabolism is needed to process the drug, or by direct application in cream or gel form on 
the skin (Ternes et al., 1998). Due to this high application level, detectable concentrations 
of drugs and their metabolites may be expected in sewage. According to INFARMED, the 
most prescribed and consumed PhACs in Portugal from 2003 to 2010 are shown Table 
2.1. 
 
The PhACs selected in many studies are those most sold or prescribed compounds in the 
market and also those showing human or animal excretion rates, where the compound is 
unchanged by the organism. According to the INFARMED data, almost all of the selected 
PhACs are still widely produced and even in some cases the consumption is increasing. 
The occurrence of PhACs in wastewater is not a temporary problem and studies are 
needed in the different countries to understand the removal behavior in the WWTP.  
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Table 2.1 - 65 target compounds, human effects statistics of the Top ranking position of 100 active substances with highest number of packages in NHS 
(INFARMED, 2008, 2009, 2010)**. 
 
Compound 
Ranking 
2003 
Number 
package 2003 
Ranking 
2007 
Number 
package 
2007 
Ranking 2008 
Number 
package 
2008 
Ranking 2009 
Number package 
2009 
Number 
package 2010 
Daily Dose of 
PhAC  (max)* 
(mg d
-1
) 
Excretion 
rates 
unchanged 
(%) 
Acidic PhAcs            
Acetylsalicylic acid 31 714545 18 1107377 12 1428978 11 1778370 3130809 500-1000 (4000)  
Ampicillin          1000-4000 30-60a 
Amoxicillin 5 1880150 4 2091167 4 2180559 5 2239124 2150900 750-1500 80-90a 
Captopril 28 739000 58 532863 62 500663 83 440138  12.5-150  
Ciprofloxacin 38 628122 40 673604 43 655694 47 640648 529272 500-1500 45c, 20d 
Clofibrate ethyl            
Clofibric acid           6b 
Diclofenac 4 1986824 7 1947175 7 1945838 10 1817520 2669287 50-150 15b 
Enalapril maleate 65 449869 96 384646 65 369296    10-40 30d 
Fentiazac          100-400  
Flurbiprofen          50-200  
Furosemide 24 826682 16 1146044 14 1227322 16 1312465  20-80 90d 
Ibuprofen 12 1276608 11 1633842 9 1794553 8 2016009 3225265 900-2400 1-8b; 10d 
Indomethacin 68 440176        50-150 10-20b 
Ketoprofen 90 364532 86 404076 78 428862 82 441070  160-320  
Naproxen     - 40488 - 61500  250-1000 1-2c 
Telmitarsen     73 450465 57 576054    
Tiaprofenic acid            
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Table 2.1 - (cont.) 65 target compounds, human effects statistics of the Top ranking position of 100 active substances with highest number of packages in NHS 
(INFARMED, 2008, 2009, 2010)**. 
 
Compound 
Ranking 
2003 
Number 
package 
2003 
Ranking 
2007 
Number 
package 
2007 
Ranking 
2008 
Number 
package 
2008 
Ranking 
2009 
Number 
package 2009 
Number 
package 
2010 
Daily Dose of 
PhAC  (max)* 
(mg d
-1
) 
Excretion 
rates 
unchanged 
(%) 
Neutral PhACs            
Allopurinol 56 497021 43 650226 37 702030 38 771022  100-300  
Alprazolam 2 2502476 2 2208290 5 2179887 4 2280686 3363097 0.75-1.5  
Atenolol 82 380196 - 106988 - 110683 - 144844  25-100 > 50c; 90d 
Azithromycin 23 856205 27 892528 26 906615 30 912055 632481 500-1000  
Betamethasone 60 474978 98 383654      4-20  
Bromazepam 9 1457640 14 1207555      3-18  
Budesonide 87 369407 80 417512 84 417202 85 426855  0.2-0.8  
Caffeine          20-40(++)  
Carbamazepine 74 410837 93 391173 - 37908 - 323872  200-1200 (1600) 1-2b 
Clorazepate          45-80  
Codeine          10-120  
Diazepam 11 1338429 15 1146901 16 1115754 21 1130220 494745 6-30  
Digoxin 40 621657 59 529235 61 503423 75 478958  0.125-1.25  
Diltiazem 55 504038 76 437312 83 418277    120-360 3c 
Dimethylamino-
phenazone 
           
Domperidone 35 660360 38 734096 36 749950 37 775022  30-60  
Escitalopram   49 605352 56 531752 64 532923    
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Table 2.1 - (cont.) 65 target compounds, human effects statistics of the Top ranking position of 100 active substances with highest number of packages in NHS 
(INFARMED, 2008, 2009, 2010)**. 
 
Compound 
Ranking 
2003 
Number 
package 
2003 
Ranking 
2007 
Number 
package 
2007 
Ranking 
2008 
Number 
package 
2008 
Ranking 
2009 
Number 
package 2009 
Number 
package 
2010 
Daily Dose of 
PhAC  (max)* 
(mg d
-1
) 
Excretion 
rates 
unchanged 
(%) 
Neutral PhACs            
β-Estradiol          1-2  
Estrone          10-20  
17α-Ethinylestradiol 14 1222358 17 1125664 25 938287 34 828145 2893722 0.02-0.03  
Etofenamate 48 557973 68 494069 60 503712 68 504178  100-1000  
Fluoxetine 30 721617 41 671204 41 678481 41 708266 505527 20-60  
Fluticasone 67 445511 84 409010 94 392352    0.2-0.5 (1)  
Glibenclamide 15 1181286 50 601419 63 491854 100 393940  5-15  
Hydroxyzine 88 367047 90 398482 89 398428 89 418354  50-100 (600)  
Indapamide 10 1450582 9 1775043 10 1794144 12 1743762  1.25-2.5  
Latanoprost 85 373446 75 440808 72 451624 78 466279  0.05-0.125  
Lorazepam 7 1682991 8 1888586 8 1869183 9 1909169 2107513 2-6 (10)  
Nifedipine 26 763697 32 783840 35 781599 39 769754  30-120  
Nimesulide 3 2254935 12 1622152 11 1487913 13 1510441 2790311 100-400  
Omeprazol 13 1260328 10 1650237   7 2029495 1345138 20-40 (120) 20d 
NSAID – Non-steroidal anti-inflammatory drug; aHirsch et al. (1999); bTernes T. (1998); cSedlak et al.(2001); dZucatto et al. (2005); *Carmona, M., Carneiro, C., Esteves, A.P., Filipe, H, 
Gonçalves, J., Macedo, T., Osswald, W., Pinheiro, R.L., Rodrigues, A., Sampaio, C., Teixeira, A.A, Prontuário terapêutico, INFARMED, Ministério da Saúde (2008); **Medicines statistics, 
Infarmed (Instituto Nacional da Farmácia e do Medicamento, 2003-2010; (++) Associated with paracetamol. 
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Table 2.1 - (cont.) 65 target compounds, human effects statistics of the Top ranking position of 100 active substances with highest number of packages in NHS 
(INFARMED, 2008, 2009, 2010)**. 
 
Compound 
Ranking 
2003 
Number 
package 
2003 
Ranking 
2007 
Number 
package 
2007 
Ranking 
2008 
Number 
package 
2008 
Ranking 
2009 
Number 
package 2009 
Number 
package 
2010 
Daily Dose of 
PhAC  (max)* 
(mg d
-1
) 
Excretion 
rates 
unchanged 
(%) 
Neutral PhACs            
Oxazepam          15-30 (50)  
Paracetamol 1 3505698 1 3520490 1 3465215 1 3642302 10345595 500-1000 (4000)  
Paroxetine 39 624423 95 385901 98 384420 98 396592  20-50  
Phenazone  
(antipyrine) 
           
Piroxicam 43 582015 91 397681 - 6995 - 6286  10-20  
Progesterone          5-10  
Propranolol   94 388750 76 430745 81 451256  40-320 < 1b 
Ramipril 75 409403 55 557552 49 583716 49 623243  1.25-10  
Ranitidine 96 356211 - 104281 - 95247 - 100947  300-600 (1200) 40d 
Reserpine            
Salbutamol 34 682926 54 580501 55 548259 62 538312  0.2-1.6 (5)  
Salicylic acid            
Sertraline 66 446561 56 551892 51 573605 48 630785  50-150 (200) 13c 
Tramadol 71 422418 89 400974 88 399709 53 615053  50-400 25-50c 
Warfarin            
Zolpidem 22 862477 21 980308 23 974065 23 1078175    
NSAID – Non-steroidal anti-inflammatory drug; aHirsch et al. (1999); bTernes T. (1998); cSedlak et al.(2001); dZucatto et al. (2005); *Carmona, M., Carneiro, C., Esteves, A.P., Filipe, H, 
Gonçalves, J., Macedo, T., Osswald, W., Pinheiro, R.L., Rodrigues, A., Sampaio, C., Teixeira, A.A, Prontuário terapêutico, INFARMED, Ministério da Saúde (2008); **Medicines statistics, 
Infarmed (Instituto Nacional da Farmácia e do Medicamento, 2003-2010; (++) Associated with paracetamol. 
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The personal care products (PCPs) are produced and used in large amounts around the 
world. Some examples are soaps, household detergents, perfumes, etc. Fragrances are 
common ingredients of PCPs and in contrast with other chemicals, almost no knowledge 
exists on their long-term environmental effects (Llompart et al., 2003). The musks are 
ubiquitous, persistent, bioaccumulative pollutants, and some generate toxicologically 
active compounds.  Musks are continuously introduced into the environment mainly via 
urban wastewater.  The musk fragrances can include e.g. galaxolide, tonalide, cashmeran, 
traseolide, celestolide and phantolide as polycyclic musks (Table 2.2) and musk xylene, 
musk moskene, musk tibetene and musk ketone as nitro musks.  
 
Table 2.2 - Uses, chemical structure, chemical proprieties of the musks studied. 
 
Compound Uses CAS Chemical structure Mw logKow 
Cashmeran 
(DPMI) 
Health care 
product 
33704-61-9 
 
206 4.84b 
Celestolide 
(ADBI) 
Health care 
product 
13171-00-1 
 
244 4.37b 
Galaxolide 
(HHCB) 
Health care 
product 
1222-05-5 
 
258 5.9a 4.6b 
Phantolide 
(AHMI) 
Health care 
product 
15323-35-0 
 
244 5.85g 
Tonalide 
(AHTN) 
Health care 
product 
1506-02-1 
 
258 
5.7a;f 
4.84b 
Traseolide 
(ATII) 
Health care 
product 
68140-48-7 
 
258 6.3g 
 a(Ternes et al., 2004); b(Carballa et al., 2008); c(Carrara et al., 2008); d(Comeau et al., 
2008); e(Lin et al., 2009);  f(Grung et al., 2007); g(Xia et al., 2005)  
 
 
The polycyclic musks account for nearly 85% of the worldwide production of musks, 
while nitro musks account for the rest (Llompart et al., 2003). The manufacturing 
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industries have introduced some limitations on the kind and proportion of musks in PCP 
formulations, mainly the nitro musk. 
 
Since 1999 in Europe, these compounds are included in the list of Persistent Organic 
Pollutants (POP) and special attention and many studies have been conducted since that 
time (Ternes et al., 1999). The sewage treatment plant have been designed to combat 
problems of organic matter removal and microbial contamination, or more advanced 
processes to treat nitrogen and phosphorus. However, there are many natural and 
synthetic compounds, such as PhACs and musks that are not being removed by these 
systems, leading to their discharge in the natural environment. Studies of occurrence of 
PhAC and musk in the wastewater influent (Joss et al., 2006, Santos et al., 2009) and 
effluent of WWTP, surface water and sediments (Hernando et al., 2006), and rivers 
(Moldovan, 2006, Ort et al., 2009), have also been done to select the most harmful 
compounds to the environment. 
In potable water and ground water some drugs like diazepam, and antibiotics have also 
been detected (Ternes in 1998). Clofibric acid for example, a metabolite of three lipid 
regulating agents, has been identified in the river and ground water in Germany and even 
in drinking water with concentration levels ranging up to 165 ng L
-1
 (Ternes, 1998). The 
behavior of drugs in their passage through the WWTP and about the treated wastewater 
contamination of the aquatic environment by PPCPs is due to the diversity of the drugs 
applied in medicine and is still not completely known nowadays. 
WWTP sludge may contain many xenobiotic (anthropogenic) organic chemicals which 
have the potential to be taken up by plants and animals and accumulate in the terrestrial 
food chain, as well as to leach into the groundwater (Kreuzinger et al., 2004). The sludge 
can also be a problem in WWTP management because many PPCP can adsorb to the 
sludge and in some countries, the main application for the sludges is the agriculture. The 
unknown behaviors of the PPCP desorption from the sludge and the possible 
contamination of surface and ground water used for drinking water can be a problem for 
human health. The management of sludge from WWTPs represents one of the major 
challenges in wastewater treatment today, with costs amounting to more than the 
treatment cost of the liquid in many cases (Carballa et al., 2007). Some micro pollutants 
adsorb onto the sludge solids during wastewater treatment. Depending on the efficiency 
of treatment technology on their degradation, these compounds will be mostly present in 
the supernatant of the sludge and thus recycled from the dewatering system or thickener 
to the entrance of the WWTP or disposed with the sludge. The inorganic compounds, 
such as heavy metals, are analyzed on a routine basis, the characterization and long-term 
observation of organic contaminants in sludge has received little attention so far, probably 
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due to the inherent difficulties associated with the analysis of sludge samples (Carballa et 
al., 2007). Some of these substances (e.g. PhACs and musks) have the potential to cause 
adverse effects on plants, soil microbes, invertebrates and other microorganisms above 
certain concentrations (Bundschuh et al., 2011). The problem is that not only those 
substances with high partitioning to sludge are recycled with it, but also a significant part 
of the non-degraded compounds which tend to remain in the aqueous phase are recycled 
(Carballa et al., 2007).  
The compounds monitored in effluent treated wastewater of the WWTPs was first 
regulated in nineties, with the most important parameters to measure being the organic 
concentration as biochemical oxygen demand (BDO5) and chemical oxygen demand 
(COD), total suspended solids (TSS), nutrients (nitrogen and phosphorus) and some 
heavy metals (Decreto-Lei nº 236/98 de 1 de Agosto and Decreto-Lei nº 152/97 de 17 de 
Junho). Between the organic compounds, only lauryl sodium sulphate, pesticides and 
some of the organic chlorinated compounds are listed in the European Union regulation 
of Water Framework Directive (2000/60/EU, WFD). The application of the WWTP in 
agriculture was regulated in 1991 but only in 1996 was it established maximum 
concentration values for heavy metals (e.g. Cd, Ni, Cu, Pb, Zn, Hg and Cr) in the sludge. 
In 2005, the legislation starts to include in the monitoring plan not only heavy metals but 
also some organic compounds such as AOX (adsorbable organic halogenated compound 
or adsorbable organic halides), LAS (linear alkyl benzenesulfonates), DEHP (di(2-
ethylhexyl)phthalate), NPE (nonylphenols and ethoxylated nonylphenols), PAHs 
(polycyclic aromatic hydrocarbons), PCB (polychlorinated biphenyl compounds), dioxin 
and PCDD/F (polychlorinated dibenzodioxins/furans). (UE Directive nº 86/278/EC, June 
12 transposed to the Portuguese legislation by the Decreto-Lei n.º 118/2006 de 21 de 
Junho and Decreto-Lei n.º 276/2009 de 2 de Outubro). 
Other unknown organic compounds (e.g. xenobiotic compounds) present in the 
wastewater need to be studied in the water, wastewater and in the sludges in order to 
extend the list of compounds that should be monitored in the future and to include in 
future legislation.  
 
2.2 Analytical methods  
 
2.2.1 Pharmaceutical active compounds 
 
Solid-phase extraction (SPE) is the most used clean-up technique for pre-concentration of 
wastewater samples prior to analysis of the pharmaceutical active compound.  Different 
sorbents can be used for clean-up wastewater samples: Oasis HLB (hydrophilic lipophilic 
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balance) cartridges and reverse phase Sep-Pak C18 cartridges, which assures good 
recovery of compounds in a wide range of polarities. For most of the PhACs, Oasis HLB 
and reverse phase (RP C18) as SPE cartridges are the most used in literature due to the 
polar nature of the compounds and the acidic and neutral characteristics of most of them 
(Ternes et al., 2004; Ternes et al., 2005). The selection of the SPE media is directly 
related with the proprieties of the compound (e.g. acidic or neutral characteristics, (see 
Table 2.3). RP C18 is most appropriate for the neutral and Oasis HLB general it can be 
more appropriate for the acidic compounds. 
For the extraction of the PhAC adsorbed to the sludges, the procedure consists of 
ultrasonic solvent extraction (USE) using solvents (e.g. methanol/acetone) or pressurized 
liquid extraction (PLE) using 100% methanol. After this extraction step, non-selective, an 
additional clean-up can be performed with SPE (Ternes et al., 2005).  
 
Table 2.3 - Human effect, chemical structure, and chemical proprieties of the pharmaceuticals 
studied. 
 
 
 
 
 
 
 
N. Compound Human effect CAS Formula Chemical structure MW 
pKa  
(at 25ºC) 
 Acidic PhACs       
1 
Acetylsalicylic 
acid 
Analgesic 50-78-2 C9H8O4 
 
180.2 3.5 
2 Ampicillin 
β-lactam 
antibiotic 
69-53-4 C16H18N3O4S 
 
349 
2.5 (-
COOH) 
7.3 (-
NH2) 
 
3 Amoxicillin 
β-lactam 
antibiotic 
26787-78-0 C16H19N3O5S 
 
365 
2.8 and 
7.2 
 
 
 
4 Captopril Antihypertensive 62571-86-2 C9H15NO3S 
 
217 
3.7 
(carboxyl 
group) 
9.8 (thiol 
group 
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Table 2.3 - (cont.) Human effect, chemical structure, and chemical proprieties of the pharmaceuticals 
studied. 
 
NSAID - Non-steroidal anti-inflammatory drug;  
 
 
 
 
 
 
N. Compound Human effect CAS Formula Chemical structure MW 
pKa  
(at 25ºC) 
5 Ciprofloxacin Antibiotic 85721-33-1 C17H18FN3O3 
 
331 
8.6 and 6.2 
 
6 
Clofibrate 
ethyl 
Lipid modifying 
agent 
637-07-0 C12H15ClO3 
 
243  
7 Clofibric acid 
Lipid modifying 
agent metabolite 
882-09-7 C10H11ClO3 
 
243 3.6-4.9 
8 Diclofenac NSAID 15307-86-5 C14H11Cl2NO2 
 
318 4.2 
9 
Enalapril 
maleate 
Antihypertensive 77549-59-8 C24H32N2O9 
 
376 3.0-5.5 
10 Fentiazac NSAID 18046-21-4 C17H12ClNO2S S
N
O
OH
Cl
 
329.8  
11 Flurbiprofen NSAID 5104-49-4 C15H13FO2 
 
244 
4.2 
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Table 2.3 - (cont.) Human effect, chemical structure, and chemical proprieties of the pharmaceuticals 
studied. 
 
NSAID - Non-steroidal anti-inflammatory drug;  
 
 
N. Compound Human effect CAS Formula Chemical structure MW 
pKa  
(at 25ºC) 
12 Furosemide Loop diuretic 54-31-9 
C12H11ClN2O5
S 
 
330.7 6.0 
13 Ibuprofen NSAID 15687-27-1 C13H18O2 
 
206 4.5-5.2 
14 Indomethacin NSAID 53-86-1 C19H16ClNO4 
 
444 4.5 
15 Ketoprofen NSAID 22071-15-4 C16H14O3 
 
254 3.9-4.2 
16 Naproxen NSAID 22204-53-1 C14H14O3 
 
230 
 4.2 
 
17 Telmitarsen Angiotensin 
 
144701-48-4 
C33H30N4O2 
 
514.6  
18 
Tiaprofenic 
acid 
NSAID 33005-95-7 C14H12O3S 
 
260  
 Neutral 
PhACs 
 
     
19 Allopurinol Gout treatment 315-30-0 C5H4N4O 
 
136 
9.4 
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Table 2.3 - (cont.) Human effect, chemical structure, and chemical proprieties of the pharmaceuticals 
studied. 
 
SAID - Steroidal anti-inflammatory drug 
N. Compound Human effect CAS Formula Chemical structure MW 
pKa  
(at 25ºC) 
20 Alprazolam 
Anxiolytic; 
Tranquilizer 
28981-97-7 C17H13ClN4 
 
308.8 
2.4 
 
21 Atenolol 
β-Blocker; Anti-
hypertensive 
29122-68-7 C14H22N2O3 
 
266 9.5 
22 Azithromycin 
Macrolide 
antibiotic 
83905-01-5 C38H72N2O12 
 
749  
23 
Betame-
thasone 
Corticosteroid 
(SAID) 
378-44-9 C29H33FO6 
 
392  
24 Bromazepam 
Anxiolytic; 
Tranquilizer 
1812-30-2 C14H10BrN3O 
 
316 2.9 
25 Budesonide 
Corticosteroid 
(asthma) 
51333-22-3 C25H34O6 
 
430 
7.6 
 
26 Caffeine CNS Stimulant 58-08-2 C8H10N4O2 
 
194 
10.4 
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Table 2.3 - (cont.) Human effect, chemical structure, and chemical proprieties of the pharmaceuticals 
studied. 
 
N. Compound Human effect CAS Formula Chemical structure MW 
pKa  
(at 25ºC) 
27 Carbamazepine Antiepileptic 298-46-4 C15H12N2O 
 
236  
28 Clorazepate 
Anxiolytic; 
Tranquilizer 
57109-90-7 
C16H11ClH2N2
O4 
 
409 
1.5 (nitro 
groups) 
10.5 
29 Codeine Analgesic 76-57-3 C18H21NO3 
 
299.4 8.2 
30 Diazepam 
Anxiolytic; 
Tranquilizer 
439-14-5 C16H13ClN2O 
 
284.7 
 
3.4 
 
 
31 Digoxin Cardiac glycoside 
20830-75-5 
 
C41H64O14 
 
781 
9.5 
 
32 Diltiazem 
Hypertension, 
calcium blocker 
42399-41-7 C22H26N2O4S 
 
451 
7.7 
 
33 
Dimethylamino-
phenazone 
Analgesic, Anti-
inflammatory, 
Antipyretic 
58-15-1 C13H17N3O 
 
231  
34 Domperidone Antidopaminergic 57808-66-9 C22H24ClN5O2 
 
425.9 
7.9 
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Table 2.3 - (cont.) Human effect, chemical structure, and chemical proprieties of the pharmaceuticals 
studied. 
 
NSAID - Non-steroidal anti-inflammatory drug;  
 
N. Compound Human effect CAS Formula Chemical structure MW 
pKa  
(at 25ºC) 
35 Escitalopram Antidepressant drug 128196-01-0 C20H21FN2O 
 
324  
36 β-Estradiol Sex hormone 50-28-2 C18H20O2 
 
272 10.5 
37 Estrone Estrogenic hormone 53-16-7 C18H22O2 
 
270 
10.8 
 
38 
17α-Ethinyl-
estradiol 
Oral contraceptive 57-63-6 C18H24O2 
 
296 
4.0 
 
39 Etofenamate NSAID 30544-47-9 C18H18F3NO4 
 
369 _ 
40 Fluoxetine Antidepressant drug 54910-89-3 C17H18F3NO 
 
345 8.7-9.87 
41 Fluticasone 
Glucocorticosteroid 
(asthma) 
90566-53-3 
 
C25H31F3O5S 
 
444.5  
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Table 2.3 - (cont.) Human effect, chemical structure, and chemical proprieties of the pharmaceuticals 
studied. 
 
 
 
 
N. Compound Human effect CAS Formula Chemical structure MW 
pKa  
(at 25ºC) 
42 Glibenclamide 
Diabetes type II 
treatment 
10238-21-8 
C23H28ClN3O5
S 
 
494  
43 Hydroxyzine 
Antihistamine, 
Antiemetic,  
Anxiolytic 
68-88-2 C21H27ClN2O2 
 
448 
2.1 and 
7.1 
44 Indapamide 
Diuretic 
(hypertension) 
26807-65-8 
C16H16ClN3O3
S 
 
365 8.8 
45 Latanoprost 
Ocular 
hypertension, 
Glaucoma 
130209-82-4 C26H40O5 
 
434  
46 Lorazepam Anxiolytic 846-49-1 
C15H10Cl2N2O
2 
 
321 1.3 
47 Nifedipine Calcium blocker 21829-25-4 C13H12N2O5S 
 
346  
48 Nimesulide 
NSAID, 
Analgesic, 
Antipyretic 
51803-78-2 C13H12N2O5S 
 
308 
6.5 
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Table 2.3 - (cont.) Human effect, chemical structure, and chemical proprieties of the pharmaceuticals 
studied. 
 
NSAID - Non-steroidal anti-inflammatory drug;  
 
 
 
N. Compound Human effect CAS Formula Chemical structure MW 
pKa  
(at 25ºC) 
49 Omeprazol 
Proton pump 
inhibitor - ulcer 
73590-58-6 C17H19N3O3S 
 
345 
 8.8 
 
50 Oxazepam Anxiolytic 604-75-1 C15H11ClN2O2 
 
286.7 
1.7 and 
11.6 
51 Paracetamol Analgesic 103-90-2 C8H9NO2 
 
151 9.7 
52 Paroxetine 
Antidepressant, 
anxiety, 
compulsive 
disorders 
61869-08-7 C19H20FNO3 
 
375 9.9-10.3 
53 
Phenazone 
(antipyrine) 
NSAID, 
Analgesic, 
Antipyretic 
60-80-0 C11H12N2O 
 
188 5.0 
54 Piroxicam 
NSAID, 
Analgesic, 
Arthritis, 
Neoplasias 
36322-90-4 C15H13N3O4S 
 
331 
5.1 and 
2.3 
 
55 Progesterone 
Contraceptive,  
C-21 steroid 
hormone 
57-83-0 C21H30O2 
 
314  
56 Propranolol β-Blocker 525-66-6 C16H21NO2 
 
259 
9.4 
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Table 2.3 - (cont.) Human effect, chemical structure, and chemical proprieties of the pharmaceuticals 
studied. 
 
 
 
N. Compound Human effect CAS Formula Chemical structure MW 
pKa  
(at 25ºC) 
57 Ramipril 
Congestive heart 
failure 
87333-19-5 C23H32N2O5 
 
416.5  
58 Ranitidine 
Histamine H2 
receptor 
antagonist, peptic 
ulcer disease 
66357-35-5 C13H22N4O3S 
 
350 
8.2 and 
2.7 
 
59 Reserpine 
Antiadrenergic 
agent 
50-55-5 C33H40N2O9 
 
609 
6.6 
 
60 Salbutamol 
β2-Adrenergic 
receptor 
antagonist 
(asthma) 
35763-26-9 
 
C13H21NO3 
 
239 
9.3 and 
10.0 
 
61 
Salicylic 
acid 
Antiseptic 69-72-7 C7H6O3 
 
138 3.3 
62 Sertraline Antidepressant 
79617-96-2 
 
C17H17Cl2N 
 
343  
63 Tramadol 
Opiod-centrally 
action 
27203-92-5 
 
C16H25NO2 
 
300 
9.4 
 
64 Warfarin Anticoagulant 
81-81-2 
 
C19H18O4 
 
308 5.1 
65 Zolpidem 
Insomnia 
treatment 
82626-48-0 C19H21N3O 
 
307.4  
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The liquid chromatography coupled with mass spectrometry (LC-MS), liquid 
chromatography tandem mass spectrometry (LC-MS/MS) and liquid chromatography 
with diode array detector and coupled with mass spectrometry (LC-DAD-MS) with MS 
in electrospray (ESI) or atmospheric pressure chemical ionization (APCI) in positive or 
negative mode are the analytical techniques most adequate for the identification and 
quantification of PhACs in wastewater since most of the compounds present neutral and 
acidic polar characteristics (Ternes et al., 2004). The spectroscopic proprieties such as the 
most characteristic absorbance wavelength obtained in the Diode Array Detector (DAD) 
and mass spectrum (MS) proprieties obtained by direct injection on the MS system in 
ESI+ is described in Table 2.4.  
 
Table 2.4 - Pharmaceutical active compounds analysed by LC-DAD-MS: analytical data. 
 
Compound Human effect CAS tr  (min) 
Wavelength 
(nm)
1
 MW m/z (ESI+) 
Acetylsalicylic 
acid 
Analgesic 50-78-2 14.14 236, 302 180 136 
Ampicillin β-Lactamic antibiotic 69-53-4 16.34 242, 352 349 350, 106, 191, 
160, 175 
Amoxicillin β-Lactamic antibiotic 26787-78-0 3.07 273 365 106, 366, 367, 
245, 142 
Captopril Antihypertensive 62571-86-2 20.87 220, 261 217 218, 115 
Ciprofloxacin Antibiotic 85721-33-1 8.65 220, 280 331 244, 115, 136, 
227, 301, 332 
Clofibric acid Lipid modifying 
agent 
882-09-7 19.60 197, 224, 
277 
243 244, 123, 197 
Diclofenac NSAID 15307-86-5 18.78 220, 277 318 111, 91, 
130,319, 232, 
250, 269 
Enalapril 
maleate 
Antihypertensive 77549-59-8 13.68 220, 258 376 175, 181, 376, 
377, 339 
Fentiazac NSAID 18046-21-4 21.95 210, 320, 
245 
330 331 
Flurbiprofen NSAID 5104-49-4 18.12 245 244 240, 245, 152, 
193 
Furosemide Loop diuretic 54-31-9 14.64 274, 344 331 91, 329, 332, 
137, 209, 285 
Ibuprofen NSAID 15687-27-1 21.91 234, 264, 
272 
206 140, 184, 53, 
192, 207, 89 
Indomethacin NSAID 53-86-1 18.81 221, 230, 
318 
444 75, 349, 125, 
355, 445 
Ketoprofen NSAID, analgesic 
and antipyretic 
22071-15-4 16.31 254, 244 254 255, 240, 231 
Naproxen NSAID 22204-53-1 16.70 272, 281 230 231, 109, 137, 
169 
NSAID - Non-steroidal anti-inflammatory drug; SAID - Steroidal anti-inflammatory drug 
1 
Underlined wavelength used for 
quantification 
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Table 2.4 - (cont.) Pharmaceutical active compounds analysed by LC-DAD-MS: analytical data. 
 
Compound Human effect CAS tr  (min) 
Wavelength 
(nm)
1
  MW m/z (ESI+) 
Meclofenamic 
acid 
Internal Standard 644-62-2 20.84 242, 276, 
336 
296 126, 106, 193, 
250, 259, 214 
Allopurinol Gout treatment 315-30-0 2.71 249 136 170, 137, 113 
Alprazolam Anxiolytic; 
Tranquilizer 
28981-97-7 17.40 233 309 310 
Atenolol Antihypertensive 29122-68-7 3.07 240, 274 266 267, 121, 104, 
178, 186 
Azithromycin Macrolide antibiotic 83905-01-5 25.84 279, 367 749 750, 420, 570, 
270 
Betamethasone Corticosteroid 
(SAID) 
378-44-9 14.07 286 392 113, 157, 178, 
393 
Bromazepam Anxiolytic; 
Tranquilizer 
1812-30-2 17.37 237,310, 
370 
316 216, 231, 303 
Budesonide Corticosteroid  
(asthma) 
51333-22-3 16.77 245 430 330, 431, 266 
Caffeine CSN Stimulant 58-08-2 6.07 220, 267, 
273 
194 126, 143, 212, 
218, 195 
Carbamazepine Antiepileptic 298-46-4 13.95 220, 285 236 137, 109, 209, 
237 
Clorazepate Anxiolytic; 
tranquilizer 
57109-90-7 14.47 238, 320 409 365, 299, 316 
Codeine Analgesic 76-57-3 14.42 210, 270 299 300 
Diazepam Anxiolytic; 
tranquilizer 
439-14-5 19.07 243, 312 285 286 
Digoxin Cardiac glycoside 20830-75-5 
 
12.18 240 781 360, 116, 190, 
397, 316, 779, 
782 
Diltiazem Hypertension, 
calcium blocker 
42399-41-7 12.32 240 451 452, 204, 248, 
325, 420, 443 
Dimethylamino-
phenazone 
Analgesic, anti-
inflammatory, 
antipyretic 
58-15-1 3.67 237, 259 231 232 
Domperidone Antidopaminergic 57808-66-9 11.25 285 425 104, 106, 145, 
426 
β-Etradiol (E2) Sex hormone 50-28-2 15.47 224, 281 272 272 
Estrone (E1) Estrogenic hormone 53-16-7 17.53 240, 281 270 158, 262, 263, 
177, 271 
17α-Ethinyl-
estradiol (EE2) 
Oral contraceptive 57-63-6 17.01 281 296 106, 145, 297 
Etofenamate NSAID 30544-47-9 21.47 238, 297 369 216, 231 
Fluoxetine Antidepressant drug 54910-89-3 13.21 276, 264 345 137, 91, 281,  
Fluticasone Glucocorticosteroid 
(asthma) 
80474-14-2 19.88 240, 254 501 104, 129, 147, 
193, 197, 478, 
500, 502 
NSAID - Non-steroidal anti-inflammatory drug; SAID - Steroidal anti-inflammatory drug; 
1 
Underlined wavelength  used 
for quantification 
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Table 2.4 - (cont.) Pharmaceutical active compounds analysed by LC-DAD-MS: analytical data. 
 
Compound Human effect CAS tr  (min) 
Wavelength 
(nm)
1
  MW m/z (ESI+) 
Glibenclamide Diabetes type II 
treatment 
10238-21-8 18.47 233, 301 494 495, 369 
Hydroxyzine Antihistamine, 
antiemetic, anxiolytic 
68-88-2 12.61 233, 240 448 356, 256, 449 
Indapamide Diuretic 
(hypertension) 
26807-65-8 14.98 242 365 167, 126, 235, 
270, 317, 366 
Latanoprost Ocular hypertension, 
glaucoma 
130209-82-4 3.84 366, 383 434 435, 437, 220, 
263, 267, 294, 
382, 351 
Lorazepam Anxiolytic 846-49-1 17.08 232, 317 321 217, 231, 261 
Nifedipine Calcium blocker 21829-25-4 16.87 281, 314 346 329, 104, 145, 
186, 188, 284, 
315, 347 
Nimesulide NSAID, analgesic, 
antipyretic 
51803-78-2 17.97 301 308 307, 309, 229 
Omeprazol Proton pump 
inhibitor (Peptic 
ulcer disease) 
73590-58-6 11.12 302 345 125, 108, 128, 
346, 335, 271 
Oxazepam Anxiolytic 604-75-1 16.82 241, 330, 
230 
287 269, 288 
Paracetamol Analgesic 103-90-2 4.77 243 151 137, 152 
Paroxetine Antidepressant, 
anxiety, compulsive 
disorders  
61869-08-7 12.66 243, 265, 
297 
375 161, 376, 249 
Phenazone 
(antipyrine) 
NSAID, analgesic, 
antipyretic 
60-80-0 9.64 220, 242 188 96, 90, 159, 168, 
171, 136, 189 
Piroxicam NSAID, analgesic, 
arthritis, neoplasias 
36322-90-4 15.45 243, 344 331 91, 332, 137, 
152, 266 
Progesterone Contraceptive 57-83-0 12.32 240 315 316, 144, 193 
Propranolol β-Blocker 525-66-6 11.50 238, 292, 
320 
259 260, 276, 248, 
255 
Ramipril Congestive heart 
failure 
87333-19-5 19.43 255 417 418, 197, 113 
Ranitidine Histamine H2 
receptor antagonist, 
peptic ulcer disease 
66357-35-5 3.11 228, 316 350 351, 118, 137, 
208, 227 
Reserpine Antiadrenergic agent 50-55-5 12.97 219, 268 609 - 
Salbutamol β2-Adrenergic 
receptor antagonist 
(asthma) 
35763-26-9 
 
3.04 240, 277 239 103, 187, 240, 
146, 164 
Sertraline Antidepressant 79617-96-2 
 
3.67 267, 259 343 253, 166, 191, 
203, 334, 344 
Tramadol Opioid-centrally 
action  
27203-92-5 9.58 272, 370 300 208, 301, 178, 
107, 150, 165 
Warfarin Anticoagulant 81-81-2 
 
17.65 220,281, 
306 
308 117, 309, 92, 
204 
NSAID - Non-steroidal anti-inflammatory drug; SAID - Steroidal anti-inflammatory drug; 
1 
Underlined wavelength  used 
for quantification 
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2.2.2 Musks 
 
The most used technique for the determination of the polycyclic musk fragrances (PMF) 
in wastewater and sludge samples of the WWTP is the headspace solid-phase micro 
extraction (SPME), followed by GC-MS analysis (Llompart et al., 2003 and Ternes et al., 
2005). Due to their elevated lipophilicity (logKow = 5.90-6.35), PMF are, therefore, sorbed 
onto sludge and suspended matter. In literature, analytical methods are reported for 
analyzing polycyclic musk fragrances (PMF) in sewage sludge using soxhlet or 
pressurized liquid extraction (PLE) with dichloromethane, silica gel, alumina columns 
and gel permeation chromatography (GPC) as clean-up methodology previous to GC-MS 
analysis (Ternes et al., 2004). In all the cases, several clean-up steps must be applied to 
the extracts before chromatographic analysis. The SPME is a solventless technique that 
simplifies the long and tedious processes of sample preparation and analyte extraction in 
a single step. Concentration levels for example for galaxolide and tonalide in municipal 
sludge have been reported to be in the range of 0.27 to 162 ng g
-1
 (Ternes et al., 2003).  
Table 2.5 shows the analytical data of the most important musks. The SPME technique is 
a very sensitive technique that can be applied to adsorb the volatile and non-polar 
compounds released from the aqueous or solid phase to the headspace completely isolated 
where a fiber of an adsorbable material or can be immerged in the liquid sample to extract 
selectively the target compounds (Ternes et al., 2003; Carballa et al., 2004; Carpinteiro et 
al., 2004). The fibers can be of polyacrilate (PA), polydimethylsiloxane (PDMS), 
divinylbenbenzene (DVB), PDMS/DVB and carboxen-PDMS (CAR-PDMS) and 
carbowax-DVB (CW-DVB), carboxen-PDMS-DVB (PDMS-DVB-CAR) and they are 
selected according to the characteristics of the compound that need to be extracted. For 
the musks, Carballa et al., (2004) used PDMS/DVB for the determination galaxolide and 
tonalide in WWTP as well as Ternes et al., 2004. The head space technique is more used 
than the immerged fiber in the liquid phase due to the matrix characteristic of some 
samples that are inappropriate for the submerged fiber. 
Sludge is a very complex sample and the extraction of the organic pollutants from the 
matrix usually implies solvent extraction of the dried sludge samples assisted by 
accelerated solvent extraction, sonication, microwave heating, solid phase extraction 
(SPE), simple agitation or solid phase micro extraction (SPME). Llompart et al., 2003 
studied the determination of musk compounds in sewage treatment plant sludge samples 
by SPME with different fibers for the determination of musks in sewage treatment plants 
sludge samples. The influence of extraction temperature, fiber coating, agitation, pH and 
salting out on the efficiency of the extraction along with the extraction kinetics was 
studied by Llompart in 2003. An extraction temperature of 100 ºC and sampling the 
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headspace over the stirred sludge sample using PDMS/DVB as fiber coating lead to best 
effective extraction of the musks in general. The method proposed was very simple and 
yields high sensitivity, good linearity and repeatability for all the analytes with limits of 
detection at the ng g
-1
 level. The total analysis time, including extraction and GC analysis, 
was only 40 min, and no manipulation of the sample was required (Llompart et al., 
2003).The GC-MS with MS in electronic impact (EI) mode analytical technique was the 
most appropriate for the identification and quantification of the polycyclic musk 
fragrances (PMF), Table 2.5.  
 
Table 2.5 - Musks analysed by GC-MS: analytical data. 
 
Compound 
 
Application 
 
CAS tr  (min) MW m/z (EI)
1
 
Cashmeran 
(DPMI) 
Health care product 33704-61-9 18.14 206 191, 135, 206 
Celestolide 
(ADBI) 
Health care product 13171-00-1 20.80 244 244, 229, 244 
Galaxolide 
(HHCB) 
Health care product 1222-05-5 22.41 258 243, 213, 258 
Phantolide 
(AHMI) 
Health care product 15323-35-0 21.34 244 229, 244, 115, 128 
Tonalide 
(AHTN) 
Health care product 1506-02-1 22.59 258 243, 159, 258 
Traseolide 
(AITI) 
Health care product 68140-48-7 21.88 258 215, 115, 128, 
141, 258 
Mirex 
 
Internal Standard 2385-85-5 30.18 546 272, 237, 119 
1) Underlined m/z was used for quantification 
 
 
2.2.3 Metabolites and reaction products 
 
The GC-MS, LC-DAD-MS and LC-MS/MS techniques are the most important techniques 
used for metabolite or reaction products identification (Agüera et al., 2005; Kosjek et al., 
2011). Because of their selectivity and sensitivity, they are the most powerful methods for 
metabolite identification. Even when a definitive assignment of chemical structures is not 
possible and, therefore, only tentative degradation pathways can be proposed, GC-MS is 
so far the most frequently used tool of analysis for identifying transformation products 
(Winckler et al., 2001, Marco-Urrea et al., 2009). Winckler and Marco-Urrea used GC-
MS for study the ibuprofen metabolites generated by biodegradation processes. Two 
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important advantages of GC-MS methods are the large amount of structural information 
they yield by the full scan mass spectra obtained under electronic impact (EI) ionization 
and the possibility of using commercial libraries, making identification of unknowns 
feasible. However GC-MS has important drawbacks because of its scan capability for 
analyzing the very polar, less volatile compounds typically generated by these photo-
processes (Ternes et al., 2011). Because of this limitation derivatization techniques 
should be considered for protection of the polar group by the chemical reaction for a 
specific period and temperature conditions to get a non-polar derivatized compound that 
is more compatible with the GC-MS analysis. Many compounds can be used as 
derivatized reagents to give this protection to the molecule (e.g. MSTFA (N-methyl-N-
trimethylsilyltrifluoroacetamide), BSTFA (N,O-bis(trimethylsilyl)-trifluoracetamide), 
TMS (Trimethylsulfonium hydroxide solution) and MTBSTFA (N-tert-
Butyldimethylsilyl-N-methyl)trifluoracetamide) depending on the chemical structure of 
the original compound to derivatize (De Witte et al., 2011).  
De Witte et al. (2011) found that the analysis of degradation products is a highly 
challenging task. First, the chemical structure of intermediates is unknown, although it 
can be assumed that primary degradation products are structurally related to the parent 
pharmaceuticals. Second, standard material for structure elucidation is seldom available. 
Third, degradation products are present at low concentrations. 
 
Therefore, advanced and extended identification methodologies are needed for full 
structural elucidation of pharmaceutical AOP degradation products. Samples are typically 
separated by LC or GC, and either directly injected or pre-concentrated by SPE, 
lyophilization, evaporation, solvent extraction (e.g. liquid–liquid extraction), or SPME 
(Ternes et al., 2003 and Carballa et al., 2004). Many chromatographic techniques can be 
applied for product isolation prior to nuclear magnetic resonance (NMR) (Yi et al., 2007, 
Marco-Urrea et al., 2009). During GC or LC separation, degradation product retention 
times may provide the first source of identification information. One major point of 
attention during GC analysis is the thermal stability of pharmaceutical degradation 
products. High GC-inlet temperatures can decompose thermal labile compounds. They 
may be used to estimate the polarity and volatility of the degradation products and can be 
compared, if available, with the standards. For a more accurate identification, degradation 
product spectral data have to be collected by use of dedicated detection instruments such 
as UV spectroscopy or mass spectrometry (MS) (Kosjek et al., 2010). When standard 
compounds are available, LC-UV or GC-MS spectral data of the unknown degradation 
products are compared with those of standard compounds. GC-MS also allows spectra 
comparison with extended databases (e.g., from NIST or Wiley). However, in the 
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majority of cases, standards or databases are not available and data on molecular weight, 
elemental composition, and chemical structure have to be collected by GC-MS, LC-MS, 
high resolution (HR)-MS, or multidimensional MS (MS
n
). Analysis of the parent 
compound molecule and analogous products as well as isotope labeling strengthens 
identification. Next to these hyphenated techniques,  direct UV photodetection, direct 
infusion  (DI)-MS, and nuclear magnetic resonance (NMR) analysis (Yi et al., 2007) may 
provide supplementary data to complement the chromatographic separation. 
The MS analysis of the sample is frequently one of the most used techniques for AOP 
degradation product identification and also for the biotransformation products of PhACs 
studies without analysis of standards, parent molecules, or analogous products. This is 
possible since the structure of the parent molecule is also known. Another possibility can 
be as suggested by Doll and Frimmel (2003), where they made clear distinction between 
unequivocally identified pharmaceutical AOP degradation products, based on comparison 
of LC retention time and UV spectrum with standards, and tentatively identified 
degradation products, based on LC-MS fragmentation analysis with comparison with 
standards. The proposed techniques can be applied for a wide range of degradation 
products, i.e., biodegradation and photodegradation products from pharmaceuticals, as 
well as degradation products from other micro pollutants such as musks. Although 
standard compounds and GC-MS spectra may be readily obtained for transformation 
products resulting from AOP treatment or biotransformation metabolites of widely 
variable PhAC chemical structures and musks studied, these resources are frequently 
unavailable commercially to confirm the chemical structures for many other 
pharmaceuticals and some of this standards need to be synthesized in laboratory.  
Chromatographic separation by GC or LC is an indispensable part of the analytical 
procedure when multi residue analysis is the focus. The choice between both 
chromatographic techniques is especially based on the polarity and thermal stability of 
the target compound.  
Another option to confirm the product and metabolite chemical structures is the use of 
combining the information of LC-DAD-MS and LC-MS/MS. This is a technique suitable 
for analytes with a wider range of polarities, and has been shown to be a powerful tool for 
the identification of by-products and unknown compounds in samples of many advanced 
oxidation studies (Razavi et al., 2009, Yuan et al., 2009, Kosjek et al., 2011). Razavi et 
al., (2009) studied the fibrate pharmaceuticals degradation by free radicals induced 
oxidative by pulse radiolysis; Yuan et al., (2009) the photodegradation of antibiotics in 
UV and UV/H2O2 and Kosjek et al., (2011) the phototransformatition products of 
ketoprofen. Agüera et al., (2005) studied the phototransformation of diclofenac, a non-
steroidal anti-inflammatory drug (NSAID) commonly used as an analgesic, antiarthritic 
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and antirheumatic by the use of the technique LC-(ESI+)MS/MS. The presence of 
diclofenac has been reported in natural waters and in wastewater treatment plant effluents 
as a consequence of its incomplete elimination with conventional wastewater treatment 
(Xue et al., 2010, Jélic et al., 2011). Xue et al., (2010) and Jélic et al., (2011) also found 
low diclofenac biodegradation and high effluent concentrations. Nakada et al. (2005) 
found high removal efficiencies for ibuprofen in the WWTP varying from 84-98% for 
influent concentrations of 69-1080 ng L
-1
. Direct photolysis can produce photo 
transformation products that are commonly analyzed by GC-MS, LC-MS and LC-MS/MS 
techniques combined in order to get confidence in the chemical structures produced 
during the process. 
LC-MS and LC-MS/MS allow the separation of semi-polar and polar degradation 
products without extensive derivatization. Moreover, aqueous samples can be directly 
injected when concentrations of intermediates are high compared to the instrument 
detection limit. Therefore, LC-MS and LC-MS/MS is also frequently applied than GC for 
analysis of pharmaceutical intermediates formed by AOPs (Razavi et al., 2009, Yuan et 
al., 2009, Kosjek et al., 2011) but it always depend of the nature compounds used in the 
studies. The retention time of the degradation products can provide information on 
degradation product polarity. This is a tool for product identification in addition to 
stronger identification methods.  
 
Kosjek et al. (2011) also agree that mass spectrometry (MS) is considered a principal tool 
for identifying new products of AOP, especially since it enables an efficient analysis of 
trace amounts of analytes in complex organic mixtures. Such complicated environmental 
or biological samples require separation of components prior to mass spectrometric 
analysis, which justifies the use of hyphenated techniques such as GC-MS or LC-MS. 
The single-stage quadrupole (Q) and an ion trap (IT) both hyphenated to a GC, and a 
quadrupole-time-of-flight (QTOF) MS coupled to an LC can also be used. In the Q mass 
analyzer, the ions generated in the source undergo electron impact (EI) fragmentation, 
which results in complex, ambiguous spectral data and hence in non-selectivity that is its 
main disadvantage (Kosjek et al., 2011). In contrast, the IT mass detector has the unique 
ability to isolate and to accumulate ions. By iterating ion trapping and scanning, it allows 
the generation of collision-induced dissociation (CID) spectra of the parent and fragment 
ions (and their fragment ions), thus increasing the level of confidence in assigning a 
particular structure (Kosjek et al., 2011). Alternatively, the hybrid QTOF, in which the 
final resolving mass filter of a triple Q is replaced by a TOF analyzer, not only allows 
MS
2
 operation but also has the necessary accuracy and resolution to give exact-mass 
measurements (Kallio et al., 2010, Yuan et al., 2011, Kosjek et al., 2011). Together with 
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MS methods, both chromatographic techniques complement each other to account for a 
wide range of polarity, acidic-basic characteristics and different functional groups formed 
during UV degradation or other oxidation techniques. LC-MS methods can also be used 
for the identification of metabolites produced by organisms like diclofenac in fish bile 
with electrospray ionization quadrupole-time-of-light mass analyser (QTOF) (Kallio et 
al., 2010).  
Kosjek et al., (2009) studied the metabolism of diclofenac and clofibric acid in activated 
sludge bioreactors. The biodegradation of clofibric acid revealed one metabolite in the 
ESI(-)-QTOF chromatogram, 4-chlorophenol, which is known to exhibit a higher toxicity 
than the parent compound. This study confirms that further research is needed on the 
formation of stable metabolites both during wastewater treatment and in the environment. 
It also highlights the need for parallel toxicity testing. In addition, this study suggests that 
more needs to be known about the environmental fate of pharmaceuticals so that we are 
able to provide a comprehensive risk assessment. 
Winckler et al., (2001) studied the degradation of ibuprofen and clofibric acid in river 
biofilm systems and identified two ibuprofen metabolites by GC-MS.  
The combined use of both GC-MS and LC-MS analysis for detection of pharmaceutical 
AOP degradation products targets two different purposes: (a) increasing the range of 
detectable degradation products or (b) confirmation of suggested degradation products. 
A large range of degradation products was detected by Pérez-Estrada et al. (2005), who 
used GC-MS for detection of non-polar degradation products and LC-MS for semi-polar 
and polar degradation products during advanced oxidation of diclofenac and dipyrone. 
The second strategy was applied by Huber et al., (2005) combining LC-MS, GC-MS, and 
GC-MS/MS analysis for identification of one of the carbamazepine ozonation products. 
For GC-MS confirmation of a large range of intermediates, whose identity was first 
suggested by LC-MS analysis, it was necessary to decrease degradation product polarity 
by derivatization, leading to increased complexity of the analysis. In this way, Huber et 
al., (2005) identified 17α-ethinylestradiol (EE2) ozonation products. 
 
The improvement of analytical methods confirms that for the majority of the organic trace 
contaminants, microbial degradation does not lead to mineralization but rather to the 
formation of a multitude of transformation products (Quintana et al., 2005; Kosjek et al., 
2009; Kern et al., 2010; Radjenovic et al., 2009). In order to evaluate whether an organic 
contaminant was transformed to non-toxic products or even mineralized, it is important to 
know the transformation pathways. Modern hybrid mass spectrometry systems provide 
the accurate masses of the new products and deliver information of mass fragments which 
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can be used to identify the chemical structure. However, with the exception of very 
simple reactions (e.g. hydrolysis of amides and esters) the MS spectra are often not 
sufficient to obtain and confirm the chemical structures of the transformation products 
(Ternes et al., 2011). In general, there are a couple of structural modifications which lead 
to products with the same accurate masses and similar mass fragments of the parent 
compound. Without the knowledge of chemical/microbial reactions and/or measurements 
with alternative methods, the suggested product chemical structure could be incorrect. 
One possible solution for structural confirmation of the transformation products is nuclear 
magnetic resonance spectroscopy (NMR). However, a drawback of NMR is the elevated 
quantity needed of a relatively pure isolated standard, not very easy to achieve for the low 
concentrations used in the lab-scale reactors and it is still a challenge. 
Only a few studies have investigated the biological transformation of emerging organic 
micro pollutants in contact to activated sludge at aerobic conditions and even less at 
anoxic or anaerobic conditions (Ternes et al., 2011). So far, the following enzyme-
catalyzed reactions turned out to be quite commonly involved in the transformation of 
emerging organic micro pollutants: mono- and dihydroxylation, alcohol and aldehyde 
oxidation, ester and amide hydrolysis, N-dealkylation and decarboxylation. Even though 
these basic reactions are known to be catalyzed by many different ubiquitous and 
constitutive enzymes with wide substrate specificity, certain structural differences can 
discriminate between alternate transformation pathways (Ternes et al., 2011).  
 
2.3 Variability and removal mechanisms of PhACs and musks in full scale WWTP 
 
Since PhACs and musks were first detected in water and treated wastewater in the 1990s, 
there have been vast developments in analytical methods and the application of these 
methods. The many chemical structures of PhACs and musks make it difficult to 
understand the behavior of these compounds in the biological treatment process of the 
WWTP. The PhACs have been investigated in WWTP for identification and 
quantification and also to determine the biodegradation removal in WWTP (Joss et al., 
2005; Göbel et al., 2005; Clara et al., 2005a). Many studies have been conducted in order 
to investigate the occurrence and fate of the PhACs and musk fragrances in WWTP (Joss 
et al., 2005, Göbel et al., 2005; Santos et al., 2009; Plósz et al., 2010). The fate of PhACs 
and musks (Joss et al., 2005; Carballa et al., 2007; Clara et al., 2010) and quantification 
of concentrations in full scale pollutant and fluxes based on samples from sewers were 
also investigated. 
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Ort et al., (2010a) studied the sampling strategies of PPCPs in WWTP by establishing 
different sampling methods, mainly the high frequency of grab samples and different 
composite sample modes. Distinct toilet flushes and wastewater packets from household 
expected to have high variable PPCP patterns in the sewers. The relatively long sampling 
intervals may also not be suitable to representatively sample for PPCPs in sewers given 
the unknown and potentially high short-term concentration variations according to Ort et 
al., (2010). The influent wastewater at WWTP seems to be a continuous stream, but 
actually it is composed of a number of variable discharged, individual wastewater from 
household, industries, or in the sewer systems. The resulting heterogeneity can cause 
significant short-term variations of pollutant loads. The sampling intervals of 5 min or 
shorter may be required to properly account for temporal PPCP variations in influents of 
WWTP according to Ort et al., 2010a, however this small sampling interval is not 
feasible in practical to the engineers to monitor micro pollutants in the plants and other 
studies should be performed in order better understand the behavior of the variability of 
PhAC and musk in the WWTP influent. Representative samples are important for 
providing meaningful analytical results and the number of samples should be adequate to 
get accuracy of the chemical analysis and to apply adequate statistical methods.   
 
Clara et al., (2011) studied the occurrence of polycyclic musk (galaxolide, tonalide, 
cashmeran, traseolide, celestolide and phantolide) in wastewaters (influent, effluent and 
sludges), surface waters discharged from the plant and sediments. The major musks 
detected include the galaxolide, tonalide and cashmeran. These compounds were mostly 
detected on the excess in the concentration ranges of 400-2650 and 4200-21000 gkg
-1
 
dry matter for tonalide and galaxolide respectively, and digested sludge in the 
concentration ranges of 1100 to 2900 and 8500 to 20000 gkg
-1
 dry matter for tonalide 
and galaxolide respectively. Tonalide and galaxolide were also detected in the wastewater 
effluents in the ranges <0.38 to <0.50 and <0.80 to 1.1 gL
-1
 respectively. 
Göbel et al., (2005) studied the occurrence of some antibiotics (sulfonamides, macrolides 
and trimethoprim) in WWTP by collecting different samples at influent, effluent and 
secondary and digested sludge using flow proportional composite samples over 24h. With 
this study, authors wanted to evaluate the occurrence of these compounds in the different 
parts of the plant and find that sorption of these compounds was not significant and the 
elimination by the plant was incomplete. 
 
The design of conventional WWTPs is not optimized to remove micro pollutants but the 
technology used to remove carbon, nitrogen and phosphorus used nowadays in the plant, 
can effectively improve the elimination of micro pollutants by means of sorption, 
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biotransformation, volatilization, and/or stripping (e.g., Ternes, 1998; Nakada et al., 
2006; Plósz et al., 2010). In the most commonly used activated sludge technologies, 
biotransformation is important but insufficient to remove hormones and antibiotics 
(Carballa et al., 2004). To increase the selection of bacteria capable of oxidizing micro 
pollutants in WWTPs, Clara et al. (2005b) show that values of the operating solids 
retention time (SRT), should be selected higher than 10 days, calculated to a reference 
liquid temperature of 10 °C. In the conventional systems, the recommended minimum 
SRT value corresponds to the requirements of meeting the effluent ammonia criteria by 
effectively retaining autotrophic nitrifying bacteria populations in activated sludge (Clara 
et al., 2005b). Biodegradation rates for hormones and antibiotics can vary under aerobic 
and anoxic conditions, prevailing in most activated sludge systems, and the impacts of 
redox conditions on the overall biotransformation efficiency can be significant for most 
estrogens and antibiotics compounds (Plósz et al., 2010a and b).  
 Joss et al., (2005) studied the removal of PhACs and musks (galaxolide and tonalide) in 
biological wastewater treatment and conclude that the main removal mechanisms of the 
WWTP for the musks was the sorption to the sludges and for the PhAC was the 
biological for sludge ages between 10 and 60-80 days however the variability found in 
the removal was not completely explained. The influent samples were collected within 
the mixing of primary clarifier with sampling frequency < 60 min enough to assess the 
influent loads. The importance of getting representative 24 h samples was also considered 
in his study. Some of these compounds are not completely degraded by the conventional 
activated sludge process and when the wastewater is subjected to UV radiation for 
disinfection purposes, they are also not completely removed.  
The enhanced tertiary treatment processes, such as, ozonation (Ternes et al., 2003), UV 
radiation (Vogna et al., 2004a and b; Nakada et al., 2005, Kim et al., 2009), in 
combination with a biological treatment, can be a robust engineering solution to eliminate 
the residual micro pollutants derived from biological systems (Plósz et al., 2010b, Xue et 
al., 2010). Since intensive daily routine monitoring of micro-pollutants is not feasible in 
WWTPs, the implementation of an appropriate monitoring plan should be considered 
because the micro pollutant discharge can exhibit seasonal, weekly and diurnal variations. 
Sewers, including influents to WWTPs, exhibit often unique transport characteristics, 
highly dynamic flows, and variable pollutant loads. Preservation and laboratory specific 
measures to prevent and control contamination are very important to get confidence in the 
results obtaining when monitoring micro pollutants (Ort et al., 2010a). 
 
Several removal mechanisms have been reported in different studies in WWTP such as 
biodegradation or biotransformation (Joss et al., 2005), adsorption (Carballa et al., 2007), 
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volatilization (Tan et al., 2007) and oxidation (Ternes et al., 2003, Nakkada et al., 2005) 
in disinfection systems for PhACs and musks. In most of the cases, incomplete removal is 
observed for the PhACs and musks. Another important point in monitoring these kinds of 
compounds is the sampling point selection and the monitoring strategies. Strategies for 
monitoring PhACs and musks have been developed by many authors (Joss et al., 2005; 
Göbel et al., 2005, Ort et al., 2010a and b, Plósz et al., 2010) in order to try to establish 
sampling frequencies and preservation techniques to get confidence in the results 
expected in the ranges of ng L
-1
 or µg L
-1
.  
In many cases, the influence of the variability of the occurrence of PhACs and musks in 
the influent of the WWTP have been studied and in other cases mass balances have been 
carried out to predict the impact of the discharges of the effluent treated wastewater in the 
environment (Joss et al., 2005, Göbel et al., 2005, Carballa et al., 2007, Weissbrodt et al., 
2009). Göbel et al., (2005) also perform mass balances to the antimicrobials 
(sulfamethoxazole, trimethoprim and clarithromycin) including primary, secondary 
(conventional activated sludge process) and tertiary (sand filtration) treatment and also 
the digestion. In this study, no completely removal was obtained even with the tertiary 
treatment and also an important fraction of this antimicrobials was removed by sorption 
to the sludges. More research is needed to extent the knowledge for other PhACs and 
musks in the WWTP that may be not completely removed after the tertiary treatment and 
optimization of this treatment process with different technologies should be considered as 
well as the sorption to the sludge was not completely studies yet and more studies should 
be performed in order to understand the fate of PhACs and musks in the WWTP. To 
assess the occurrence and behavior of micro pollutants in sewage and treatment systems, 
optimal sampling time resolution and sampling sites need to be selected with some 
criteria. In sewer systems and in the WWTP, for the assessment of average micro 
pollutant load, in addition to an accurate flow meter, the substance's load pattern, the 
sampling frequency and the length of the composite sample are decisive (Ort and Gujer, 
2006). Many studies in monitoring full scale WWTP show that grab samples can only 
serve to obtain preliminary results in mostly screening studies. For calculating the loads 
or mass-fluxes in WWTPs, 24-hour composite sample collection is recommended (Ternes 
and Joss, 2006, Plósz et al., 2010a; Ort et al., 2010). 
 
2.4 Sampling of PhACs and musks in full scale WWTP 
 
Until now, there is no online instrumentation to analyze for PPCPs directly in sewers and 
the monitoring plan can be found similar to the norms and guidelines already used for 
45 
 
macro pollutants. Due to the high analytical costs per sample, 24 h composite samples are 
most commonly reported (75% of analyzed papers) (Ort et al., 2010a and b). 
There are also events in sewers and WWTPs that influence the pollutant concentrations. 
Some authors explicitly mention that samples were taken during dry weather conditions, 
knowing that rain can impact the occurrence and fate of pollutants, particularly in 
combined sewer systems. The sewer systems, toilet flushes and wastewater from other 
household contain the majority of the pharmaceutical load and can be considered 
sometimes as ―events‖. These events can lead to significant short-term variations in 
combined and separate sewers in the range of minutes. This integrated volume is 
sufficient to calculate the environmental pollutant flux from an average concentration in a 
sample after sampling. However, if flow variations occur within the sampling period, they 
must be taken into account during sampling to weight individual subsamples and obtain a 
representative 24 h composite sample (average concentration) (Ort et al., 2010a). 
 
The sampling frequency should not be reduced just because the storage capacity in the 
available sampling device is limited. This may lead to an inadequate sampling frequency 
and cannot be compensated for with a large number of samples, or a sophisticated 
analytical technique or statistical analysis. The time and money spent on chemical 
analysis and subsequent interpretation of data, it is counterproductive to attempt to save 
costs for sampling personnel and equipment. 
Ort et al., (2010a) suggests performing sampling campaigns over a number of 
consecutive days, rather than nonconsecutive days. The different sampling locations 
should consider the comparison of the WWTP influent and effluent (effect of hydraulic or 
sludge retention time) and WWTP influent (variable travel times in sewers) (Ort et al., 
2010a). In the case of WWTP, there is usually more freedom to choice the best location 
to collect the samples. The untreated raw wastewater can theoretically be collected only 
at the influent of a WWTP, it may, for many studies, also be opportune to take samples 
after the primary clarifier where concentration variations are expected to be attenuated. 
Depending on the layout and the hydraulic retention time longer sampling intervals 
should be considered for attenuation of the concentration variability. Some particulate 
matter is removed in the first treatment step and the concentrations of dissolved 
compounds are unlikely to be significantly affected. Filtration of samples before chemical 
analysis also removes particulate matter which is often not analyzed any further such as 
the case for the analysis of organic compounds dissolved in the wastewater. In the case of 
existing internal recirculation flow, entering before the effluent of the primary clarifier, it 
might need to be taken into account because it will affect the mass balances of influent 
loads, according to the Ort et al., (2010a) suggestions. 
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Municipal micro pollutants discharge can exhibit seasonal, weekly and diurnal variations 
(Plósz et al., 2010). To assess the occurrence and behavior of micro pollutants in WWTP, 
optimal sampling time resolution and sampling sites are recommended. To assess the 
daily variation in influent concentrations, 8 h composite samples of primary effluent 
though only during one day, and the data obtained was not proportional to flow (Joss et 
al., 2005, Plósz et al., 2010). Göbel et al. (2005) assessed diurnal variations in WWTP 
influent using three 8-hour flow-proportional composite samples obtained in one 
sampling day, and suggested that daily antimicrobials loads can correlate with the 
respective water flows and ammonium loads. The diurnal variations in the influent 
antimicrobial load can correlate with the theoretically expected distribution pattern 
influenced by the half-life in the human body and the typically prescribed oral 
administration pattern (Göbel et al., 2005). The results obtained by Göbel et al., (2005) 
illustrate a possible daily variance for antimicrobials where the flow proportional 
composite samples at least during 24 h is crucial to assess the fate and occurrence in 
WWTP. Mass balances are also an important tool used for many authors to predict 
impacts of the variability in the plants to help in management of the WWTP (Göbel et al., 
2005, Carballa et al., 2007; Weissbrodt et al., 2009).  
Carballa et al., (2007) perform mass balances with two different methods in the WWTP. 
The methodology applied in the mass balances can have implications in the results 
obtained. Combining the influent, effluent and sludge loads to get the mass balances to all 
plant, sometimes negative degradation results can be obtained for example for estrone and 
-estradiol (Carballa et al., 2007). Similar results were obtained by other authors (Göbel 
et al., 2005), but the reason for this is still unclear, even using 24 h composite sampling.  
 
2.5 Biodegradation and oxidation studies of PhACs 
 
2.5.1 Biodegradation studies 
 
Many other studies have been carried out with PhACs and musks in lab scale reactors in 
order to more easily understand some of the biological transformations of these 
compounds under controlled conditions. The transformation of this group of compounds 
can also generate higher toxicity compounds to the aquatic organisms in the environment. 
Different technologies have been applied in these studies like Sequencing Batch Reactors 
(SBR) (Evangelista et al., 2010; Marco-Urrea et al., 2010), Membrane Bioreactors 
(MBR) (Clara et al., 2005; Kimura et al., 2007), Biofilm reactors (Winckler et al., 2001; 
Zwiener et al., 2003), and continuous biological reactors (Yi et al., 2007; Kosjek et al., 
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2009). Marco-Urrea et al. (2010) studied the oxidation of atenolol, propranolol, 
carbamazepine and clofibric acid by white-rot fungus Trametes versicolor to evaluate the 
biodegradation of this PhAC and the metabolite formation. Evangelista et al., (2010) also 
studied the effect of secondary carbon sources (glucose) on the microbial degradation of 
chorophenoxy acids (e.g. clofibric acid) with different bacteria cultures. Other works 
reported the effect of nitrifier cultures on PhAC removal, 17α-ethinylestradiol (Yi et al., 
2007) and clofibric acid, diclofenac, carbamazepine and propyphenazone (Tran et al., 
2009). Almost all the lab-scale biological reactors studied the biodegradation kinetics and 
metabolites produced when the compounds are not completely biodegraded by varying 
the operational conditions (e.g. pH, type of carbon source, carbon source concentration, 
SRT, HRT, and temperature). 
Yi et al., (2007) studied the link between nitrification and biotransformation of 17 -
ethinylestradiol (EE2) using enriched cultures of autotrophic ammonia oxidizer bacteria 
(AOB). The degradation of EE2 was mainly by conjugation and hydroxylation of the ring 
of the chemical structure of steroid corresponding to the electrophilic initiator of the 
reaction. In this study a linear relationship between nitrification and EE2 removal in 
enriched nitrifying cultures was obtained. The EE2 biotransformation can be 
cometabolically mediated under operating conditions with enriched nitrifiers (Yi et al., 
2007). 
Tran et al., (2009) studied the degradation of PhAC (clofibric acid, diclofenac, 
carbamazepine and propyphenazone) by enriched nitrifier cultures. Results showed high 
degradation of ibuprofen and partial degradation of other selected pharmaceuticals in the 
presence of allylthiourea (ATU), an ammonia monooxygenase inhibitor, reflecting the 
activity of heterotrophic bacteria, while without ATU addition, the contribution of the 
nitrification was dominant. The results suggest that nitrification can enhance the 
biotransformation of pharmaceutical substances. The contribution of autotrophs and 
heterotrophs in the biotransformation of the pharmaceuticals by the enriched nitrifier 
culture was successfully estimated by the addition of inhibitors in this study. 
Furthermore, high removal was obtained for clofibric acid, diclofenac, ibuprofen, 
fenoprofen, carbamezaepine when organic substrate (e.g. acetate) was added. Clofibric 
acid, carbamazepine and propyphenazone did not exceed the 25% removal even in the 
presence of 100 ppm of acetate concentration.  
 
Evangelista et al., (2010) studied the effect of structure and a secondary carbon source 
(e.g. glucose) on the biodegradation of chorophenoxy acids (e.g. clofibric acid, 
methylchlorophenoxypropionic acid and 4-chloro-2-methylphenoxyacetic acid). The 
formation of metabolites was observed in the presence of different microbial cultures 
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such as Pseudomonas putida, Aspergillus niger, Bacillus subtilis, Pseudomonas 
fluorescens, Sphingomonas herbicidovorans and Rhodococcus rhodochrous. The 
metabolite, 4-chloro-2-methylphenol, was only identified in trace amounts for 
methylchlorophenoxypropionic acid and 4-chloro-2-methylphenoxyacetic acid 
degradation in the presence of S. herbicidovorans and glucose in Evangelista´s study in 
2010. The presence of an easily degradable carbon source such as glucose was able to 
biotransform the original compound to metabolites even in low concentrations. In order 
to understand the biodegradation and biotransformation of the refractory compounds such 
as clofibric acid and the metabolites produced during the process, further studies should 
be performed with other bacterial consortia. In the same way, different operational 
conditions should be tested and optimized to help the environmental engineers to deal 
with this problem.    
 
Marco-Urrea et al., (2009) screening four white-rot fungi (Trametes versicolor, Irpex 
lacteus, Ganoderma lucidum and Phnerochaete chrysosporium) for the degradation of 
ibuprofen, clofibric acid, carbamazepine after 7 days of incubation for a concentration of 
10 ppm. Ibuprofen was found degraded by all the fungi studied but clofibric acid and 
carbamazepine was only affected by some strains of fungi. The biodegradation 
metabolites were also studied and identified for the ibuprofen and additional should be 
done for the identification products of the biodegradation of clofibric acid and 
carbamazepine. 
Other strategies used in the biodegradation studies involve the acclimatization of the 
activated sludge, collected in municipal WWTP, for long periods of time to the reactors 
by spiking the PhAC and supplemented with an extra carbon source. Control studies are 
also performed in combination without spiking the PhACs in this case. The 
biodegradation studies involve changes in operating conditions e.g. hydraulic retention 
time, substrate composition and concentration (Kosjek et al., 2009). The light and 
temperature are also controlled in the reactors to avoid interference effects of these two 
parameters. 
 
Biofilm reactors have also been used for PhAC biodegradation studies in rotating annular 
reactors operating with raw river water serving as continuous inocula and nutrient source. 
Then, without any previous biomass acclimatization to the biodegradation of any specific 
compound, the PhAC was added to the reactor. Other bioreactors were fed with artificial 
wastewater over a long period of acclimatization time with exposure to the PhAC 
(Winkler et al., 2001, Kraigher et al., 2008). Studies focus on the operation of lab scale 
reactors has also included the biomass characterization (Winkler et al., 2001; Zwiener et 
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al., 2003, Kraigher et al., 2008). Zwiener and Frimmel, (2003) studied the biodegradation 
in biofilm reactors and including the sorption of the PhAC in the biofilms without and 
with acetone to a toxic level. In this study clofibric acid and diclofenac were eliminated 
only in 5% and ibuprofen was eliminated in 60% with the biofilm reactor operating with 
oxic and anoxic conditions. The biofilm was created in the reactor with biomass from 
activated sludge. However, the anoxic conditions tend to favor the removal of the 
clofibric acid, ibuprofen and diclofenac. Some of the most studied PhAC and microbial 
cultures used in lab scale reactors are listed in Table 2.6. 
 
 
Table 2.6 - Some of the most studied PhAC and microbial cultures in lab scale reactor. 
 
Author Compounds Microorganisms 
Yi et al., 2007  17 -ethinylestradiol Nitrifiers 
Kraigher et al., 2008 ibuprofen, naproxen, ketoprofen, 
diclofenac and clofibric acid 
Nitrifiers (Nitrospira sp.) 
Betaproteobacteria (Thauera, 
Sphaerotilus, Ideonella and 
Acidovoraz spp.)  
Tran et al., 2009 clofibric acid, carbamazepine, 
diclofenac, propyphenazone 
Nitrifiers 
Marco-Urrea et al., 2009 ibuprofen, clofibric acid, 
carbamazepine 
White-rot fungi (Trametes 
versicolor, Irpex lacteus, 
Ganoderma lucidum and 
Phnerochaete chrysosporium) 
Marco-Urrea et al., 2010 clofibric acid, carbamazepine, 
atenolol and propranolol 
Trametes versicolor 
 
Evangelista et al., 2010 clofibric acid, methylchloro-
phenoxypropionic acid, 4-chloro-
2-methylphenoxyacetic acid 
Pseudomonas putida, 
Aspergillus niger, Bacillus 
subtilis, Pseudomonas 
fluorescens, Sphingomonas 
herbicidovorans and 
Rhodococcus rhodochrous 
 
Other strategies for the operation of these reactors include starvation experiments with 
different changes in PPCP feeding periods to study this effect on the biodegradation of 
phenol, such as 4-chorophenol, 2,4-dichlorophenol and 2,4,6-trichlorophenol (Buitrón et 
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al., 2011). Biodegradation kinetic studies of mixture of 4-chlorophenol (reported as 
metabolite generated from the clofibric acid biotransformation (Kosjek et al., 2009), in 
sequencing batch reactors (SBR) subject to starvation and shock load had a transient 
effect on the microorganisms degradation rate show very fast removal of this compound 
after 15 h led to 90% removal of 4-chlorophenol and it is used as cometabolite in the 
clofibric acid biodegradation. The small concentration of this metabolite was too low to 
be characterized. In the same way, Buitrón et al., (2011) suggests that the substrate 
removal rate decreases when perturbations are applied to the SBR. The specific 
dehydrogenase activity of suspended biomass was higher than in the biomass attached 
before starvation. Increasing the starvation period did not affect significantly the removal 
and only the dehydrogenase activity was more affected. The operation of SBR under 
variable influent concentrations need to be further studied in order to understand the 
effects on the removal of the compounds.  
 
The identification of the new products formed (metabolites) during the biotransformation 
process (Winkler et al., 2001, Kosjek et al., 2009, Marco-Urrea et al., 2009, Evangelista 
et al., 2010) and the metabolic biodegradation pathways is one of the most studied 
subjects in the biological reactors (Yi et al., 2007, Marco-Urrea et al., 2009 and 2010, 
Evangelista et al., 2010). Winkler et al., (2001) identified two metabolites of ibuprofen 
biodegradation, hydroxyibuprofen and carboxyibuprofen by GC-MS analysis. Kosjek et 
al., 2009 identified biotransformation products of diclofenac by UPLC-ESI(+)-QTOF-MS 
and clofibric acid by UPLC-ESI(-)-QTOF-MS. Seven main metabolite products were 
detected but only one chemical structures have been proposed for diclofenac, 1-(2,6-
dichlorophenyl)-1,3-dihydro-2H-indol-2-one) and 4-chlorophenol was identified as the 
main metabolite of clofibric acid biotransformation. Marco-Urrea et al., (2009) also 
identified three biodegradation products of ibuprofen, 2-hydroxyibuprofen, 1-hydroxy-
ibuprofen, 1,2-dihydroxyibuprofen by GC-CIRMS (combustion isotope ratio mass 
spectrometry) and 
1
H and 
13
C NMR. Evangelista et al., (2010) identified ethyl clofibrate 
as metabolite of clofibric acid and other metabolites have been detected but not identified. 
The results obtained from this studies justify that further studies should be done in order 
to understand the metabolites generated from the different PhAC in biological treatment 
process.  
 
2.5.2 Advanced Oxidation techniques 
 
To reduce the input of pharmaceuticals into the environment, physicochemical end-of-
pipe technologies such as advanced oxidation processes (AOPs) are indispensable after 
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the biological treatment in the WWTP (De Witte et al., 2011). AOPs are characterized by 
the generation of hydroxyl radicals at ambient conditions. Degradation of 
pharmaceuticals and endocrine disrupting agents by AOPs, with focus on parent 
compound removal and kinetics, has gained a lot of attention. Full mineralization of 
pharmaceuticals by AOPs is reported to be not cost effective. Partial degradation, with 
formation of more biodegradable or less toxic intermediates, is the key to optimize 
treatment. This involves careful process control because intermediates can still have 
endocrine activity, antibiotic activity, or other biological effects. Moreover, degradation 
products can be more toxic than the parent compound. For example, Vogna et al., (2004a) 
found that mutagenic and carcinogenic acridine intermediates are formed during 
UV/H2O2 treatment of carbamazepine.  
Many studies using oxidation techniques have been applied to the transformation of 
PhAC in lab scale reactors with pure water and wastewater (Radjenovic et al., 2009); 
surface water (Pereira et al., 2007a) and ground water, drinking water (Canonica et al., 
2008) and tap water (Kim et al., 2009), resulting in recent emerging concerns of the 
safety of drinking water, ground water, surface water, reclaimed wastewater and aquatic 
ecosystems. Pilot plant studies on ozononation and UV have also been applied to study 
pharmaceuticals, iodinated X-ray contrast media (ICM) and musk fragrances from 
municipal wastewater (Ternes et al., 2003). Ultraviolet (UV) light radiation is an 
established method for drinking-water disinfection and also a technology for wastewater 
purification (Canonica et al., 2008). It has long been recognized that even at such 
(relatively low) UV doses organic compounds dissolved in water may undergo 
photochemical transformation. Since surface waters are often used as a source for 
drinking-water production, and treated wastewaters are utilized to recharge groundwater 
tables or reused for washing facilities or other purposes, the question about 
transformation products is still an unclarified problem when oxidation technologies are 
applied. Canonica et al., 2008 studied the extent of the degradation (expressed as 
depletion of the parent compound) of four selected pharmaceuticals in a UV drinking 
water treatment system for disinfection purposes. They determined the pH dependence on 
direct phototransformation, quantum yields and how they can be used to quantify the 
extent of degradation of the pharmaceuticals under low-pressure (LP) and medium-
pressure (MP) mercury lamp UV irradiation conditions. It was an important contribution 
to understand the extent of degradation of pharmaceuticals at higher UV doses used in 
disinfection of drinking water and in the UV treatment of wastewaters.  
 
The limited removal of some PhACs in the biological process of WWTP could be 
responsible for the contamination in the water environment, resulting in recent emerging 
52 
 
concerns with the application of oxidation technologies as tertiary treatment (e.g. 
ozonation, UV radiation, chlorine) for disinfection. These technologies used for the 
inativation of microorganisms could also lower the concentrations of other micro 
pollutants. Vogna et al., (2004b) have conducted a study on diclofenac oxidation with 
UV/H2O2 and ozone, showing that both ozonation and UV/H2O2 systems proved to be 
effective in inducing diclofenac degradation. In other study, they have reported that 
UV/H2O2 process could degrade carbamazepine very effectively, while UV alone process 
was not effective for reducing carbamazepine concentration (Vogna et al., 2004b). The 
potential effectiveness of UV and UV/AOP (UV coupled with another advanced 
oxidation process) as drinking water remediation technologies for PhACs most 
commonly found in surface waters has been studied (Pereira et al., 2007b). Kim et al., 
2009 studied the removal of six PhACs such as carbamazepine, naproxen, clofibric acid, 
ciprofloxacin and ketoprofen from surface water to evaluate their degradation by the use 
of fundamental photodegradation parameters in laboratory-grade water during UV and 
UV/H2O2. Canonica et al., (2008) have evaluated the extent of photodegradation of four 
selected pharmaceuticals such as 17α-ethinylestradiol, diclofenac, sulfamethoxazole and 
iopromide in UV drinking water treatment for disinfection purpose. Nakada et al., (2005) 
studied NSAIDs (Ibuprofen, naproxen, mefenamic acid and ketoprofen) removal in 
WWTP, and showed that UV radiation, used for disinfection, could also increase the 
PhAC removal when compared with other disinfection techniques, such as chlorination, 
and in particular for ketoprofen.  
Rosario-Ortiz et al., (2010) studied the effect of low pressure UV light coupled with 
hydrogen peroxide (UV/H2O2) on the removal of six pharmaceuticals (meprobamate, 
carbamazepine, dilantin, atenolol, primidone and trimethoprim) in the effluent wastewater 
of 3 WWTP  and obtained a range from zero removal to >90%. The efficacy of UV/H2O2 
treatment for the removal of pharmaceuticals from wastewater was a function of not only 
the concentration of the effluent dissolved organic matter but also its inherent reactivity 
towards the hydroxyl radicals. The removal of pharmaceuticals also correlated with 
reductions in ultraviolet absorbance at 254 nm. The advanced oxidation processes (AOPs) 
have been shown to be effective at the removal of various organic contaminants from 
drinking water and wastewater (Huber et al., 2003; von Gunten, 2003; Rosario-Ortiz et 
al., 2010). Ozone, ozone with hydrogen peroxide (H2O2), and UV with H2O2 are three of 
the most commonly studied AOPs. During ozone and ozone with H2O2, pharmaceutical 
oxidation occurs via reactions with molecular ozone and the hydroxyl radical. Both of 
these oxidants contribute to the oxidation of trace contaminants. 
Ozonation using 5-15 mg L
-1
 of ozone is appropriate to oxidize pharmaceuticals, musk 
fragrances, estrogens and to simultaneously inactivate relevant microorganisms studied in 
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a pilot plant (Ternes et al., 2003). Even not optimized, ozone based AOPs (O3/H2O2 and 
O3/UV) slightly increased the oxidation efficiency for some iodinated contrast media in 
comparison to ozonation (Ternes et al., 2003). The ability of a particular treatment 
process to remove organic contaminants depends mostly on the structure and 
concentration of the contaminant. In addition, the operational parameters of the process 
(e.g., oxidant dose and contact time) will also determine the degree of attenuation of a 
particular contaminant (Ternes et al., 2003). Trace levels of hormones and 
pharmaceuticals are ubiquitous contaminants of municipal wastewater effluents. The 
detection of these chemicals is a direct function of analytical detection limits (Ternes et 
al., 2003). Therefore, more and more trace contaminants will continue to be discovered. 
Water treatment processes have various levels of efficacy in the attenuation of these 
contaminants. In drinking water, oxidation provides a cost effective means for 
disinfection and simultaneous contaminant removal (Falconer, 2006, Canonica et al., 
2008). In an evaluation of estrogenicity as a class of toxicity, the estrogenicity of 
common food items is far beyond that of any wastewater or drinking water evaluated. The 
relative risk factors of common exposure to endocrine disrupting compounds (EDCs) 
through foods and beverages appear to be far greater than the exposure through drinking 
water (Falconer, 2006). The potential risk to health exists, however the estrogenic 
contamination of drinking water is very unlikely to result in physiologically detectable 
effects in consumers (Falconer, 2006). More research is needed to adequately address 
relevance of EDCs and pharmaceuticals to human health, but it is likely that most 
drinking waters do not provide substantial concentrations that are expected to be 
detriment to human health. Very few studies, using oxidation technologies for the study 
of PhAC and musks, combine the kinetic parameter determination, the energy supplied to 
the phototransformation process and the by-product identification in wastewater. Most of 
the studies carried out are applied to pure water or to drinking water.  
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CHAPTER 3 
 
 
 
ANALYSIS OF 65 PHARMACEUTICALS AND PERSONAL CARE 
PRODUCTS IN 5 WASTEWATER TREATMENT PLANTS IN 
PORTUGAL USING A SIMPLIFIED ANALYTICAL METHODOLOGY 
 
 
3.1 Introduction 
3.2 Methods 
3.3 Results and discussion 
3.4 Conclusions 
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3. Analysis of 65 pharmaceuticals and personal care products 
in 5 wastewater treatment plants in Portugal using a 
simplified analytical methodology 
 
Pharmaceuticals and personal care products (PPCPs) are becoming increasingly 
recognised as important micropollutants to be monitored in wastewater treatment plants 
(WWTPs), since WWTP effluents represent an important point source to natural aquatic 
systems. In this study, the abundance of 65 PPCPs was analysed in 5 Portuguese WWTPs 
during the spring and autumn. Due to the fact that analytical approaches normally used to 
quantify the abundance of these compounds are labour intensive and require various 
specific procedures, this study proposes a set of simplified analytical methods for the 
quantification of pharmaceutically active compounds (PhACs) and polycyclic musks in 
liquid and sludge samples. The analytical methods were validated using influent 
wastewater matrices, showing comparable limits of detection and quantification as 
literature values for most PPCPs, with the exception of the estrogenic compounds. The 
PhACs concentrations detected in the WWTP survey were in the range of 0.050 - 100 μg 
L
-1
 in the influent and up to 50 μg L-1 in the effluent, where the non-steroidal anti-
inflammatory drugs (NSAIDs) were the most abundant and frequently detected group. 
Some musks were detected up to 11.5 g L
-1
 in the influent and 0.9 g L
-1
 in the effluent, 
and adsorbed in the sludge up to 22.6 g g
-1
. 
  
3.1 Introduction 
 
Pharmaceuticals and personal care products (PPCPs) are commonly occurring 
micropollutants with a potentially significant environmental impact. The impact in the 
environment and public health arises not only from wastewater effluents discharged in 
aquatic media (Bartelt-Hunt et al., 2009), but also from sludge application in agriculture, 
since they can desorb and contaminate the groundwater (Carrara et al., 2008). Therefore, 
it is important to monitor these compounds to know their concentration in the liquid and 
solid phases after treatment in wastewater treatment plants (WWTP). While many studies 
have been carried out in different countries and geographical locations (Comeau et al., 
2008; Okuda et al., 2008; Santos et al., 2009), the occurrence of PPCPs in wastewater 
and environmental samples is highly dependent on the local diseases, treatment habits and 
market profiles, thus, the pollution profile and can vary significantly between different 
countries (Zuccato et at., 2006). This was the motivation for the present study, since little 
information on the occurrence of PPCPs in WWTPs in Portugal is available.  
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The most common PPCPs are the pharmaceutical active compounds (PhACs) and the 
polycyclic musk fragrances. PhACs include the antidepressives, anticonvulsants, non-
steroidal anti-inflammatory drugs (NSAID), steroidal anti-inflammatory drugs (SAID), 
drugs for asthma and allergic diseases, antihypertensives, β-blockers, lipid regulators, 
antibiotics, and estrogens.  
 
Due to the high diversity of compounds displaying a wide variance of chemical 
structures, many previous studies have elected to perform a combination of analytical 
methods targeting specific families of compounds (Sacher et al., 2001; Ternes et al., 
2001). While this strategy can be advantageous for the analysis of each target group, the 
time-consuming and labour-intensive nature of the analytical procedures makes numerous 
methodologies undesirable when the goal is to make an overall assessment of PPCPs 
present in environmental samples and WWTPs. This work proposes a simplified 
methodology adapted from previously published analytical methods that can be applied to 
wastewater and sludge samples for the detection of 65 PhACs and musks. All PhACs 
were analysed through LC-DAD-(ESI+)MS with the same set of conditions after solid-
phase extraction (SPE) using two different materials for either neutral or acidic 
compounds. The musks were analysed by GC-MS after solid-phase microextraction 
(SPME). Sludge samples were pre-treated with an ultrasonication step prior to PhAC and 
musk analysis. 
 
The methodology proposed in this study was applied to the influent, effluent and sludge 
samples from 5 Portuguese WWTPs. The validity of the simplified analytical 
methodology was assessed using the influent of the different plants. The PhAC 
compounds covered in this survey were selected based on the top-ranking sales figures 
for 2003 and 2007 provided by INFARMED (Portuguese Authority for Medication and 
Health Products), which is a similar approach as adopted by e.g. Erickson (2002) and 
Zuccato et al. (2006).  
 
 
3.2 Materials and methods 
 
3.2.1 Chemicals and reagents 
 
HPLC-grade acetonitrile, methanol, n-hexane and formic acid were purchased from 
Panreac (Portugal), all pharmaceutical active compound standards from Sigma-Aldrich 
(Steinheim, Germany) and the musks from LGC-Promochem (Spain). Stock solutions (1 
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mg mL
-1
) of each pharmaceutical and musk were prepared in methanol or hexane, 
respectively, and stored at 4 ºC.  
 
3.2.2 Sampling collection and properties of the WWTPs 
 
The characteristics of the 5 WWTPs assessed in this study are presented in Table 3.1. All 
plants contained screening and primary clarification prior to the secondary treatment 
process, as well as secondary clarifiers. Grab samples were collected at the influent (prior 
to primary treatment), the final effluent and the sludge (in the recycle from the secondary 
clarifier). 5 L samples were collected in plastic (PET) bottles and preserved at 4 ºC during 
transportation. The samples were filtered by 0.45 μm glass fiber membranes (GF 6, 
Whatman, England) and stored at -20 ºC. 
 
Table 3.1- Characteristics of the WWTPs. 
 
 Setúbal Cucena Valdeão 
Quinta da 
Bomba 
Fernão 
Ferro 
Average Influent 
Flow (m3d-1) 
11 195 773 1634 15 536 3579 
Wastewater  
Domestic + 
Hospital + 
Industrial (8%) 
Domestic + 
Industrial 
(20%) 
Domestic + 
Hospital 
Domestic Domestic 
Process 
Activated sludge 
1 
Activated 
sludge 
Activated 
sludge 
Trickling 
filter 
Trickling 
filter 
Volume biological 
reactor (m3) 
765 * 
7000 ** 
2083 *** 
696 * 1352 * 9120 628 
Hydraulic retention 
time (h) 
33.6 h 11 h 20 h 14 h 7.6 h 
Sludge age (d) 15 9 - - - 
Sludge waste flow 
(m3d-1) 
354 40 No wastage 28 12 
*Aerobic; ** Anaerobic; *** Anoxic, 1Process includes tertiary treatment by UV-radiation  
 
3.2.3 Extraction and clean-up 
 
3.2.3.1 Acidic and neutral pharmaceuticals by SPE  
 
SPE was used for the extraction and clean-up of the liquid wastewater samples. Oasis 
HLB cartridges (60 mg, 30 μm, Waters, Eschborn, Germany) were used for the acidic 
PhACs and RP-C18ec cartridges (500 mg, 50 μm, Waters, Milfort, U.S.) for the neutral 
PhACs. Each cartridge was previously conditioned with 1 mL methanol followed by 1 
mL of MilliQ water, then dried in a N2-stream. For the acidic PhACs, 200 mL of filtered 
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wastewater and 10 μL of meclofenamic acid (as internal standard) were passed through 
the Oasis HLB cartridges at pH 2-3. For the neutral PhACs, 500 mL of filtered 
wastewater and 50 μL of meclofenamic acid were passed through the RP-C18ec cartridges 
at pH 7-7.5. Samples were passed through the SPE cartridges at a flow rate of  20 mL 
min
-1
 and vacuum pressure of -5 psi, and the cartridges were eluted four times with 1 mL 
of methanol. The methanol extracts were evaporated to 1 mL by a N2-stream. Then, 50 
L of extract was injected into the LC-MS. 
 
3.2.3.2 Sludge samples – ultrasonic solvent extraction prior to SPE 
 
The secondary sludge collected in the WWTPs was centrifuged for 5 min at 10 000 rpm. 
2 g of the centrifuged sludge was mixed with 4 mL methanol in an ultrasonic bath for 5 
min. The slurry was then centrifuged for 1 min at 10 000 rpm. The supernatant was 
collected in a separate vial and 2 mL of methanol were again added to the sludge. 
Centrifugation and supernatant collection were then repeated. To ensure the extraction 
was complete, 2 mL of acetone were then added to the sludge and the same procedure 
(i.e. ultrasonic bath, centrifugation, supernatant collection) was repeated. Then, the 4 
extracts (2 x 2 mL of methanol and 2 x 2 mL of acetone) were combined and evaporated 
to a volume of ca. 1 mL. The concentrated extract was diluted in 150 mL of MilliQ water 
prior to SPE.  
 
3.2.3.3 Polycyclic musk fragrances by SPME 
 
The extraction of musks from the wastewater and sludge samples was carried out by solid 
phase micro extraction (SPME) with 65 μm polydimethylsiloxane/divinylbenzene 
(PDMS/DVB) fibers (Supelco, Spain). The fibres were pre-conditioned prior to use for 30 
min at 250 ºC. 2 g of wastewater or sludge was added to 0.5 g NaCl and 10 μL of mirex 
as internal standard. The PDMS/DVB fibre was exposed to the sample headspace in a 
sealed vial with a Teflon lid for 15 min at 90 ºC. The fibre was thermally desorbed and 
analysed by GC-MS. 
 
3.2.4 Analytical procedures 
 
3.2.4.1 Detection of acidic and neutral PhACs by LC-MS 
 
Reverse-phase chromatography (LiChroCART 250-4 Purospher Star RP18 column, 
Merck) was performed with a diode array detector (DAD) from 200 to 400 nm with a 0.6 
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mL min
-1
 flow, using a degassed mobile phase with 0.1% water/formic acid (A) and 
acetonitrile (B). The following binary gradient was used: start with 2 min, 15% B at 0.6 
mL min
-1
; 20 min, 100 % B at 0.6 mL min
-1
; 25 min, 100 % B at 1.0 mL min
-1
; 27 min, 
15 % B at 1.0 mL min
-1
 and 35 min, 15 % B at 0.6 mL min
-1
. HPLC-DAD-(ESI+)MS was 
carried out in a HPLC system (Waters) coupled with a pump and controller (Waters 600), 
an in-line degasser (X-Act-4 channels, Jour Research), an autosampler (Waters 717 plus), 
a photodiode array detector (DAD, Waters 996) and a quadropole VG Platform 
spectrometer (Micromass, UK) equipped with an electrospray ionisation (ESI) source 
operating in positive mode. A split ratio of 1:10 was used between the
 
HPLC column and 
the mass spectrometer. The capillary temperature was 100-120ºC, the scanning cone 
voltage was 35-100 V and the capillary voltage was 3.5 kV. Nitrogen was used as drying 
and nebulising gas at 300 mL min
-1
 and 10 mL min
-1
, respectively. The mass/charge 
spectrum range used was 100-450 amu with a MassLynx
TM
 software data acquisition 
system. All samples were analysed in triplicate. 
 
3.2.4.2 Detection of polycyclic musk fragrances  
 
Analysis was performed using a Hewlett-Packard 5890 GC fitted with a QMD1000 Carlo 
Erba mass spectrometric detector. The injection port was operated in splitless mode. A 
DB-5MS, 5% phenyl and 95% dimethylpolysiloxane fused-silica capillary column (30 m 
x 0.32 mm i.d., 0.25 μm film thickness, Agilent-J&W Scientific, Spain) was used with 
helium as carrier gas at a flow rate of 1.5 mL min
-1
. The injection port temperature was 
250 ºC. The ion source and the transference line were kept at 200 and 310 ºC, 
respectively. The oven temperature was maintained at 60 ºC for 3 min, increased to 250 
ºC at 10 ºC min
-1
, then raised to 310 ºC at 20 ºC min
-1
, and held for 13 min. The MS 
spectra were obtained with 70 eV, mass range m/z 50-500 amu and using MassLab
TM
 
software (Micromass). The injector temperature during SPME splitless analysis was 250 
ºC for PDMS/DVB. 
 
3.2.5. Method validation  
 
3.2.5.1 Determination of recoveries  
 
Samples were spiked with analytes dissolved in a stock solution (each at 1 mg mL
-1
 
methanol). The influent wastewater samples were spiked with 100 μg L-1 of analyte and 
internal standard (i.e. meclofenamic acid). After spiked, the samples were stirred for 
homogenisation and to enable a sufficient contact of analytes and standards with the 
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matrix. Relative recoveries were determined relative to a MilliQ water standard solution, 
also spiked with 100 μg L-1 of analyte and internal standard. Recoveries of the 
pharmaceuticals in the individual clean-up steps were determined by SPE in wastewater 
influent matrices and in MilliQ water, and analysed by LC-DAD-MS as described above. 
The relative recoveries were calculated from the analyte areas in the influent matrix, 
subtracting the analyte area quantified in the original unspiked matrix, divided by the area 
of the MilliQ standard sample. 
 
3.2.5.2 Calibration curves, limits of detection (LOD) and quantification (LOQ) 
 
Standards were prepared from the stock solutions diluted in methanol. A six-point 
calibration curve was used for each compound, ranging from 5-200 ng L
-1
. The regression 
coefficient of the resulting calibration curves was >0.95 for all compounds. Ten blank 
samples were analysed by LC-MS (with methanol) and GC-MS (with n-hexane) to 
determine the lowest signal/noise ratio of each analyte. Limits of detection (LOD) for the 
analytes were calculated by the formula 3xSD/m, where SD is the standard deviation of 
the lowest signal/noise ratio of the analyte and m is the slope of the calibration curve. 
Limits of quantification (LOQ) were calculated as 10xSD/m.  
 
3.3. Results and discussion 
 
3.3.1 Validation of the Analytical Approach 
 
The analytical methodology selected for the PhAC survey carried out in this work was 
based on SPE followed by LC-DAD-(ESI+)MS. Although two different SPE materials 
were used to best enrich either acidic or neutral pharmaceuticals, the analysis of both 
extracts was done using the same LC-MS conditions (see methods), in order to detect the 
highest number of compounds with the lowest analytical effort. The selection of positive 
mode for the MS electrospray ionisation was based on preliminary tests using standards 
of the target compounds. For the majority of the compounds it was found that, when 
compared to ESI-, the ESI+ resulted in precursor molecular ions ([M+H]
+
 or [M-H]
-
, 
respectively for ESI+ or ESI-) with higher relative peak intensity, thus ESI+ was selected. 
The LOD, LOQ and recoveries obtained with this approach are presented in Table 3.2 for 
the compounds detected in this study. The results showed that the analytical procedure for 
PhACs enables the detection of a substantial number of pharmaceuticals with LOD and 
LOQ comparable to those reported in literature using a combination of analytical methods 
designed for specific groups of compounds. The estrogens are the main exception, where 
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tandem MS should be used in order to detect these compounds to a concentration that is 
relevant to assess their potential environmental impact (Ternes, 2001). However, some 
other compounds, namely carbamazepine, showed lower LOD and LOQ with SPE (RP-
C18) followed by LC-DAD-(ESI+)MS when compared to results obtained with SPE (RP-
C18) and GC-MS (Sacher et al., 2001). The LOQ for carbamazepine in this study was 
similar to that found by Ternes (2001) through LC-MS/MS. In Sacher et al. (2001), three 
separate analytical methods were used for antibiotics, whereas in this study, antibiotics 
were analysed together with the other acidic compounds. While Sacher et al. (2001) 
found lower LOD and LOQ for amoxicillin, their recovery was lower than in this study 
(36% vs. 83%). The remaining compounds that were not detected in this study had LOD 
values ranging from 1-25 ng L
-1
 and LOQ values ranging from 3-83 ng L
-1
. 
 
Table 3.2 - Limits of detection and quantification, and recovery of the PhACs found in this 
study. The results are compared with literature studies. 
 
Compound 
LOD 
ng L
-1 
LOQ 
ng L
-1
 
Recovery* 
% 
LOD 
ng L
-1
 
LOQ
 
ng L
-1
 
Recovery 
% 
LOQ 
ng L
-1
 
Recovery 
% 
Neutral PhACs         
Atenolol 3 10 >94±5 2.4
a 8.2a 67a 50b 98b 
Caffeine 27 91 >82±1      
Carbamazepine 2 7 >75±1 9.6
a 32a 74a 10b 92b 
Clorazepate 17 57 -      
Dimethylamino- 
phenazone 
29 95 >83±3 4.3
a 14a 66a 100b 93b 
Domperidone 3 9 -      
Etofenamate 20 67 -      
Fentiazac - - -      
Fluoxetine 17 57 >60±6      
Fluticasone 25 85 >87±1      
Hydroxyzine 18 60 73±1      
Indapamide 6 18 >86±1      
Nimesulide 14 46 >82±6      
Paroxetine 27 89 >86±12      
Piroxicam - - -      
Ramipril 9 31 -      
Salbutamol 11 36 >94±1 2.6
a 9.1a 66a 50b 61b 
Tramadol 20 67 >86±2      
* signifies that the recoveries were obtained with WWTP influent. The value presented is the minimum 
value obtained from the 5 WWTPs.a Sacher et al. (2001); recoveries obtained with surface water.b Ternes 
(2001); recoveries obtained with WWTP effluent.c Ternes et al. (2005); recoveries obtained with 
groundwater.d Smyth et al. (2008) 
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Table 3.2 - (cont.) Limits of detection and quantification, and recovery of the PhACs found in 
this study. The results are compared with literature studies. 
 
Compound 
LOD 
ng L
-1 
LOQ 
ng L
-1
 
Recovery* 
% 
LOD 
ng L
-1
 
LOQ
 
ng L
-1
 
Recovery 
% 
LOQ 
ng L
-1
 
Recovery 
% 
Acidic PhACs         
Captopril 5 15 66±10      
Clofibric acid 15 50 >98±1 5.3
a 18a 103a 50b 82b 
Diclofenac 7 24 >79±5 8.7
a 29a 70a 50b 89b 
Enalapril 8 28 >88±3      
Flurbiprofen 18 58 >65±1      
Furosemide 19 63 -      
Ibuprofen 14 46 >89±9 3.5
a 12a 110a 50b 81b 
Indomethacin 7 23 >96±5 5.4
a 18a 114a 50b 90b 
Ketoprofen 21 69 >86±2 4.8
a 16a 104a 50b 94b 
Naproxen 18 59 102±6 3.8
a 13a 105a 50b 91b 
Meclofenamic acid 4 14 >74±4    50
b 89b 
Antibiotics         
Amoxicillin 13 43 >83±4 4.6
a 15a 36a   
Ampicillin 3 11 >67±1      
Estrogens         
17α-Ethinylestradiol 21 69 -    1
b 76b 
Estrone 18 60 104±12    1
b 82b 
β-Estradiol 4 12 -    1
b 76b 
Musks         
Cashmeran 1 4 83±3 21
d     
Celestolide 2 6 85±4 16
d     
Galaxolide 1 4 94±2 11
d   20c 82c 
Phantolide 1 4 97±2 17
d     
Tonalide 1 2 82±3 8.4
d   20c 78c 
Traseolide 2 6 85±4 13
d     
Mirex 1 2 89±3      
* signifies that the recoveries were obtained with WWTP influent. The value presented is the minimum 
value obtained from the 5 WWTPs.a Sacher et al. (2001); recoveries obtained with surface water.b Ternes 
(2001); recoveries obtained with WWTP effluent.c Ternes et al. (2005); recoveries obtained with 
groundwater.d Smyth et al. (2008) 
 
PhACs recoveries for the analytical process (SPE followed by LC-DAD-MS) were 
obtained with samples of influent wastewater for the compounds that were detected in 
that plant. These tests aimed at assessing the effect of the wastewater matrix on the 
analytical method as well as interferences due to the manipulation associated with the 
extraction and analytical process. The precision and reproducibility of the method 
indicated a relative standard deviation varying from 1 to 12 %. Despite some variation of 
the PhACs recoveries with the matrix (results not shown), the results were above 70% 
except for four compounds (Table 3.2). Fluoxetine showed the lowest recovery (60±6%) 
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with wastewater from Valdeão, suggesting that a different SPE material or GC after 
derivatisation should have been used for better detection of this compound. Nevertheless, 
the recoveries of fluoxetine for other WWTPs were >79±1%. With this methodology, a 
very wide range of compounds with different structures were covered, using a reduced 
number of analytical processes. 
 
3.3.2 Measurement of PPCPs in wastewater influents  
 
Table 3.3 - Pharmaceuticals and musks detected at the influent, effluent and secondary sludge of 5 
different WWTPs in Portugal during the spring (23 May to 7 July) and autumn (2 to 
25 October).  
Compound 
Influent 
Occurence 
Influent 
minimum 
ng/L±SD 
Influent 
maximum 
ng/L±SD 
Effluent 
Occurrence 
Effluent 
minimum 
ng/L±SD 
Effluent 
maximum 
ng/L±SD 
Secondary 
Sludge 
Occurrence 
Secondary 
sludge 
minimum 
ng/g±SD 
Secondary 
sludge 
maximum 
ng/g±SD 
Neutral 
PhACs 
 
        
Atenolol 5/10 
65± 5 4757±25 4/9 119±25 1297±14 0/9   
Caffeine 10/10 
258±13 36160±36 4/9 437±20 4392±22 3/9 1788±12 8423±29 
Carbamazepin
e 
2/10 
664±49 994±11 1/9 238±17 238±17 0/9   
Clorazepate 1/10 6227±16 6227±16 0/9   1/9 181± 9 181± 9 
Dimethylamin
o-phenazone 
4/10 
158± 8 3664±19 6/9 252±65 4278±12 3/9 158± 8 1361±17 
Domperidone 1/10 163±67 163±67 0/9   0/9   
Etofenamate 7/10 
58±12 7333±26 2/9 229± 6 1620±33 2/9 24785±121 
134431± 
438 
Fentiazac 1/10 
5297±19 5297±19 0/9   0/9   
Fluoxetine 5/10 
85± 1 1704±15 0/9   1/9 77±10 77±10 
Fluticasone 3/5 196± 1 1298±82 3/9 33±0.3 2848±14 2/9 1473±17 2330±42 
Hydroxyzine 1/10 
9344±80 9344±80 0/9   1/9 43339±86 43339±86 
Indapamide 3/10 177±19 1236±23 2/9 90± 2 329±13 3/9 47± 3 1362±31 
Nimesulide 1/10 6911±13 6911±13 0/9   0/9   
Paroxetine 3/10 
182±19 1312±15 3/9 224±15 3367±30 0/9   
Piroxicam 2/10 2575±49 9298±34 0/9   0/9   
Ramipril 1/10 
5445±49 5445±49 0/9   1/9 488±62 488±62 
Salbutamol 3/10 
104±21 2158±13 1/9 572±27 572±27 2/9 12±0.6 104±21 
Tramadol 2/5 158± 2 1344±17 2/9 51± 3 134± 4 0/9   
Acidic 
PhACs 
  
       
Captopril 5/10 32± 2 13335±26 1/9 1376±56 1376±56 3/9 875±16 5516±49 
Clofibric acid 9/10 40± 1 
6785±21 8/9 198± 3 7286±19 4/9 117±7 15655±18 
Diclofenac 7/10 207±44 
6674±24 2/9 26± 2 1612±18 3/9 2259± 5 17785±48 
Enalapril 4/10 51± 4 10238±32 3/9 624±21 19888±22 1/9 61±13 61±13 
Flurbiprofen 5/10 918± 2 9631±69 3/9 684± 2 3011±56 2/9 1018±84 3544±18 
Furosemide 2/10 3618±29 
15244±48 0/9   1/9 3602±30 3602±30 
Ibuprofen 8/10 550±33 
106490±42 8/9 518±33 43653±54 3/9 550±33 3398±16 
Indomethacin 5/10 240±17 8899±17 2/9 1470±53 2393± 5 2/9 20± 3 88± 3 
Ketoprofen 10/10 260±41 14275±98 5/9 20± 4 160±13 5/9 47±10 21989±52 
Naproxen 2/10 283± 2 
3894±28 0/9   0/9   
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Table 3.3 - (cont.) Pharmaceuticals and musks detected at the influent, effluent and secondary 
sludge of 5 different WWTPs in Portugal during the spring (23 May to 7 July) and autumn (2 to 25 
October). 
Compound 
Influent 
Occurence 
Influent 
minimum 
ng/L±SD 
Influent 
maximum 
ng/L±SD 
Effluent 
Occurrence 
Effluent 
minimum 
ng/L±SD 
Effluent 
maximum 
ng/L±SD 
Secondary 
Sludge 
Occurrence 
Secondary 
sludge 
minimum 
ng/g±SD 
Secondary 
sludge 
maximum 
ng/g±SD 
Antibiotics          
Amoxicillin 4/10 232± 5 
5698±99 2/9 1097±35 4801±45 2/9 112± 5 166±28 
Ampicillin 3/10 306± 2 4120±19 1/9 410± 5 410± 5 0/9   
Estrogens   
       
17α-Ethinyl 
-estradiol 
2/10 103±12 
106± 1 0/9   1/9 221± 8 221± 8 
Estrone 2/10 189±27 
2484±15 1/9 25± 2 25± 2 2/9 8±0.5 181±18 
β-Estradiol 1/10 344±10 344±10 0/9   0/9   
Musks   
       
Galaxolide 10/10 55±17 11463±20 10/10 4± 1 889±61 6/6 119±63 22649±154 
Tonalide 10/10 1±0.1 2933±51 10/10 1±0.1 225±20 6/6 11± 3 5968±47 
Cashmeran 10/10 50± 2 
7206±125 10/10 4±0.4 640±11 5/6 35±13 1865±108 
Celestolide 5/10 5± 1 338± 2 0/10   0/6   
 
 
In this study, two sampling campaigns were performed for the 5 WWTPs analysed, in the 
spring and in autumn (Table 3.3). The results showed that 33 out of 59 pharmaceuticals 
were detected in the influents to the plants, at varying frequencies of occurrence. The 
concentrations detected were in the range of approximately 50 ng L
-1
 to 100 μg L-1. The 
most dominant class of compounds present in the WWTPs were the non-steroidal anti-
inflammatory drugs (NSAIDs), which appeared at significantly higher concentration 
levels than the other PhACs groups (Figure 3.1). 
The total quantity of the major PhACs families present in the influent of most plants 
surveyed in this study (with the exception of Quinta da Bomba, see Figure 3.1) was found 
to be between 30 and 70 g L
-1
, and went up to 120 g L
-1
 in one sample. In previous 
surveys covering a wide range of PhACs in other countries, the total PhAC concentration 
reported was approximately 23 μg L-1 in a Japanese study (Okuda et al., 2008), 143 μg L-1 
in a Spanish study (Rosal et al., 2009) and 320 μg L-1 in the U.K. (Kasprzyk-Hordern et 
al., 2009).  
The most commonly detected and abundant NSAIDs found in the WWTP analysed were 
ibuprofen, ketoprofen, flurbiprofen, diclofenac and indomethacin. Caffeine was present in 
all plants and generally detected in high concentrations. Santos et al. (2009) also found 
ibuprofen, ketoprofen, and caffeine in the μg L-1 range of concentrations in WWTP 
influents of Seville, Spain, which is consistent with the present study. In addition to the 
NSAIDs, the antihypertensive (enalapril, captopril and furosemide) and lipid regulator 
groups were also occasionally found at μg L-1 levels, whereby clofibric acid represented 
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the sole lipid regulator detected. No readily observable pattern was found between the 
frequency of detection and quantity of PhACs measured in influent samples collected in 
the spring or autumn from the different plants (Figure 3.1).  
 
 
Figure 3.1- Occurrence of the most important PhAC families observed in the spring (s) and 
autumn (a) campaigns in the 5 studied WWTPs in the influent (‗left‘ column of 
each pair) and effluent (‗right‘ column of each pair). 
 
 
Three of the musks analysed (galaxolide, tonalide and cashmeran) were found in each 
plant (Table 3.3), while celestolide also appeared punctually, and traseolide and 
phantolide were not detected. In this case, the results show that in the spring the 
concentrations are, in general, higher than in the autumn (Figure 3.2). The concentration 
of the musks ranged from 117 ng L
-1 
to 5.0 g L
-1
, going up to 21.6 g L
-1
 in one sample. 
In literature studies, galaxolide and tonalide are generally the most frequently detected 
musks, as found in this study. Most previous reports indicate that the total musk 
concentrations are within a similar range for domestic/industrial wastewater. For 
example, in a study of 11 polycyclic musks in 6 WWTPs, Smyth et al. (2008) found them 
in a concentration range of 2-40 μg L-1 in the influent to the plants, while other literature 
studies report similar values or lower (Bester, 2004; Rosal et al., 2009).  
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Figure 3.2 - Occurrence of the musks observed in the spring (s) and autumn (a) campaigns in 
the 5 studied WWTPs in the influent (‗left‘ column) and effluent (‗right‘ 
column). 
 
 
3.3.3 Measurement of PPCPs in wastewater effluents and adsorption to the secondary 
sludge 
 
As expected, the effluent concentrations of most PhACs were generally much lower than 
the influent concentrations, suggesting at least some degree of transformation via 
biological degradation, UV degradation or adsorption to the sludge (Table 3.3). Also, the 
diversity of compounds detected was substantially lower, as well as the frequency in their 
occurrence. It is noteworthy that clofibric acid and dimethylaminophenazone were 
present at a similar frequency and abundance in the influent and effluent of most plants 
(Table 3.3), suggesting that these compounds were difficult to degrade by the WWTPs. 
Clofibric acid has previously been found to have a very high persistence in the 
environment (Winkler et al., 2001), which is consistent with the results of this study. 
The range of total PhAC concentrations found in the effluent of the different plants varied 
between 2-50 μg L-1. When compared with surveys of WWTP effluents in other 
countries, a similar range of total PhAC concentrations were reported. The total PhAC 
concentrations observed in the effluent in some other locations is as follows: in Japan, 2-
10 μg L-1; in Atlantic Canada, 2 μg L-1; in Spain, 26 μg L-1; and Italy, 3 μg L-1 (Zuccato et 
al., 2006; Comeau et al., 2008; Okuda et al., 2008; Rosal et al., 2009). In the U.K., an 
activated sludge effluent contained 43 μg L-1 of PhACs, while a trickling filter plant 
contained 93 μg L-1, where the influent concentration to each plant was similar 
(Kasprzyk-Hordern et al., 2009). In this study, no apparent differences were observed in 
the range of total effluent concentrations of the activated sludge plants (3-43 μg L-1), 
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versus the trickling filters (2-50 μg L-1). In addition, similarities were observed between 
the main families of compounds detected in literature surveys (i.e. NSAIDs, antibiotics, 
-blockers, lipid regulators, analgesics and caffeine), though each geographical region 
generally displayed differences in the particular compounds that were most abundant.  
In relation to the musks, galaxolide, tonalide and cashmeran were detected in the effluent 
of each plant, but at lower concentrations than in the influent (Table 3.3). Celestolide was 
not detected in the effluent of any of the WWTPs. The range of musk concentrations in 
the effluent were between 9 ng L
-1
 and 1.4 μg L-1, from which 5 ng L-1 to 1.1 μg L-1 were 
either galaxolide or tonalide. Previous studies reporting galaxolide and tonalide 
concentration in WWTP effluents found on average 1.3 μg L-1 (Rosal et al., 2009) or 4.8 
μg L-1 (Smyth et al., 2008), which is a comparable range to that found in Portuguese 
plants.  
The high frequency of occurrence of musks in the sludge suggests that adsorption was 
one of the important removal mechanisms, which agrees well with previous studies 
(Bester, 2004; Ternes et al., 2005). The total galaxolide and tonalide found in the sludge 
ranges from 0.130-28.6 μg g-1, while Bester (2004) found 4.5 g g-1 and Ternes et al. 
(2005) observed 2.3-8.5 g g
-1
. The high adsorption levels detected for the musks are due 
to their high hydrophobicity. Some pharmaceuticals were also found in the secondary 
sludge at high levels, however, they were less persistent since they were not detected as 
frequently in all of the plants tested. The most abundant PhACs in the sludge were 
diclofenac, ketoprofen, etofenamate, clofibric acid and hydroxyzine, which were present 
at levels above 10 μg g-1.  
 
3.4 Conclusions 
 
The results of this study show that the adapted analytical methodology employed in this 
work was effective for monitoring pharmaceutical and personal care products in 
wastewater treatment plants. This method reduced the analytical effort necessary to cover 
a wide range of compounds with different natures, and still achieved good LOD and LOQ 
levels (with the exception of the estrogens), with high recoveries in influent wastewater. 
The total PhAC and musk concentrations found in this work were in a similar range as 
previously reported studies. The most abundant PhACs were the NSAIDs (particularly 
ibuprofen), while the antihypertensives (particularly enalapril), caffeine, and clofibric 
acid were also present in relatively high concentrations in the influent and effluent. 
Clofibric acid represented one of the few compounds present at a similar range of 
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concentrations in the influent and effluent of the plants, suggesting that little 
biodegradation and adsorption of this compound took place. 
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CHAPTER 4 
 
 
 
ASSESSING THE DIURNAL VARIABILITY OF PHARMACEUTICAL 
AND PERSONAL CARE PRODUCTS IN A FULL-SCALE ACTIVATED 
SLUDGE PLANT 
 
 
 
4.1 Introduction 
4.2 Materials and Methods 
4.3 Results and discussion 
4.4 Conclusions 
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4. Assessing the diurnal variability of pharmaceutical and 
personal care products in a full-scale activated sludge plant 
An intensive sampling campaign has been carried out in a municipal wastewater 
treatment plant (WWTP) to assess the dynamics of the influent pharmaceutical active 
compounds (PhACs) and musks. The mass loadings of these compounds in wastewater 
influents displayed contrasting diurnal variations depending on the compound. The musks 
and some groups of PhACs tended to follow a similar diurnal trend as compared to 
macropollutants, while the majority of PhACs followed either the opposite trend or no 
repeatable trend. The total musk loading to the WWTP was 0.74 ± 0.25 g d
-1
, whereas the 
total PhACs mass loading was 84.7 ± 63.8 g d
-1
. Unlike the PhACs, the musks displayed a 
high repeatability from one sampling day to the next. The range of PhAC loadings in the 
influent to WWTPs can vary several orders of magnitude from one day or week to the 
next, representing a challenge in obtaining data for steady-state modelling purposes.  
  
4.1 Introduction  
Pharmaceuticals and personal care products (PPCPs) are xenobiotics that can be detected 
in wastewater treatment plants (WWTPs) at the influent, effluent and in waste sludges 
(Ternes et al., 1999; Kolpin et al., 2002; Richardson et al., 2005; Zuccato et al., 2005; 
Ternes et al., 2005; Jones et al., 2007; Miége et al., 2009; Sim et al., 2010; Santos et al., 
2009). Many studies have been previously performed concerning the occurrence and fate 
of PPCPs in WWTPs from various countries. However, only few studies have attempted 
to assess the variability that can be expected in the diurnal PPCP loadings in the influent 
to WWTPs (Joss et al., 2005; Göbel et al., 2005; Weissbrodt et al., 2009; Plósz et al., 
2010). Wastewater treatment plants are known to receive discharges that vary widely 
according to the time of day. Diurnal variations (in particular peak loads) are important to 
consider for successful WWTP design and operation, not only with respect to flow, but 
also the pollutant loading rates in order to achieve sufficient effluent quality. Further, 
peak pollutant loads can have toxic or inhibitory impacts on the WWTP sludge. The 
inhibition of heterotrophs and nitrifiers by pharmaceutical active compounds has 
previously been shown (Dokianakis et al., 2004; Carucci et al., 2006; Wang et al., 2008) 
and can reduce treatment efficiency. 
The typical dry weather diurnal variations of organic matter, ammonia, phosphate and 
wastewater flow consist of a relatively large morning peak, smaller variations throughout 
the day and low levels overnight (Tchobanoglaus and Burtan, 1995; Almeida et al., 
1999). It is still unknown if a similar-type pattern exists with respect to PPCP 
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concentrations, and if so, how repeatable this pattern is from one day to the next. Such 
information is important in order to incorporate PPCP compounds into WWTP models. 
Thus far, the studies that have addressed the diurnal variability of PPCPs in the influent 
of WWTPs have generally observed lower overnight concentrations, consistent with the 
wastewater flow variation (Joss et al., 2005; Göbel et al., 2005; Weissbrodt et al., 2009; 
Plósz et al., 2010). Most of these studies collected the influent sample after primary 
clarification, dampening the effect of diurnal flow and PPCP loading variations. 
However, since the monitoring plan of WWTPs generally requires that pollutant 
characterisation is done at the sewer entrance of the plant (and treated effluent), it is 
desirable to understand quantitatively how raw influent loadings fluctuate diurnally, and 
indeed, how repeatable is this assessment from one day to the next in a WWTP. 
In this study, 79 PPCPs, including 73 pharmaceutical active compounds (PhACs) of 
different families and 6 musk fragrances, have been monitored for characterising their 
diurnal variation in the raw influent prior to primary sedimentation. This analysis was 
performed along 2 days per week over 2 consecutive weeks at a municipal WWTP in 
Portugal in order to investigate the repeatability of the profiles. The goals of this study 
were to assess the diurnal variations of PPCPs in the influent, as well as the 
reproducibility of the mass loading of PPCPs detected during the different days and 
weeks analysed. To the best of our knowledge, this is the first study to investigate the 
diurnal variations of this broad range of PPCPs in the raw influent of municipal 
wastewater. 
4.2 Materials and methods 
 
4.2.1 Influent WWTP sampling and sample preservation 
 
The influent samples were collected at the WWTP of Fernão Ferro (Seixal, Portugal), 
which has a design capacity for 32 700 population equivalents and treats 2790 m
3
 d
-1
 of 
domestic municipal wastewater. Two consecutive 48 hour periods over two successive 
weeks have been monitored during dry-weather conditions. Samples of the influent (1L) 
were collected on Monday from 10 a.m. until Wednesday 10 a.m. (a sample was collected 
every 2 hours) using a refrigerated auto-sampler. The samples were transported to the 
laboratory in a refrigerated isothermal container and immediately extracted and stored at -
20 
o
C until the analysis was performed. The samples were prepared for analysis of two 
different classes of pharmaceutical compounds (acidic and neutral) and of polycyclic 
musk fragrances according to the procedures described below.  
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4.2.2 Chemicals and reagents 
 
HPLC-grade acetonitrile, methanol, and formic acid were purchased from Panreac 
(Portugal). Ultrapure water was obtained from a MilliQ water purification system 
(Millipore, Bedford, MA., USA). All of the pharmaceutical active compound (PhAC) 
standards were purchased from Sigma-Aldrich (Steinheim, Germany), while the musks 
were purchased from LGC-Promochem (Spain). Stock solutions (1 mg mL
-1
) of each 
PhAC or musk were prepared and diluted in methanol or n-hexane, respectively. All 
samples were analysed in triplicate. 
 
4.2.3 Extraction and analysis 
 
4.2.3.1 Acidic and neutral pharmaceutical compounds 
 
Solid phase extraction (SPE) was used for clean-up and concentration of the samples, as 
detailed in Salgado et al. (2010). All wastewater samples were filtered through glass fiber 
filters (GF 6, <1 μm pore diameter, Whatman, England. 350 mL of filtered wastewater 
were spiked with an internal standard (meclofenamic acid) to a final concentration of 100 
μg L-1. SPE was carried out on the filtered and spiked wastewater samples with Waters 
Oasis HLB cartridges (60 mg, 30 μm, Waters, Eschborn, Germany) for the acidic 
pharmaceutical compounds, while Waters RP-C18 cartridges (500 mg, 50 μm, Waters, 
Milfort, U.S.) were used for the neutral compounds. The pH of the samples was adjusted 
to 2 for the acidic compounds and 7 for the neutral compounds. The wastewater samples 
were passed through the cartridges at a flow rate of approximately 20 mL min
-1
. The 
solid-phase material was then dried through a continuous nitrogen stream for 1 h and then 
the analytes were eluted four times with 1 mL methanol (total 4 mL). The extracts were 
evaporated to 1 mL by a gentle nitrogen stream.  
 
The acidic and neutral PhACs extracts were analysed through high performance liquid 
chromatography coupled to mass spectrometry (HPLC-MS).  For HPLC, a reverse-phase 
column was employed (LiChroCART 250-4 Purospher Star RP18 endcapped, 5 μm 
column, Merck) using a degassed mobile phase of water/formic acid 0.1% (A) and 
acetonitrile (B). The following binary gradient was used: 2 min, 15% B at 0.6 mL min
-1
; 
20 min, 100 % B at 0.6 mL min
-1
; 25 min, 100 % B 1.0 mL min
-1
; 27 min, 15 % B at 1.0 
mL min
-1
 and 35 min, 15 % B at 0.6 mL min
-1
. The HPLC system (Waters) was coupled 
with a pump and controller (Waters 600), an in-line degasser (X-Act-4 channels, Jour 
Research), an auto-sampler (Waters 717 plus), a photodiode array detector (DAD, Waters 
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996, used at 200-400 nm) and a quadropole VG Platform (Micromass, UK Ltd) 
spectrometer equipped with an electrospray ionisation (ESI) source operating in positive 
mode. An accurate splitter (split ratio of 1:10) was used between the
 
HPLC column and 
the mass spectrometer. Capillary temperature was kept between 100 ºC and 120 ºC, using 
a scanning cone voltage from 35 to 100 V and capillary voltage of 3.5 kV. Nitrogen was 
used as drying and nebulising gas at 300 mL·min
-1
 and 10 mL min
-1
, respectively. Spectra 
mass/charge range used was 100-450 amu with a MassLinx
TM
 software data acquisition 
system.  
 
4.2.3.2 Polycyclic musk fragrances  
 
The extraction of the musks was carried out by headspace solid-phase microextraction 
(SPME) using fibres coated with 65 μm polydimethylsiloxane/divinylbenzene 
(PDMS/DVB, Supelco, Spain). Two grams of wastewater sample were combined with 
0.5 g NaCl and spiked with Mirex (internal standard) to a concentration of 100 μg L-1 in 8 
mL glass vials with magnetic stirring. The PDMS/DVB fibre was exposed to the sample 
headspace in the sealed glass vial for 15 min at 90 ºC. The fibre was inserted into the 
injection port of the GC-MS during 3 min, where the volatile compounds were desorbed.  
 
Analysis was performed using a Hewlett-Packard 5890 gas chromatographer fitted with a 
QMD1000 Carlo Erba mass spectrometric detector (GC-MS). The injection port was 
operated in splitless mode. A DB-5MS, 5% phenyl and 95% dimethylpolysiloxane fused-
silica capillary column (30 m x 0.32 mm i.d., 0.25 μm film thickness, Agilent-J&W 
Scientific, Spain) was used, with helium as carrier gas at a flow rate of 1.5 mL min
-1
. The 
injection port temperature was 250 ºC. The ion source and the transference line were kept 
at 200 and 310 ºC respectively. The oven temperature was maintained at 60 ºC for 3 min, 
raised to 250 ºC at 10 ºC·min
-1
, and then to 310 ºC at 20 ºC·min
-1
, where it was held for 13 
min. The MS spectra were obtained with electron energy 70 eV, mass range m/z 50-500 
amu and using MassLab
TM
 software (Micromass).  
 
4.2.4 Determination of recovery, LOD and LOQ  
 
Recoveries, limits of detection (LOD) and limits of quantification (LOQ) were 
determined as detailed in Salgado et al. (2010). In brief, for determination of the recovery 
percentages, samples were spiked with standards of each of the PPCPs studied (100 μg L-
1
 in methanol) and an internal standard (meclofenamic acid, also at 100 μg L-1). After 
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homogenisation for 30 min, the extraction and analysis was performed as detailed above. 
Relative recoveries were determined relative to MilliQ water. 
 
The LOD for each of the PPCPs were calculated by the formula 3·SD/m, where SD is the 
standard deviation of the lowest signal/noise ratio of the analyte and m is the slope of the 
calibration curve. The LOQ were calculated as 10·SD/m. Ten blanks were analysed by 
LC/MS (with methanol) and GC-MS (with n-hexane) to determine the lowest signal/noise 
ratio of each analyte. 
 
4.2.5 Statistical analysis 
 
Contingency tables were used to determine if the results obtained in this study with 
respect to the frequency of detection of the PhACs was statistically significant from one 
day to the next. The entries of the contingency tables for each compound consisted of the 
number of detection and non-detection events in each of the four sampling days (12 
sampling events per day). The corresponding χ2-test for each compound was performed 
and the results are presented in Table 4.1. Further detail regarding this analysis is 
provided in appendix I. 
 
4.3 Results and Discussion  
 
4.3.1 Most frequently detected compounds 
 
The number of PhACs detected in each sample over the four days (2 consecutive 
Mondays and Tuesdays) of the campaign is plotted in Figure 4.1. It can be observed that a 
small, relatively constant number of compounds were found throughout the first day 
(5±1), which increased to 23 compounds at 10am of Day 2. After 4pm, the number of 
compounds detected decreased steadily to 10-12 until midnight, where afterwards it 
decreased further overnight (7-8 compounds). In the second week, a high number of 
compounds were detected throughout Day 3 (21±3) and Day 4 (17±4). The difference in 
the number of compounds observed between the 1
st
 week and the 2
nd
 week illustrates the 
high variability of PhACs, and the difficulty in obtaining a repeatable assessment of the 
compounds being discharged to the WWTP.  
 
77 
 
0
5
10
15
20
25
30
10 14 18 22 2 6 10 14 18 22 2 6 10 14 18 22 2 6 10 14 18 22 2 6
Time of day
N
u
m
b
e
r 
o
f 
c
o
m
p
o
u
n
d
s
 
                                              Week 1                                                                            Week 2
                                        Day 1                                                Day 2                                                 Day 3                                                   Day 4
 
Figure 4.1 - Number of pharmaceutical compounds detected throughout the sampling campaign of 
4 days: 2 consecutive Mondays and Tuesdays (mean and standard deviation: 1st week: 
Monday 5±1; Tuesday 13±7; 2nd week: Monday 21±3; Tuesday 17±4). 
 
While different compounds were detected at different times of the day, some compounds 
were detected more frequently than others. The most frequently detected compounds are 
shown in Table 4.1, while those infrequently detected are listed in Table 4.2 and those 
never detected are listed in Table 4.3. From Table 4.1, it can be observed that diclofenac, 
ibuprofen, ketoprofen and clofibric acid were frequently detected at the WWTP influent 
during each sampling day. Etofenamate, clorazepate, hydroxyzine, indapamide, enalapril, 
captopril, atenolol, ampicillin, fluoxetine and estrone were all commonly detected in the 
second week of sampling, but were either not detected or were seldomly detected during 
the first week. Paroxetine was commonly detected on the first Tuesday (Day 2) and 
second Monday (Day 3) of the campaign, but not detected on the other two sampling 
days. Interestingly, 5 of the 6 musks studied (galaxolide, tonalide, cashmeran, celestolide 
and traseolide) were present in every sample analysed during the campaign. It should also 
be noted that the differences observed in the frequency of detection from one day to 
another were statistically significant for 14 of the 15 PhACs analysed (Table 4.1). This 
reflects the large differences in the PhACs composition of the wastewater observed 
between each sampling day. 
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Table 4.1 - Range of concentration, mean concentration, and frequency of detection of the 20 most frequently detected PhACs and musks analysed. Limits of detection and 
quantification, as well as the relative recovery are also shown. 
       Week 1      Week 2    
Compound 
Human effect 
LOD  
(ng L
-1
) 
LOQ 
(ng L
-1
) 
Relative 
recovery  Monday   Tuesday   Monday   Tuesday  
 
 
(n=10) (n=10) WW (%) 
(n=3) 
Range 
(ng L
-1
) 
Mean 
(ng L
-1
) 
Freq of 
Detection 
Range 
(ng L
-1
) 
Mean 
(ng L
-1
) 
Freq of 
Detection 
Range 
(ng L
-1
) 
Mean 
(ng.L
-1
) 
Freq of 
Detection 
Range 
(ng.L
-1
) 
Mean 
(ng.L
-1
) 
Freq of 
Detection 
Diclofenac NSAID 7 24 65 ± 6 n.d.-26598 10898 11/12 11299-64479 38674 12/12 1257-16963 4534 12/12 n.d.-11742 5456 11/12 
Etofenamate *** NSAID 20 67 89 ± 4 n.d. n.d. 0/12 n.d.-40168 7444 8/12 n.d.-3164 1541 11/12 n.d.-2979 1507 10/12 
Ibuprofen * NSAID 14 46 70 ± 2 n.d.-52201 9102 7/12 235-13905 4476 12/12 358-1795 1059 12/12 n.d.-1298 562 9/12 
Ketoprofen* NSAID 21 69 102 ± 13 1106-29496 28269 12/12 47-104114 9255 12/12 n.d.-211 71 8/12 n.d.-250 85 8/12 
Clorazepate*** Anxiolytic 17 57 92 ± 2 n.d. n.d. 0/12 n.d.-3332 416 5/12 n.d.-427 249 11/12 n.d.-463 316 11/12 
Hydroxyzine*** Antihistamine 18 60 73 ± 5 n.d. n.d. 0/12 n.d. n.d. 0/12 162-1168 470 12/12 n.d.-570 216 8/12 
Indapamide*** Antihypertensive 6 18 86 ± 1 n.d n.d. 0/12 n.d. n.d. 0/12 n.d.-15386 2668 8/12 n.d.-6737 3476 11/12 
Enalapril*** Antihypertensive 8 28 88 ± 3 n.d. n.d. 0/12 n.d. n.d. 0/12 n.d.-4162 696 8/12 n.d.-6244 1532 10/12 
Captopril*** Antihypertensive 5 15 66 ± 10 n.d.-978 82 1/12 n.d.-509 96 3/12 n.d.-4231 784 9/12 n.d.-2267 1015 11/12 
Atenolol*** β-Blocker 3 10 115 ± 6 n.d.-4341 362 1/12 n.d.-427 36 1/12 141-944 476 12/12 77-1474 815 12/12 
Clofibric acid** Lipid mod. agent 15 50 96 ± 12 n.d.-41428 8461 6/12 137-1602 602 12/12 116-722 276 12/12 n.d.-1723 442 7/12 
Estrone*** Estrogen 18 60 104±12 n.d. n.d. 0/12 n.d. n.d. 0/12 n.d.-177 82 12/12 n.d.-73 28 7/12 
Ampicillin*** Antibiotic 3 11 68 ± 3 n.d. n.d. 0/12 n.d.-126 11 1/12 n.d.-252 157 10/12 n.d.-240 100 7/12 
Paroxetine *** Antidepressant 27 89 86 ± 12 n.d. n.d. 0/12 n.d.-39732 9676 11/12 n.d.-1927 251 10/12 n.d n.d 0/12 
Fluoxetine*** Antidepressant 17 57 41 ± 3 n.d. n.d. 0/12 n.d.-3465 359 4/12 n.d.-971 219 6/12 n.d.-3090 946 10/12 
Galaxolide Musk 1 1 94 ± 2 119-1698 478 12/12 152-526 396 12/12 50-2780 465 11/11 53-617 204 11/11 
Tonalide Musk 1 1 82 ± 3 57-270 124 12/12 85-421 178 12/12 23-816 140 11/11 18-190 72 11/11 
Cashmeran Musk 1 1 83 ± 3 97-1275 599 12/12 127-2477 1362 12/12 93-4040 1447 11/11 66-2151 698 11/11 
Celestolide Musk 2 2 85 ± 4 6-428 216 12/12 288-1442 470 12/12 30-885 149 11/11 19-308 101 11/11 
Traseolide Musk 2 2 85 ± 4 35-165 87 12/12 125-676 207 12/12 7-309 53 11/11 10-79 37 11/11 
 n.d. – not detected 
Differences in frequency of detection (occurrences per samples analysed) between sampling days are:  * statistically significant (p< 0.05), ** very significant (p< 0.01), *** highly significant (p< 0.001).  
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Table 4.2 - Range of concentration, mean concentration, and frequency of detection of infrequently detected PhACs and musks. Limits of detection and quantification are 
indicated where available. 
     Monday   Tuesday   Monday   Tuesday  
Compound Human effect 
LOD 
(ng L
-1
) 
LOQ 
(ng L
-1
) 
Range 
(ng L
-1
) 
Mean 
(ng L
-1
) 
Freq of 
Detection 
Range 
(ng L
-1
) 
Mean 
(ng L
-1
) 
Freq of 
Detection 
Range 
(ng L
-1
) 
Mean 
(ng L
-1
) 
Freq of 
Detection 
Range 
(ng L
-1
) 
Mean 
(ng L
-1
) 
Freq of 
Detection 
Allopurinol Gout treatment 22 73 n.d.-8234 1498 3/12 n.d. n.d. 0/12 n.d. n.d. 0/12 n.d. n.d. 0/12 
Dimethyl-
phenazone 
Analgesic; 
antiinflamatory 
29 95 n.d. n.d. 0/12 n.d.-221 18 1/12 n.d. n.d. 0/12 n.d. n.d. 0/12 
Paracetamol Analgesic 3 9 n.d. n.d. 0/12 n.d.-342 29 1/12 n.d.-91 8 1/12 n.d.-266 22 1/12 
Codeine Analgesic - - n.d. n.d. 0/12 n.d.-351.2 55 3/12 n.d. n.d. 0/12 n.d. n.d. 0/12 
Acetylsalicylic acid Analgesic - - n.d. n.d. 0/12 n.d. n.d. 0/12 n.d.-172 28 2/12 n.d.-404 88 3/12 
Caffeine CSN stimulant 27 91 n.d.-11751 1047 2/12 n.d.-2380 287 2/12 n.d.-4684 1205 10/12 n.d.-9175 1389 3/12 
Omeprazole 
Proton pump 
inhibitor 
- - n.d. n.d. 0/12 n.d.-148 21 3/12 n.d. n.d. 0/12 n.d. n.d. 0/12 
Domperidone Antidopaminergic 3 9 n.d.-9145 1108 2/12 n.d.-77349 19150 12/12 n.d. n.d. 0/12 n.d. n.d. 0/12 
Propranolol β-Blocker 4 15 n.d. n.d. 0/12 n.d.-23446 2840 4/12 n.d. n.d. 0/12 n.d. n.d. 0/12 
Ramipril 
Congestive heart 
failure 
9 31 n.d. n.d. 0/12 n.d. n.d. 0/12 n.d.-2265 227 3/12 n.d. n.d. 0/12 
Betamethasone 
Corticosteroid 
(SAID) 
6 20 n.d.-61 5 1/12 n.d.-64 10 2/12 n.d.-343 145 7/12 n.d. n.d. 0/12 
Carbamazepine Antiepileptic 2 7 n.d. n.d. 0/12 n.d.-1950 461 4/12 n.d. n.d. 0/12 n.d. n.d. 0/12 
Nimesulide NSAID 14 46 n.d. n.d. 0/12 n.d.-671 70 3/12 n.d. n.d. 0/12 n.d. n.d. 0/12 
Naproxen NSAID 18 59 n.d. n.d. 0/12 n.d.-244 37 4/12 n.d. n.d. 0/12 n.d.-78 16 3/12 
Flurbiprofen NSAID 18 58 n.d.-15480 4564 5/12 n.d.-1777 299 4/12 n.d.-18608 3645 5/12 n.d.-5385 752 6/12 
Indomethacin NSAID 7 23 n.d. n.d. 0/12 n.d.-1639 254 5/12 n.d.-686 99 6/12 n.d. n.d. 0/12 
Fentiazac NSAID - - n.d. n.d. 0/12 n.d.-317 - 1/12 n.d.-208 25 2/12 n.d. n.d. 0/12 
β-Estradiol Estrogen 4 12 n.d. n.d. 0/12 n.d.-937 97 4/12 n.d. n.d. 0/12 n.d.-750 95 4/12 
17α-Ethinylestradiol Estrogen 21 69 n.d. n.d. 0/12 n.d.-76 7 2/12 n.d.-80 39 10/12 n.d. n.d. 0/12 
n.d. – not detected 
80 
 
Table 4.2 - (cont.) Range of concentration, mean concentration, and frequency of detection of infrequently detected PhACs and musks. Limits of detection and quantification 
are indicated where available. 
 
    Monday   Tuesday   Monday   Tuesday  
Compound 
Human effect 
LOD 
(ng L
-1
) 
LOQ 
(ng L
-1
) 
Range 
(ng L
-1
) 
Mean 
(ng L
-1
) 
Freq of 
Detection 
Range 
(ng L
-1
) 
Mean 
(ng L
-1
) 
Freq of 
Detection 
Range 
(ng L
-1
) 
Mean 
(ng L
-1
) 
Freq of 
Detection 
Range 
(ng L
-1
) 
Mean 
(ng L
-1
) 
Freq of 
Detection 
Escitalopram Antidepressant 14 47 n.d.-32228 3506 2/12 n.d. n.d. 0/12 n.d. n.d. 0/12 n.d.-1104 381 8/12 
Salbutamol 
β2-Adrenergic 
receptor antagonist 
11 36 n.d. n.d. 0/12 n.d. n.d. 0/12 n.d. n.d. 0/12 n.d.-1301 317 4/12 
Budesonide 
Corticosteroid 
(asthma) 
21 69 n.d. n.d. 0/12 n.d.-12302 1051 2/12 n.d.-191 16 1/12 n.d.-51 4 1/12 
Fluticasone 
Glucocorticosteroid 
(asthma) 
25 85 n.d. n.d. 0/12 n.d.-7809 658 2/12 n.d.-569 67 4/12 n.d.-96 23 5/12 
Tramadol 
Opioid centrally 
action 
20 67 n.d. n.d. 0/12 n.d. n.d. 0/12 n.d. n.d. 0/12 n.d.-1130 94 1/12 
Furosemide Loop diuretic 19 63 n.d. n.d. 0/12 n.d. n.d. 0/12 n.d.-801 116 2/12 n.d. n.d. 0/12 
Alprazolam 
Anxiolytic, 
tranquilizer 
- - n.d. n.d. 0/12 n.d.-4705 548 6/12 n.d.-89 12 2/12 n.d.-153 66 9/12 
Oxazepam Anxiolytic - - n.d. n.d. 0/12 n.d. n.d. 0/12 n.d-36 - 1/12 n.d.-155 22 2/12 
Bromazepam 
Anxiolytic, 
tranquilizer 
- - n.d. n.d. 0/12 n.d. n.d. 0/12 n.d.-36 5 2/12 n.d. n.d. 0/12 
Amoxicillin Antibiotic 13 43 n.d. n.d. 0/12 n.d. n.d. 0/12 n.d.-569 252 9/12 n.d. n.d. 0/12 
Azithromycin Antibiotic 3 11 n.d. n.d. 0/12 n.d. n.d. 0/12 n.d. n.d. 0/12 n.d.-210 97 8/12 
Ciprofloxacin Antibiotic 1 3 n.d. n.d. 0/12 n.d.-22074 1840 1/12 n.d. n.d. 0/12 n.d.-15397 3985 4/12 
Telmitarsen 
Angiotensive; 
hypertension 
- - n.d. n.d. 0/12 n.d.-20 3 2/12 n.d.-187 18 2/12 n.d. n.d. 0/12 
Tiaprofencic acid NSAID - - n.d. n.d. 0/12 n.d.-1175 131 3/12 n.d.-914 303 9/12 n.d. n.d. 0/12 
Lovastatin Antideslipidemic - - n.d. n.d. 0/12 n.d. n.d. 0/12 n.d.-251 145 10/12 n.d. n.d. 0/12 
Clofibrate ethyl 
Lipid modifying 
agent 
- - n.d.-15568 1398 3/12 n.d.-917 111 6/12 n.d.-56 20 6/12 n.d.-44 11 4/12 
Salicylic acid Analgesic - - n.d. n.d. 0/12 n.d. n.d. 0/12 n.d.-2780 561 5/12 n.d. n.d. 0/12 
Penincillin G Antibiotic 14 47 n.d. n.d. 0/12 n.d. n.d. 0/12 n.d.-127 11 1/12 n.d. n.d. 0/12 
n.d. – not detected 
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Table 4.3 - PhACs and musks that were never detected. Limits of detection and quantification 
are indicated when available. 
 
Compound Human effect 
 
LOD 
(ng L
-1
) 
 
LOQ 
(ng L
-1
) 
Compound Human effect 
 
LOD 
(ng L
-1
) 
 
LOQ 
(ng L
-1
) 
Sertraline Antidepressant - - Reserpine Antiadrenergic agent 8 28 
Digoxin Cardiac glycoside 25 83 Warfarin Anticoagulant - - 
Diazepam 
Anxiolytic, 
Tranquilizer 
- - Progesterone 
Steroid contraceptive 
hormone 
2 6 
Diltiazem 
Hypertensive, calcium 
blocker 
6 18 
Ecstasy 
(MDMA) 
Psychoactive drug 18 61 
Glibenclamide 
Diabetes type II 
treatment 
6 20 
Tetrahydro-
cannabinol 
Psychoactive drug 17 58 
Latanoprost 
Ocular hypertension 
(glaucoma) 
- - Triprolidine Antihistaminic - - 
Lorazepam Anxiolytic - - Zolpiden Insomnia treatment - - 
Nifedipine Calcium blocker 19 62 Mexazolam 
Anxiolytic, 
tranquilizer 
- - 
Phenazone NSAID 7 22 Valerian 
Anxiolytic,  
tranquilizer 
- - 
Piroxicam NSAID 1 4 Mirtazepine Antidepressant - - 
Ranitidine 
Histamine H2 receptor 
antagonist 
- - Phantolide Musk 1 1 
 
 
4.3.2 Diurnal variations of the PhACs and musks in the WWTP 
 
The diurnal variations of the total concentration of PhACs and musks detected in the filtered influent 
are shown in Figures 4.2a and 4.2b, respectively. In general, the total concentration of musks tended to 
follow a trend where higher concentrations were observed during the day and low concentrations were 
observed at night (with the exception of 2 outliers, the 4 a.m. sample on Day 3 and the 24 h sample on 
Day 2). Further, this trend was repeatable between the 4 sampling days, and the total concentration of 
musks measured was in a similar range in each case. However, the PhACs profile observed throughout 
each day was less repeatable as compared to the musks. On Days 1 and 2 (Monday and Tuesday from 
the first week of sampling), there appeared to be a higher PhAC concentration in the evening or night 
as compared to during the day. On Days 3 and 4 (Monday and Tuesday from the second week of 
sampling), there was a lower total concentration of PhACs compounds throughout the day with much 
smaller fluctuations. The reason for this difference is unclear, since the sampling strategy and weather 
conditions were consistent during each sampling day. 
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Figure 4.2 - Diurnal variations of the total concentration of PhACs (a) and the total concentration of 
musks (b) in the influent to the WWTP during each day of the campaign. 
 
Figure 4.3 shows the relative contribution of the main PhAC (a) and musk (b) compounds towards the 
total concentration detected. It can be observed that diclofenac and ketoprofen were the most abundant 
of the analysed compounds, and usually responsible for the peak concentrations that were occasionally 
observed. Throughout the four sampling days analysed, diclofenac comprised an average of 40 ± 24 % 
of the total PhACs concentration and was regularly present in relatively high levels. This correlates 
well with sales data from the official Portuguese database (INFARMED, 2005), where diclofenac 
showed the highest sales when compared to the other compounds detected in this study. Ketoprofen 
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was present in high abundance more sporadically than diclofenac, comprising 36 ± 24 % of the PhAC 
concentration on Day 1, but only 1 ± 1 % on the other 3 days, excluding the 8 a.m. sample on Day 2 
(36%). Overall, NSAIDs (such as diclofenac and ketoprofen) were the family of PhACs detected in 
highest abundance (55 ± 21 %), which is consistent with findings from some literature studies 
(Comeau et al., 2008; Lin et al., 2009; Miége et al., 2009). Cashmeran was the dominant musk 
detected, forming on average 52 ± 18 % of the total musk concentration, while galaxolide was the 
second most abundant musk (22 ± 10 %), with both compounds consistently present in relatively high 
abundance. 
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Figure 4.3 - Mean concentrations of the most frequently detected PhACs and musks throughout each 
sampling day (Days 1, 2, 3 and 4 are plotted for each 2 h-sample). 
 
While a small number of PhACs generally constituted the bulk of the total PhAC concentration, 
occasionally some compounds that were only rarely detected appeared at high levels. One example of 
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this happened at 16 h on Day 2, where omeprazole was primarily responsible for the PhAC peak load 
observed at this time (67% of the total PhAC concentration).  
 
Table 4.4 shows the diurnal variations in the influent throughout the periods of 8-16 h (day), 16-24h 
(evening) and 0-8 h (night). It can be observed that the total PhACs did not display a particular trend, 
while the musks were more abundant during the day. Also, the overnight mass loadings were generally 
quite low for the musks, with the exception of a peak load at 4 a.m. on Day 3. This pattern is similar to 
the wastewater flow. The WWTP influent flow rate (Table 4.4) shows that the wastewater flow was 
almost constant during the day, however, a notable decrease in flow was observed at night. 
Nevertheless, the total PhACs mass flow does not follow this pattern. 
 
 Table 4.4 - Diurnal variations of total pharmaceuticals and musks during the 
periods of 8-16 h, 16-24 h and 0-8 h for each day of the campaign. 
 
  % of Total Mass Flow 
 Time 8-16 h 16-24 h 0-8 h 
 Day 1 19 40 41 
PhACs Day 2 33 25 42 
 Day 3 29 41 30 
 Day 4 23 44 33 
 Average 26±6 38±8 36±6 
 Day 1 43 41 16 
Musks Day 2 43 39 17 
 Day 3 38 20 42 
 Day 4 74 17 9 
 Average 50±16 29±13 21±14 
Flow m
3
 h
-1
 147±11 143±18 103±27 
 
Figure 4.4 shows the relative contribution of the 15 most frequently detected PhACs throughout the 
sampling days. Eight of these 15 compounds average less than 25% of their total mass flow during the 
night period, including ibuprofen, etofenamate, clorazepate, atenolol, captopril, ampicillin, estrone and 
hydroxyzine. Etofenamate presented the lowest average mass flow of the PhACs at night (9 ± 8%), 
which could be related to the fact that this compound is administered as a gel, lotion or cream. This is 
similar to the musk compounds, and correspondingly, etofenamate appears to follow the same diurnal 
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pattern as most musks. Four compounds (ketoprofen, indapamide, paroxetine, enalapril) averaged > 
50% of the total mass flow during the night period, thus displaying the opposite diurnal profile. The 
other three compounds (diclofenac, clofibric acid and fluoxetine) did not display any repeatable 
diurnal trend. The differences observed between the diurnal patterns of these PhACs likely reflect the 
varying frequencies of administration by consumers. Indeed, PhACs are administrated for specific 
medical reasons and the demand for these compounds is highly variable with time, as opposed to 
musks, which are more often used as part of routine hygiene habits.  
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Figure 4.4 - Average percentage of PhAC mass flow that were detected during the periods of 8-16 h, 16-24 h 
and 0-8 h, for different families of the most frequently detected PhACs. Error bars indicate the 
standard deviation found for the 4 sampling days. 
 
4.3.3 Mean and peak concentration of the PhACs and musks 
 
The variability of the mean concentration of the 20 most commonly detected PhACs and musks for the 
4 days of the campaign is shown in Figure 4.5. It can be observed that the 5 musks presented a 
relatively small variability in the mean concentration among the different days of the campaign as 
compared to the PhACs. The total musk loading to the WWTP was 0.74 ± 0.25 g d-1, showing a 34 % 
relative standard deviation. By comparison, the total PhAC mass loading was 84.7 ± 63.8 g d-1, a 
relative standard deviation of 75 %. Of the 5 PhACs that were detected each day of the campaign 
(diclofenac, ibuprofen, ketoprofen, clofibric acid and atenolol) the mean concentration varied between 
1-3 orders of magnitude. Nine of the remaining 10 PhACs shown in Figure 4.5 were detected in both 
days of the second week, showing generally consistent mean concentrations for each compound on 
these days. Eight of these nine compounds were not detected during Days 1 and 2, thus, the loading of 
PhACs changed significantly for this WWTP from one week to the next. This implies that frequent 
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sampling campaigns will be required over time to obtain a representative description of the PhAC 
loading to the WWTP for e.g. modelling purposes. 
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Figure 4.5 - Mean concentrations of the most frequently detected PhACs and musks during each sampling day 
of the campaign. 
 
In contrast, relatively little variability was observed for the musk compounds detected in this study. 
The differences in the mean concentration from each day were always far less than one order of 
magnitude apart. The occurrence of musks was in the same concentration range or lower than the 
PhACs (Figure 4.5), showing that the higher repeatability observed with these compounds was not due 
to higher abundance.  Rather, the fact that these compounds were ubiquitously present in the influent 
is likely reflective of their more regular and widespread usage than PhACs. This implies that obtaining 
a representative description of the musk compounds entering the WWTP is a far simpler task as 
compared to the PhACs. 
 
The ratio of the maximum concentration detected to the mean concentration (max/mean) provides an 
indication of the occurrence of peak loads as well as their relative magnitude. Figure 4.6 shows the 
ratio of max/mean for the top 20 most frequently detected PhACs and musks. In general, the 
max/mean values are more variable for the PhACs as compared to the musks. For the musks, the 
max/mean was between 2 and 4 for three of the four sampling days, while a value above 6 was 
observed for most musks on Day 3, corresponding to the peak load at 4 a.m. of that day. For the 
PhACs, the max/mean ratio of the samples from the first week generally varied more than the second 
week, which was more consistent. The max/mean of ketoprofen approached the theoretical maximum 
on Day 2 (11.2) despite the fact that this compound was detected in every sample analysed on this day. 
         PhACs                                              Musks 
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This shows that the ketoprofen maximum peak load on Day 2 (8 a.m.) far outweighed the 
concentration observed throughout the rest of the day; indeed, the concentration of this sample was 
greater than 2 orders of magnitude higher than the average ketoprofen concentration of the remaining 
samples. Paroxetine and clorazepate also displayed high variability in the max/mean ratio, where the 
highest value observed was approximately 8. On Day 1, captopril was only detected once, while 
atenolol was only detected once during Days 1 and 2, thus, at these times the max/mean ratios were 
the theoretical maximum for these two compounds.  
 
Figure 4.6 - Max/mean concentrations of the most frequently detected pharmaceuticals and musks for the 4 days 
of the campaign. Since 12 samples were analysed per day, the highest possible max/mean is 12, 
while the lowest possible ratio is 1, unless the compound was not detected on that day, in which case 
the max/mean value is represented as zero.  
 
The max/mean generally ranges between 2 and 3 for BOD, suspended solids (SS), nitrogen and 
phosphorus in the influent to WWTPs (Tchobanoglaus and Burtan, 1995). While shock loads of these 
macropollutants are also known to occur occasionally, there is often a more repeatable pattern as 
compared to micropollutants such as PPCPs. As seen from Figures 4.3 and 4.6, the influx of most 
PhACs do not follow a repeatable pattern and peak loads of different compounds appear to occur 
sporadically. However, the results of this study suggest that musk compounds do, in general, follow 
the typical pattern exhibited by macropollutants (i.e. higher loadings throughout the day, lower at 
night) and are quite repeatable over the 4 sampling days, although occasionally higher peak loads can 
also be expected, such as those observed for most musks during day 3 (max/mean ~ 6).  
 
 
 
 
         PhACs                                                             Musks 
88 
 
4.3.4 Implications of the results and comparison with literature 
 
Upon comparing the results from this study with those who have studied diurnal variations of PPCPs 
in literature, it can be observed that most studies have generally found that the micropollutants studied 
followed a similar pattern as compared to macropollutants; i.e. a clear decrease in the loading of these 
compounds was observed at night (Joss et al., 2005; Göbel et al., 2005; Plósz et al., 2010). This study 
has investigated a higher number of compounds, many differing from those analysed in previous 
works. Thus, we have focussed this comparison with literature on either the same compounds, or 
similar compounds (i.e. from the same therapeutic family).  
 
For example, Joss et al. (2005) studied the diurnal pattern of two musks also found in this study, 
galaxolide and tonalide. Our results indicate that these compounds, as well as the other musks 
detected, were generally less abundant at night (Figures 4.2 and 4.3), which agrees well with the 
results of Joss et al. (2005). Similarly, Plósz et al. (2010) found that estrone was also present in lower 
abundance at night, which was in accordance with our results (Figure 4.4). Previous studies 
investigating antibiotic compounds (Joss et al., 2005; Göbel et al., 2005; Plósz et al., 2010) also 
observed a similar diurnal pattern. Although the specific antibiotic compounds detected in those 
studies were not widely detected at the Fernão Ferro WWTP, the one antibiotic that was frequently 
detected (ampicillin) was also present in low abundance at night (Figure 4.4). Thus, the results of this 
study are in accordance with literature findings. However, many other compounds were detected in 
this study that displayed differing diurnal patterns (e.g. ketoprofen, paroxetine, enalapril and 
indapamide) where the mass loadings were higher at night. This highlights the fact that patterns 
observed for some micropollutant groups cannot be readily extrapolated to other types of 
micropollutants. It is clear that different types of PPCPs display dissimilar diurnal variations, likely 
due to their varying administration patterns.  
 
Furthermore, the results from this study show that even for the most commonly detected PhACs, 
variations in the mean concentration greater than 1 order of magnitude were found from one day to the 
next. The diurnal trend observed for PhACs was also variable between the first and second weeks and 
the occurrence of peak loads varied widely and was highly unpredictable. Obtaining a representative 
description of PhAC loading to WWTPs for modelling purposes is clearly a challenging task. Indeed, 
a ―steady-state‖ did not exist for PhACs, unlike the musks. It is possible that obtaining a representative 
description of PhACs is not practically feasible due to the typically intermittent consumption of many 
different compounds, where some substances are consumed and excreted only on certain days by a 
small number of point sources (i.e. consumers). The high cost associated with analysing these 
compounds further inhibits the practical feasibility of performing multiple sampling campaigns. These 
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issues are important to be resolved in order to model the fate of these compounds in WWTPs, since 
wastewater influent characterisation is important for model calibration and application, and these 
models usually describe typical ―steady-state‖ conditions of the WWTP. Nevertheless, it should be 
noted that a much higher repeatability was observed among the musks analysed, suggesting that less 
intensive monitoring is needed for acquiring the necessary data to model these compounds in WWTPs. 
  
4.4 Conclusions  
 
The dynamics of PPCPs in a WWTP was evaluated through an intensive sampling campaign covering 
a large number of pharmaceuticals and musks. It was found that the PhAC concentrations in the 
influent were subject to a wider variability than the musks, which were more repeatable. The typical 
diurnal pattern for macropollutants (i.e. higher loading during the day as compared to the night) was 
observed for the musks and some PhACs, while other frequently detected PhACs (e.g. ketoprofen) 
displayed the opposite trend or no trend. In general, the mean PhAC loadings varied between 1-3 
orders of magnitude from one sampling day or week to the next, whereas the mean musk loadings 
were far less than one order of magnitude apart. This information is relevant to the design of sampling 
campaigns for modelling purposes. 
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CHAPTER 5 
 
 
 
ASSESSING THE REMOVAL OF PHARMACEUTICAL AND PERSONAL CARE 
PRODUCTS IN A FULL-SCALE ACTIVATED SLUDGE PLANT  
 
 
 
5.1 Introduction 
5.2 Materials and Methods 
5.3 Results and discussion 
5.4 Conclusions 
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5. Assessing the Removal of Pharmaceuticals and Personal Care 
Products in a Full-Scale Activated Sludge Plant 
 
This study aimed to investigate the removal mechanisms of pharmaceutical active compounds 
(PhACs) and musks in a wastewater treatment plant (WWTP).  Biological removal and adsorption in 
the activated sludge tank as well as the effect of UV radiation used for disinfection purposes were 
considered when performing a sampling campaign. The fluxes of the most abundant compounds (13 
PhACs and 5 musks) out of 79 compounds studied were used to perform a mass balance of the 
WWTP. Results show that incomplete removal of diclofenac was observed via biodegradation and 
adsorption, and that UV radiation was the main removal mechanism for this compound found in the 
highest abundance. The effect of adsorption to the secondary sludge was often negligible for the 
PhACs, with the exceptions of diclofenac, etofenamate, hydroxyzine and indapamide, however, the 
musks showed a high level of adsorption to the sludge. UV radiation reduced the concentration of 
some of the target compounds (e.g. diclofenac, ibuprofen, clorazepate, indapamide, enalapril and 
atenolol) not removed in the activated sludge tank. The removal of PhACs and musks studied in the 
WWTP was most often biological (45%), followed by adsorption (33%) and by UV radiation (22%). 
In the majority of the cases, the plant achieved > 75% removal of the most detected PhACs and musks, 
with the exception of diclofenac.  
 
5.1 Introduction  
The discharge of pharmaceutical active compounds and personal care products (PPCP) from 
wastewater treatment plants (WWTP) is a growing concern worldwide, due to their potentially 
harmful effects on aquatic life and tendency to infiltrate into drinking water supplies (Kreuzinger et 
al., 2004, Andersen et al., 2003 and 2005; Gagné et al., 2006; Nakada et al., 2005 and 2006, Oulton, et 
al., 2010, Sim et al., 2011).  
Studies focused on their fate in WWTP have shown that these compounds are mainly a) adsorbed to 
the primary and secondary sludges (Carballa et al., 2004 and 2007; Jélic et al., 2011), b) biologically 
removed during secondary treatment (Clara et al., 2005; Carballa et al., 2007; Radienovic et al., 2009; 
Jélic et al., 2011); and c) removed in tertiary treatment via e.g. advanced oxidation processes 
(Méndez-Arriaga et al., 2009, Naddeo et al., 2009a and 2009b, Bundschuh et al., 2011).   
Artola-Garicano et al., (2003), Joss et al. (2005) and Clara et al., (2011) reported no substantial 
biodegradation of musks and that adsorption is the main mechanism that should be taken into account 
for these compounds. In contrast, biodegradation has often been the primary removal mechanism for 
some PhACs. Carballa et al., (2007) observed 50-70% biodegradation for PhACs such as ibuprofen, 
naproxen and sulfamethoxazole, while Joss et al. (2005) and Plósz et al. (2010) observed a similar 
range for the biodegradation of naproxen and sulfamethoxazole, although ibuprofen was >80% 
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biodegraded. While many studies have investigated PPCP removal during secondary treatment (i.e. 
biodegradation and adsorption to secondary sludge), these studies are seldom combined with an 
evaluation of PPCP removal via tertiary treatment.  
Advanced oxidation technologies have been carried out in WWTP and applied to the transformation of 
PhAC by the use of ozone (De Witte et al., 2009), different chemical oxidants (Sharma, 2008) and 
sonolyis (Hartmann et al., 2008) but only a few have considered the effect of UV radiation used for 
disinfection on the removal of PhACs (Nakada et al., 2005) and musks. Most of the studies on UV 
radiation and UV combined with hydrogen peroxide have been carried out in lab scale reactors rather 
than in full-scale treatment systems.  
Göbel et al., (2005) studied the occurrence of sulfonamides, macrolides, and trimethoprim in 
wastewater samples from the raw influent to the final effluent as well as activated and digested sewage 
sludge samples in municipal wastewater treatment plants. These authors found that clarithromycin and 
trimethoprim were not biodegraded or adsorbed, but partly removed during sand filtration, while 
sulfamethoxazole was mostly removed biologically, and not removed via tertiary treatment. The 
removal mechanisms of biodegradation, adsorption and oxidation processes (e.g. UV) combined 
together and their effects on the final loads of PhAC and musks in the treated wastewater and sludge 
have seldom been investigated in detail in previous works.  
The main goal of this study is to provide insight, through the use of mass balances, on the removal of 
PPCPs in a full-scale WWTP taking into account the raw influent, effluent prior to UV, effluent post-
UV and secondary sludge loads. A sampling campaign was performed during 4 different days over 
two consecutive weeks in order to fulfill this objective. A large number of compounds were analysed 
(79 PPCPs, including 73 PhACs and 6 musks), whereby the mass balance was performed on the most 
abundant 13 PhACs and 5 musks. 
 
5.2. Materials and methods  
 
5.2.1 Full-scale wastewater plant 
 
The WWTP of Fernão Ferro (Seixal, Portugal) has the design capacity to handle approximately 32 700 
population equivalents (Figure 5.1).  
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Figure 5.1 - Schematic diagram of the municipal wastewater treatment plant studied. 
 
In the liquid stream, the treatment comprises, retention of coarse solids in a receiving chamber (8 m
3
), 
two lines of mechanical pre-treatment (removal of sand and coarse solids and oil and grease), followed 
by the elevation of pre-treated effluent through pumps to the primary sedimentation tank. The 
activated sludge process in carried out in two aerobic reactors with a Carrousel  configuration of 900 
m
3
 each, where aeration is provided by two surface aerators. A selector is installed previous to the two 
biological reactors to combine the influent wastewater of the primary settler and the recycled sludge. 
The solid phase removed from the secondary settler is pumped and recycled to the aeration tank and a 
waste fraction is removed for sludge treatment with the primary sludge. Finally, the disinfection of the 
effluent is carried out in two channels, of 6 m
3
 each, with UV lamps (low pressure, wavelength of 254 
nm, operating at maximum flow rate of 760 m
3
h
-1
 and total suspended solids (TSS) of approximately 
25 mg L
-1
).  
 
5.2.2 Sampling collection 
 
The influent composite samples were collected in the receiving chamber and effluent composite 
samples were collected at the inlet and outlet of the UV channel. Grab samples of primary and the 
secondary sludge were also collected for analysis. Two consecutive weeks were monitored. In both 
weeks, influent samples on Monday and Tuesday (24 h composite samples of sampling interval of 2 
hour - see Salgado et al. (2011)) and Wednesday (24 h composite samples of sampling interval of 1 
hour) were taken with an auto-sampler. The effluent samples (before and after the UV channel) 
consisted of 24h composite samples (sampling interval = 1 hour) collected with an auto-sampler. The 
effluent samples were taken one day following the inlet samples (i.e. Tuesdays, Wednesdays and 
Thursdays), which approximately corresponded to the hydraulic retention time (HRT) of the plant 
(0.9±0.1 d). Secondary sludge samples were collected on Tuesday and Thursday of the first week and 
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Wednesday and Thursday of the second week. Thus, biological removal vs. adsorption was calculated 
for the 4 days where sludge sampling was carried out, whereas the overall removal (influent - final 
effluent) was calculated for the 6 sampling days. The samples were transported to the laboratory in a 
refrigerated isothermal container and immediately extracted and stored at -20
o
C until the analysis was 
performed. The samples were prepared for analysis of two different classes of pharmaceutical 
compounds (acidic and neutrals) according to the procedure described below. 
  
5.2.3 Analytical methods 
 
Analytical details, including information on materials and reagents used and limits of detection and 
quantification, are described for wastewater and sludge samples in Salgado et al. (2010). The 
compounds monitored in this study included those described in Salgado et al. (2011). Solid phase 
extraction (SPE) was used for PhAC analysis in the liquid phase (influent and effluent samples). SPE 
was carried out with Waters Oasis HLB for the acidic pharmaceutical compounds, while Waters RP-
C18 cartridges were used for the neutral compounds.  
The analysis of the PhAC and musk content of the secondary sludge was performed according to 
Ternes et al. (2005). Sludge samples were centrifuged at 10 000 rpm for 5 min to separate the solid 
from the liquid fraction. Ultrasonic solvent extraction (USE) was used as the extraction procedure of 
the PhAC from the sludge samples prior to SPE. The detection of acidic and neutral pharmaceutical 
active compounds by LC-MS (HPLC-DAD-(ESI)MS) in reverse-phase chromatography 
(LiChroCART 250-4 Purospher Star RP18 endcapped, 5 μm, column, Merck) of the samples was 
performed with DAD (diode array detector) detection. 
The extraction of polycyclic musk fragrances was carried out by headspace solid-phase 
microextraction (HS-SPME). The detection of these compounds was performed by GC-MS using a 
Hewlett-Packard 5890 GC fitted with a QMD1000 Carlo Erba mass spectrometric detector. A DB-
5MS fused-silica capillary column (30 m x 0.32 mm i.d., 0.25 μm film thickness) purchased from 
Agilent-J&W Scientific (Spain), was used for analytical separation.  
 
5.2.4 Mass balance and removal calculations 
 
In the mass balances carried out in this study, it was assumed that no biological or chemical reactions 
took place in the primary and secondary settlers. It was also assumed that the adsorption equilibrium 
of the PPCPs and primary sludge was attained in the sewer. The liquid influent PPCP load to the 
receiving chamber of the WWTP is therefore equal to the liquid PPCP load of the supernatant of the 
primary settler. The PPCPs concentrations in the solid fraction (Cs) of the activated sludge were 
measured in the sludge recycling from the secondary settler to the activated sludge tank.  
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The adsorption fraction was determined based on the new biomass generation rate in the aeration tank, 
which was assumed to be responsible for adsorbing the PhACs and musks that entered via the influent 
wastewater (Joss et al., 2005). This new biomass generated is, thus, the new surface available for 
additional sorption, and can be estimated based on the purged sludge flow rate, according to equation 
5.1: 
 
in
wsld
new
Q
QSS
SS
.
                                                                    (eq. 5.1) 
 
Where Qw is the excess sludge flow rate (m
3
 d
-1
), Qin is the influent wastewater flow rate (m
3 
d
-1
), SSsld 
is the suspended solids concentration in the excess sludge and SSnew is the sludge production per unit 
of treated wastewater (kgSS m
-3
). The new biomass produced daily in the aeration tank was used in 
equation 5.2 to determine the load of PPCP eliminated by sludge wastage: 
 
snewinww
w
s
newinwwsld CSSQCQ
C
C
SSQQCL ......       (eq. 5.2) 
 
Lsld is the total load of the PPCP in the excess sludge ( g d
-1
),  Cs is the sorbed concentration of PPCP 
per amount of suspended solids (µg kgSS
-1
), Cw is the soluble concentration of PPCP (µg m
-3
).  
The biological transformation was calculated from difference mass balance of the loads of the influent, 
effluent (prior to UV) and excess sludge: 
 
Lbio = Lin – (Lsld + Lout)                                                                                      (eq. 5.3) 
 
The removal by UV photolysis was obtained by the load difference before and after the UV chamber. 
 
5.3. Results and Discussion  
 
5.3.1 Removal mechanisms of PhACs and musks in the WWTP 
 
5.3.1.1. Biological removal 
 
Out of the 79 PPCPs assessed in this study, mass balances were carried out for the 13 most abundant 
PhACs and 5 musks with the aim of identifying the most relevant removal mechanism. The daily 
average inlet flow rate used to calculate the loadings into the WWTP had minimum and maximum 
values of 2485 and 3117 m
3 
d
-1
, respectively. PhACs and musks biodegradation in the activated sludge 
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tank was quite variable for the different days analyzed (Table 5.1), but the overall level of biological 
removal could be classified into 3 separate groups as: a) low; b) medium and c) high biological 
removal.  
 
Table 5.1 - Removal via biological degradation of  the 13 most detected PhACs and 5 musks.  
 Biological Removal (g d
-1
) 
Level of 
removal by 
biodegradation Δ 
Day Day 1 Day 3 Day 9 Day 10 Average StDev 
Diclofenac -23.1 -4.1 -47.5 -24.1 -24.7 17.8 low 
Etofenamate -0.3* -1.1 -2.6 12.4 2.1 6.9 medium 
Ibuprofen 45.1 0.5 0.4 -0.3 11.4 22.5 high 
Ketoprofen 83.3 -0.2 0.0 -0.3* 20.7 41.7 high 
Fluoxetine 0.0* 0.0* 2.1 0.0* 0.5 1.1 high 
Clorazepate 0.0* 0.2 -1.3 0.9 -0.1 0.9 low 
Hydroxazine -2.3* -1.6* 0.3 1.1 -0.6 1.6 low 
Indapamide -0.9* -0.1* -22.8 -3.0 -6.7 10.8 low 
Enalapril 0.0* -0.3 3.1 0.0 0.7 1.6 medium 
Captopril 2.1 -0.6 1.6 1.4 1.1 1.2 medium 
Atenolol 12.8 2.8 2.0 0.9 4.6 5.5 high 
Clofibric acid 49.9 0.2 -0.3* 0.0 12.4 25.0 high 
Ampicillin -0.1* 0.0* 0.2 0.5 0.2 0.3 high 
Galaxolide -0.4 -3.7 -32.0 -29.0 -16.3 16.5 low 
Tonalide 0.2 -0.3 -3.8 -3.9 -1.9 2.2 low 
Cashmeran -0.8 -3.8 -64.3 -41.5 -27.6 30.7 low 
Celestolide 0.5 -0.3 -3.9 -0.2 -1.0 1.9 low 
Traseolide 0.2 -0.1 -1.1 -0.1 -0.3 0.6 low 
Δ
Low removal represents <25% removal from the average influent load, medium represents >25% and <75% removal,  
while high removal represents >75% removal;*Compound was below the detection limit in the influent. 
 
The compounds were considered to display low biological removal when the average removal was      
< 25% of the average influent load for the 4 days analyzed. The low biological removal of some of the 
PhAC could be related with the influent load variability and sampling uncertainty in the influent, as 
discussed below. Medium biological removal corresponds to average removal loads between 25% and 
75% of the average influent load. 
Medium biological removal loads were found for etofenamate, enalapril and captopril. The high 
biological removal corresponds to situations when the removal was consistently high (>75%) relative 
to the average influent load during the campaign. The days where compounds were not detected in the 
influent (see Appendix II) were exempted from these calculations. The biological removal rates 
showed a large variability from one week to another in most of the compounds studied, and the total 
removal observed also varied within a pharmaceutical group. For example, within the therapeutical 
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group of the non-steroidal anti-inflammatory drugs (NSAIDs), diclofenac displayed low biological 
removal, etofenamate exhibited medium biological removal and ibuprofen and ketoprofen had high 
biological removal.  
In some days within the study, the output loads were substantially greater than the influent loads (i.e. 
negative removal rates), such as diclofenac on days 1, 9 and 10, and indapamide on day 9, as well as 
the musks, particularly galaxolide and cashmeran on days 9 and 10. The reason for this could be due to 
either (i) sampling uncertainty, particularly in the raw influent where loading rates are more dynamic. 
Ort et al. (2010) found that time-dependent composite samples in the raw influent may be insufficient 
to adequately characterize PPCP removal in WWTPs; (ii) conjugate compounds not detected at the 
influent but retransformed into the original compound due to biological processes; (iii) desorption 
processes in the activated sludge tank of previously adsorbed PhACs and musks.   
The results from previous studies have generally agreed well with the experimental results. Xue et al., 
(2010) and Jélic et al., (2011) also found low diclofenac biodegradation and high effluent 
concentrations. Nakada et al. (2005) found high removal efficiencies for ibuprofen in the WWTP 
varying from 84-98% for influent concentrations of 69-1080 ng L
-1
. This result is in the same range of 
removal efficiencies observed by Joss et al. (2005) and Plósz et al. (2010) for ibuprofen. Ketoprofen 
was almost completely removed biologically (>80%) in Jélic et al., (2011), which also agrees well 
with the results shown in Table 1. For the musks, the biological degradation of galaxolide and tonalide 
was reported as 15 and 30 %, respectively, for the influent loads of galaxolide of 602-671 g d
-1
 and 
tonalide of 248-402 g d
-1
 (Carballa et al., 2007). Joss et al., (2005) found that biodegradation of 
galaxolide was between 0-30% and tonalide was 0-10% in their study. In our study we also found low 
biological removal of both compounds. 
 
5.3.1.2 Removal by adsorption in the activated sludge tank  
 
In Table 5.2, removal by adsorption to the activated sludge is expressed taking into account that only 
the newly formed biomass has available adsorption sites (see Joss et al., 2005) and the remaining 
sludge is fully saturated with the previously adsorbed PPCPs. Similarly to the biological removal 
loads, a scale was established to classify the adsorption removal loads of the PhAC and musks in three 
categories as: a) low, b) medium and c) high adsorption.  
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Table 5.2 - Removal via adsorption of the 13 most detected PhACs and 5 musks. 
 
  Adsorption Removal (g d
-1
)     Theoretical 
logKow 
Level of 
removal by 
adsorption 
Δ
 Day Day 1 Day 3 Day 9 Day 10 Average StDev 
Diclofenac 1.3 1.0 14.9 12.7 7.5 7.3 4.0-4.7 medium 
Etofenamate 0.1* 0.9 2.9 2.5 1.6 1.3 4.2 medium 
Ibuprofen 0.0 0.2 0.2 1.1 0.4 0.5 3.5-4.0 low 
Ketoprofen 0.0 0.0 0.0 0.1* 0.0 0.1 3.0-3.2 low 
Fluoxetine 0.0* 0.0* 0.0 0.0* 0.0 0.0 1.8 low 
Clorazepate 0.0* 0.0 0.7 0.1 0.2 0.4 2.1 low 
Hydroxazine 1.1* 0.8* 0.0 3.1 1.2 1.3 2.4 medium 
Indapamide 0.4* 0.0* 7.1 3.1 2.7 3.2 2.7 high 
Enalapril 0.0* 0.1 0.0 0.4 0.1 0.2  - low 
Captopril 0.4 0.5 0.4 0.7 0.5 0.1 1.7 low 
Atenolol 0.0 0.0 0.0 0.0 0.0 0.0 0.2-1.4 low 
Clofibric 
acid 0.0 0.0 0.7 0.0* 0.2 0.3 2.6-3.6 low 
Ampicillin 0.1* 0.0* 0.0 0.0 0.0 0.0 1.4 low 
Galaxolide 0.9 1.8 14.7 13.2 7.6 7.3 4.6-5.9 high 
Tonalide 0.1 0.1 1.8 1.8 1.0 1.0 4.8-5.7 high 
Cashmeran 1.2 1.8 29.9 18.9 12.9 14.0 4.8 high 
Celestolide 0.1 0.2 1.8 0.1 0.6 0.9 4.4 high 
Traseolide 0.0 0.0 0.5 0.1 0.2 0.2  - high 
Δ
Low removal represents <25% removal from the average influent load, medium represents >25% and <75% removal,  
while high removal represents >75% removal; Compound was below the detection limit in the influent. 
 
 
The adsorption of PhACs to the secondary sludge was important for some NSAIDs (e.g. diclofenac 
and etofenamate) and some other PhACs such as hydroxyzine and indapamide. Adsorption clearly 
outweighs the biological removal for diclofenac, hydroxyzine, indapamide, galaxolide, tonalide, 
cashmeran and celestolide. Low adsorption was observed for fluoxetine, clorazepate, enalapril, 
captopril, and ampicillin. Occasionally high biological removal was found for ibuprofen, ketoprofen, 
atenolol and clofibric acid, thus only negligible amounts of these compounds remained undegraded 
and could be found adsorbed to the sludge (regardless their hydrophobicity). 
The adsorption of PhACs and musks in the secondary sludge is generally in agreement with their 
hydrophobicity (expressed by the octanol - water partition coefficient Kow). LogKow values found in 
literature varies from 3.0 to 5.9 for musks (galaxolide, tonalide, cashmeran, celestolide and traseolide) 
and NSAIDs (diclofenac and etofenamate), which in most cases corresponded to high and medium 
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adsorption observed, with exception of the NSAIDs ibuprofen and ketoprofen that presented a high 
value of logKow but low adsorption was observed. This effect could be due to the high biodegradation 
rates observed for these two compounds. Most of the other compounds detected in the influent 
wastewater have low octanol - water partition coefficients (logKow < 3.0) and low adsorption capacity 
to the sludge. Furthermore, this is in agreement with the low values of adsorption coefficients (Kd) for 
the PhACs and high values for the musks found in literature (Ternes et al., 2004; Joss et al., 2005; 
Clara et al., 2011). These results suggests that only a few PhACs are removed by adsorption  and that 
biodegradation is the most important removal mechanism, however the musks show the opposite trend 
and adsorption is the primary removal mechanism for this group of compounds.   
 
5.3.1.3 Removal by UV radiation  
 
The effluent loads before and after UV disinfection were also calculated in this campaign to evaluate 
the effect of this step on the removal of the PPCPs studied. The removal loads of the PhACs and 
musks in the UV channel of the WWTP are presented in Table 5.3. 
 
Table 5.3 - Removal in the UV channel of the 13 most detected PhAC and 5 musks. 
  UV Removal (g d
-1
) Level of 
removal by UV 
photolysis
Δ
 Day Day 1 Day 3 Day 9 Day 10 Average StDev 
Diclofenac 10.2 1.0 28.2 6.6 11.5 11.8 medium 
Etofenamate 0.0* 0.2 0.0* 0.0* 0.1 0.1 medium 
Ibuprofen 0.8 1.1 0.2 0.1 0.5 0.5 medium 
Ketoprofen 0.0* 0.1 0.1 0.0* 0.0 0.0 medium 
Fluoxetine 0.0* 0.0* 0.0 0.0* 0.0 0.0 low 
Clorazepate 0.0* 0.6 0.6 0.2 0.4 0.3 medium 
Hydroxazine 0.0* 0.0* 0.1 0.0* 0.0 0.0 medium 
Indapamide 0.0* 0.0* 15.9 0.0* 4.0 7.9 high 
Enalapril 0.0* 0.9 0.8 0.1 0.4 0.5 high 
Captopril 0.0* 0.0* 0.1 0.0* 0.0 0.1 high 
Atenolol 0.0* 0.7 0.0* 0.0* 0.2 0.3 high 
Clofibric acid 0.0* 0.0* 0.0* 0.0* 0.0 0.0 n/a 
Ampicillin 0.0* 0.0* 0.0* 0.0* 0.0 0.0 n/a 
Galaxolide -0.01 0.05 0.01 0.02 0.02 0.02 medium 
Tonalide 0.01 0.03 0.00 0.00 0.01 0.01 n/a 
Cashmeran 0.07 0.00 0.03 0.01 0.03 0.03 medium 
Celestolide 0.00 0.06 0.01 0.01 0.02 0.03 medium 
Traseolide 0.01 0.02 0.00 0.01 0.01 0.01 n/a 
Δ
Low removal represents <25% removal from the average load entering the UV channel, medium represents >25% and  
<75%  removal, while high removal represents >75% removal;*Compound was below the detection limit in the entrance  
to the UV channel; n/a – not applied 
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The highest removal by UV relative to the load entering the UV channel (secondary effluent) was 
detected for indapamide, enalapril captopril and atenolol. Medium removal by UV radiation was 
observed for diclofenac, etofenamate, ibuprofen, ketoprofen (the NSAIDs), clorazepate, hydroxyzine 
and the musks. 
 
The removal of musks by UV was less clear due to the fact that most of these compounds were close 
to fully removed via adsorption. One of the PhACs most significantly removed in the UV radiation 
was diclofenac (11.5 g d
-1
). This is likely due to the higher load of this compound in the influent to the 
UV channel when compared to the other NSAIDs, that were mostly removed biologically or by 
adsorption. After UV radiation, new chromatographic peaks were detected by LC-DAD-(ESI)MS 
analysis of the effluent, suggesting the formation of new compounds, which were not identified in the 
scope of this study. The UV radiation used for disinfection seems to have an important contribution to 
the removal of PhACs and musks that were not removed biologically or by adsorption in spite of the 
brief 5 minutes of hydraulic retention time (HRT) in the UV channel.  
 
5.3.2 Overall removal of PPCPs in the WWTP 
 
The relevance of each mechanism for the overall PPCP removal was assessed in Figure 5.2, which 
represents the percent number of compounds that were mainly removed via each mechanism: 45% of 
the PPCPs were mainly removed biologically, 33% of the compounds (mostly musks) were principally 
removed by adsorption, and the remaining 22% were mostly removed via UV. It should be noted that 
although UV was the least important mechanism, many of the compounds had already been removed 
biologically or by adsorption, thus UV represented an important effluent polishing step.  
45%
33%
22%
Biological
Adsorption
UV
 
Figure 5.2 - Percentage of the PhACs and musk compounds removed principally by biological mechanisms, 
adsorption to the secondary sludge and UV photolysis in the WWTP.  
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Figure 5.3 shows the combined removal achieved biologically, by adsorption and by UV for the 13 
PhACs and 5 musks that were most highly detected in this study. The box and whisker figure shows 
the raw influent minus the final effluent (after UV), where the top and bottom of the box represent the 
75
th
 percentile and 25
th
 percentile, respectively, and the whiskers show the 95
th
 and 5
th
 percentiles, 
respectively.  
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Figure 5.3 - Overall removal of the 13 most detected PhACs and the 5 musks in the WWTP for the six days over 
two consecutive weeks of the campaign. The lower and upper extremes of the boxes represent the 
25th percentile and 75th percentile of % removal achieved, respectively, while the lower and upper 
extremes of the whiskers represent the 5th and 95th percentiles, respectively.  
 
From Figure 5.3, it can be observed that most of the compounds were >75% removed in most cases, 
except for diclofenac, which varied more than all the other compounds studied.  Indapamide, captopril, 
atenolol, clofibric acid and ampicillin have very consistent removals of almost 100% during the 6 
sampling days. Other compounds present higher variability, though only ketoprofen exhibited an 
overall negative removal on one day, in addition to diclofenac. The remaining compounds achieved 
removal rates consistently higher than 75% of the influent loading rate. This level of removal is quite 
high as compared to that achieved for PPCPs in previous studies (Göbel et al., 2005; Carballa et al., 
2007; Jelic et al., 2011).  
The treatment sequence of the WWTP in this study was able to remove all the studied PhACs and 
musks, with the exception of diclofenac. A prior study (Salgado et al., 2010) carried out in this plant, 
yielded a similar removal efficiency (i.e. >75% removal of PPCPs in the spring and autumn). It should 
be noted that this study was conducted during the winter (January), suggesting that the observed 
removal efficiency was independent of temperature. Since biological removal was the dominant 
removal mechanism observed, this could suggest that a Carrousel-type configuration is an efficient 
configuration for PPCP removal. While this hypothesis requires further confirmation, is corroborates 
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the results of Joss et al. (2006), which suggest that a plug-flow configuration significantly improves 
the biological removal of non-sorbing and biodegradable micropollutants . 
 
5.4. Conclusions  
 
The combination of biodegradation, adsorption and removal by UV irradiation are each important 
mechanisms that lead to the transformation of PPCPs in WWTPs. Biodegradation was found to be the 
principal degradation mechanism, followed by adsorption and UV, which was found to be an effective 
effluent polishing step for PhAC and musk removal. In this study, >75% removal was usually found 
for 17 of the 18 most commonly detected PPCPs, with the sole exception being diclofenac, which 
often showed negative values for the biological removal rate in the activated sludge and was mostly 
degraded by UV photolysis. While further investigation should be focussed on ways to optimise PPCP 
removal in WWTPs, it is possible that the Carrousel-type configuration may be an efficient 
configuration for effective PPCP removal. 
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CHAPTER 6  
 
 
 
BIODEGRADATION OF CLOFIBRIC ACID AND IDENTIFICATION OF ITS 
METABOLITES 
 
 
 
6.1 Introduction 
6.2 Materials and Methods 
6.3 Results and discussion 
6.4 Conclusions 
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6. Biodegradation of clofibric acid and identification of its metabolites 
 
Clofibric acid (CLF) is the pharmaceutically active metabolite of the lipid regulator clofibrate, and it is 
considered environmentally persistent and refractory. This work studied the biotransformationof CLF 
in two sequencing batch reactors (SBR) with microbial mixed cultures, monitoring the efficiency of 
biotransformation of CLF and the production of metabolites. The inoculum for both SBRs was an 
enriched culture that degraded the herbicide propanil, a structurally similar compound as CLF. One 
SBR was fed only with clofibric acid and the other was fed with CLF and propanil as carbon sources 
in order to enhance the co-degradation of both substrates. In the reactor fed only with clofibric acid it 
was possible to remove only 15% of the CLF, while the reactor fed with clofibric acid and propanil 
achieved 51% removal. Kinetic studies were performed in order to investigate whether nitrifiers or 
heterotrophic bacteria were primarily responsible for the biotransformation of the CLF. Tests with 
nitrification inhibition showed only slightly lower removal as compared to tests without nitrification 
inhibition showing that the observed CLF biodegradation was mainly carried out by heterotrophic 
bacteria .Four transformation products of clofibric acid were identified by GC-MS, although one of 
them in quantities was below the level of quantification of HPLC-DAD. The main metabolites were  
-hydroxyisobutyric acid, lactic acid and 4-chlorophenol. The latter is known to exhibit a higher 
toxicity than the parent compound, but did not accumulate in either SBR. -hydroxyisobutyric acid 
and lactic acid accumulated for a certain period, where nitrite accumulation may have been 
responsible for inhibiting their degradation. A metabolic pathway for the biodegradation of CLF is 
proposed in this study. 
 
6.1 Introduction  
 
Clofibric acid (CLF) is the active metabolite of clofibrate, a lipid regulator. This drug is resistant to 
biodegradation and, due to its polar nature, has a very high persistence in the environment (Hernando 
et al., 2007, Winkler et al., 2008). Clofibric acid is one of the most widely and routinely reported 
drugs found in open waters (Matamoros et al., 2008a and 2008b). The presence of pharmaceutically 
active compounds (PhACs) and their metabolites in aquatic systems has become a concern in the past 
years due, in part, to their ubiquity in the environment. However, at present, the persistence and 
ecotoxicity of many of these compounds remains unknown. CLF was detected in most aquatic systems 
(e.g. rivers) where pharmaceutical contaminants were monitored and is reported to be persistent 
(Ternes, 1998, Winkler et al., 2001, Joss et al., 2006). In a survey study of 5 different Portuguese 
wastewater treatment plants (WWTPs), CLF was consistently detected in the influent in the ngL
-1
 to 
µgL
-1 
range (Salgado et al., 2010). Peak loads of up to 41.4 g L
-1
 were found in one plant, 
representing one of the most abundant of all PhACs detected (Salgado et al., 2011). Furthermore, a 
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mass balance performed on this plant suggested that CLF was mostly removed biologically (see 
chapter 5). Nevertheless, previous results revealed that clofibric acid was resistant to microbial 
degradation by several types of microorganisms, including wastewater treatment plant biomass 
(Kimura et al., 2007, Evangelista, 2008, Evangelista et al., 2008 and 2010). This apparent 
contradiction motivated the study of a CLF biodegrading culture and its metabolic pathway.  
Carvalho et al., (2010) obtained a microbial enrichment capable of converting propanil into 
dichloroaniline (DCA), its metabolite, and degrading both compounds completely. Propanil is an 
herbicide used on rice cultures, and structurally similar to clofibric acid since it contains both a 
chlorinated aromatic ring and a derivative of propionic acid connected to it (Table 6.1). Thus, this 
enrichment was used as an inoculum for attempting to generate a CLF-degrading microbial 
consortium. 
 
Table 6.1 - Chemical structures of propanil and clofibric acid. 
Compound CAS Formula MW Chemical structure 
propanil 709-98-8 C9H9Cl2NO 
218.08 
 
 
clofibric acid 882-09-7 C10H11ClO3 214.65 
 
 
Biodegradation studies of clofibric acid (in the presence of propanil) were performed by exposing the 
compounds to aerobic cultures of microorganisms acclimatized for propanil biodegradation in 
sequencing batch reactors (SBRs). The objective of this study was to develop a microbial community 
capable of degrading CLF, which would be valuable for bioremediation or bioaugmentation purposes. 
Moreover, the metabolites generated from the CLF biotransformation were also identified and 
monitored. This study gives an important contribution towards the elucidation of biodegradation 
mechanisms of refractory PhAC that could affect the environment after discharge.  
 
6.2 Materials and methods  
 
6.2.1 Chemical and reagents 
 
HPLC-grade acetonitrile, formic acid and phosphoric acid were purchased from Panreac (Portugal). 
Ultrapure water was obtained from a MilliQ water purification system (Millipore, Bedford, MA., 
108 
 
USA). The clofibric acid ((2-4-chorophenoxy)-2-methylpropionic acid) standard was purchased from 
Sigma-Aldrich (Steinheim, Germany) and the metabolite standards, -hydroxyisobutyric acid, lactic 
acid, 4-chlorophenol and also the derivatizing reagent, MSTFA (N-Methyl-N-
(trimethylsilyl)trifluoroacetamide) ≥98.5% (GC grade) was purchased from Aldrich (Portugal). The 
allylthiourea (ATU) and the reagents used in the preparation of mineral media ≥98% (grade) of the 
reactors were all purchased from Panreac (Portugal). 
 
6.2.2 Microbial enrichments 
 
Microbial enrichments were initiated from a mixture of soil contaminated with several herbicides, 
including propanil, and soil from organic rice agriculture supplemented with (NH4)2SO4 and propanil 
(Barreiros et al., 2003). These cultures were further pre-enriched in a mixed culture that was used to 
inoculate a sequencing batch reactor (SBR), which was operated with a fed-batch strategy as detailed 
in Carvalho et al., (2010). This culture was used to seed the SBRs employed in this study, which were 
supplied with either clofibric acid or a mixture of clofibric acid and propanil over a period of 20 
months. 
 
6.2.3 Composition of the feed solution of the SBR  
 
6.2.3.1 Mineral media 
 
The mineral media (phosphate buffer) was prepared with 2.620 g of Na2HPO4.H2O; 1.162 g of 
KH2PO4 and 0.530 g of NH4Cl dissolved in 1 L of MilliQ water. The pH was adjusted to 7.2 with 
NaOH, and then sterilized in an autoclave for 15 min at 120 ºC.   
 
6.2.3.2 Nutrient Solution 
 
The nutrient solution was prepared by combining solutions A, B and C in the following proportion: 0.1 
mL of A, 0.6 mL of B and 0.1 mL of C per 100 mL of mineral media. Solution A (Micronutrient 
solution): 0.1 mM of NiCl2.6H2O; 0.15 mM of NaMoO4.2H2O; 0.5 mM of  ZnCl2; 1 mM of 
MnCl2.4H2O; 0.1 mM of CuCl2.2H2O; 0.8 mM of CoCl2.6H2O; 1 mM of H3BO3 and 10 mM of HCl 
(25% vol) dissolved in MilliQ water. This solution was sterilized in an autoclave for 15 min at 120 ºC. 
Solution B (Macronutrients solution): 0.135 M of MgCl2.6H2O, 0.865 M of FeCl2.4H2O and 1.26 M of 
NaCl was dissolved in MilliQ water. This solution was sterilized in an autoclave for 15 min at 120 ºC 
and was filtered through 0.45 μm glass fiber membranes (GF 6, <1 μm, diameter 47 mm from 
Wathman, England). Solution C: 0.2 M of CaCl2 dissolved in MilliQ water.  
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6.2.3.3 Carbon source: clofibric acid and propanil 
 
A clofibric acid stock solution of 1000 mg L
-1
 of concentration in MilliQ water and a 100 mg L
-1
 
propanil prepared in mineral media and stored at 4 ºC to feed the reactors as carbon source. 
 
6.2.4 Lab-scale SBR operation 
 
6.2.4.1 SBR start-up and operation 
 
Two 150 mL SBRs were fed with 1 mg L
-1
 clofibric acid and 3 mg L
-1
 NH4
+
-N in addition to mineral 
media, and nutrient solution. SBR A was fed with CLF as the sole carbon source and in SBR B, 
propanil was also added to a concentration of 3 mg L
-1
 in the reactor. The reactors hydraulic retention 
time (HRT) was approximately 9.3 days and no sludge wastage was made beyond sampling. 75% of 
the reactor media (supernatant after centrifugation) was replaced every 7 days. The two reactors were 
magnetically stirred, aerated through ceramic air dispersers, and kept in a air-conditioned room at 
temperature of 25±2 ºC, while the pH was uncontrolled.  
 
After 6 months of reactor operation, CLF was added at 2 mg L
-1
 in both reactors and the propanil was 
increased to 6 mg L
-1
 in SBR B. After 9 months, both reactors A and B were supplemented with 
ammonium sulfate solution to get 20 mg L
-1
 NH4
+
-N in both reactors. In reactor B, propanil was 
spiked to get a 6 mg L
-1
 concentration in the reactor three times during the cycle period of 7 days. 
Once per day the pH of both reactors was adjusted to 7.0±0.1. 
After replacing the supernatant, the biomass concentration was monitored through optical density 
measurements at 610 nm, and the pH was again measured in each reactor. Samples were periodically 
taken to monitor clofibric acid, propanil, ammonia, nitrite and nitrate and also the biodegradation 
metabolites of propanil and clofibric acid.  
 
6.2.4.2 Test with non-limiting ammona concentration  
 
After acclimatization to higher ammonia concentration, an experiment was carried out where the SBR 
B was operated with additional ammonia spikes during the cycle to prevent limitation. The SBR 
initially was fed with 2 mg L
-1
 of clofibric acid and 20 mg L
-1
 NH4
+
-N, as usual, but no propanil. The 
SBR was operated with pH controlled automatically to 7.0±0.1. Spikes of 5 mg L
-1
 NH4
+
-N were 
added on days 1 and 2 of operation and reactor performance was monitored for 5 days. Samples were 
taken daily to analyse for clofibric acid and metabolites, ammonia, nitrite and nitrate.  
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6.2.4.3 Nitrification inhibition test 
 
The SBR was fed with mineral and nutrient and spiked with 2 mg L
-1
 clofibric acid and 20 mg L
-1
 
NH4
+
-N ammonia but no propanil, as described above. Additionally, 1 mg L
-1
 of allylthiourea (ATU) 
was added to inhibit nitrification. After the reactors‘s performance was monitored throught 5 days, 
where the optical density was measured, while daily samples were collected to measure the clofibric 
acid, metabolites, ammonia, nitrite and nitrate concentrations. 
 
6.2.4.4 Adsorption studies in the biomass 
 
A fraction of biomass from SBR B was centrifuged and washed with mineral media. The biomass was 
ressuspended with mineral media and nutrient solution  in the same proportion used in the reactor, and 
also 2 mg L
-1
 of clofibric acid was spiked. The initial biomass concentration was measured throught 
the optical density at 610 nm and a sample was collected to measure the CLF concentration in the 
supernatant  as well as in the biomass. This procedure was repeated after 3 days. The samples were 
centrifuged and the liquid was directly analyzed by HPLC-DAD, while the extraction procedure 
detailed below was used to determine the amount of CLF adsorbed to the sludge. 
The compounds adsorbed to the biomass were determined by the use of the modified method of 
ultrasonic solvent extraction described by Salgado et al., (2011). In brief, 2x2 mL of methanol was 
added to the centrifuged biomass sample and the extraction was carried out for 5 min in an ultrasonic 
bath. The solvent/biomass mixture was centrifuged, and the supernatant collected in a vial and 
evaporated to 1 mL by a gentle nitrogen stream and the compounds extracted from the sludge  were 
analyzed in HPLC-DAD.  
 
6.2.4.5 Abiotic CLF degradation 
 
Two 150 mL SBRs were fed with 1 mg L
-1
 clofibric acid and 20 mg L
-1
 NH4
+
-N in addition to mineral 
media, and nutrient solution. SBR A was fed with CLF as the sole carbon source and in SBR B, 
propanil was also added to a concentration of 6 mg L
-1
 in the reactor. No biomass was added in this 
tests in both reactors. The reactors‘s performance was monitored throught 5 days with daily samples 
collection to measure the clofibric acid, proanil, DCA, ammonia, nitrite and nitrate concentrations. 
Once per day the pH of both reactors was measured. 
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6.2.5 Analytical procedures 
 
6.2.5.1 HPLC-DAD analysis 
 
Samples of both reactors were centrifuged for 5 min at 10000 rpm and injected in a high performance 
liquid chromatography (HPLC) for quantification of the clofibric acid, propanil, nitrite, nitrate and 
dichloroaniline (DCA, the primary metabolite of propanil degradation). Standard solutions in the range 
of 0-2 mg L
-1
 for clofibric acid, and 0-10 mg L
-1
 for propanil and dichloroaniline were used to obtain 
the respective calibration curves. The quantification of the CLF metabolites was carried out by using 
the same procedure as for clofibric acid, using the metabolite standards. HPLC-DAD was carried out 
in a HPLC system (Waters) coupled with a pump and controller (Waters 600), an in-line degasser (X-
Act-4 channels, Jour Research), an autosampler (Waters 717 plus), and a photodiode array detector 
(DAD, Waters 996). Reverse-phase chromatography (LiChroCART 250-4 Purospher Star RP18 
endcapped, 5 μm, column, Merck) of the samples was performed with diode array detection from 200 
to 400 nm with a 0.6 mL min
-1
 flow, rate of  a degassed mobile phase with 70 % methanol and 30% 
water with pH adjusted to 3 with phosphoric acid, and diode array detection from 200 to 400 nm. The 
chromatograms were acquired with a MassLinx
TM
 software data acquisition system.  
 
6.2.5.2 GC-MS analysis of CLF metabolites 
 
In order to identify the metabolites generated during CLF biodegradation in the SBRs, samples of both 
reactors were collected and prepared to be analysed by gas-chromatograpy-mass spectrometry (GC-
MS). Samples and standards were previously chemically derivatized. 
 
6.2.5.2.1 Derivatization of the SBR samples 
 
200 μL of sample of the SBR reactor and standard solutions of the metabolites were totally dried with 
a N2 stream and then 20 μL of the derivatization reagent MSTFA was added to the vial. The reaction 
took place for 60 min at 60 ºC and it was then injected in the GC-MS. 
 
6.2.5.2.2 GC-MS Analysis 
 
GC-MS analysis was performed using an Agilent 6850 GC fitted with a 5975 VL MSD (Triple Axis 
Detector) Agilent mass spectrometric detector. The injection port was operated in splitless mode, 
during 5 min. A DB-5MS 5% phenyl and 95% dimethylpolysiloxane capillary column (30 m x 0.25 
mm i.d., 0.25 µm film thickness) from Agilent was used, with helium as carrier gas at a flow rate of 1 
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mL min
-1
. The injection port temperature was 250 ºC. The ion source, the quadrupole and the 
transference line were kept at 230, 150 and 280 ºC, respectively. 
The oven temperature was maintained at 60 ºC for 3 min, programmed to 250 ºC at an increase of 10 
ºC min
-1
, then increased to 310 ºC at 20 ºC min
-1
, and held for 13 min. The MS spectrum was obtained 
with electron energy 70 eV, mass range m/z 40-650 amu and using MSD ChemStation software 
(Agilent).  
The identification of the metabolites was performed by the use of mass spectrum database libraries of 
NIST (2005) and Wiley (2005), that suggest possible chemical structures for metabolites, which were 
confirmed by the injection of the derivatized standard. The ChemStation library of the MS search uses 
probability based matching (PBM) algorithm and a reverse search technique. The PBM algorithm 
compares an unknown mass spectrum to the reference spectrum using a reverse search routine. A 
prefilter within the search routine assigns significance to each of the peaks in the unknown spectrum 
and uses these to find the most probable matches in the condensed reference library. The selected 
condensed spectra are then compared with the complete unknown spectrum. The prefilter immediately 
eliminates approximately 95% of the compounds in the database and greatly speeds up the search 
(when using the default strategy parameters). Each condensed spectrum selected from the database 
(reference spectrum) by the prefilter is compared with all the peaks in the unknown (which has been 
normalized). The probability is then calculated. Each condensed spectrum selected from the database 
(reference spectrum) by the prefilter is compared with all the peaks in the unknown (which has been 
normalized). The probability is then calculated. After identifying the metabolites generated in the 
reactors, standards of each compound were also injected to confirm the structures suggested from the 
libraries databases of the GC-MS. The standards previously identified in GC-MS were also analysed 
by HPLC-DAD to obtain the chromatographic characteristics of the standards (retention time and 
absorption spectra in the DAD). Calibration curves were done in order to quantify the metabolites that 
were generated. This was performed by using the same analytical strategy as for monitoring CLF. 
Three of the four metabolites were possible to quantify by HPLC-DAD (see section 6.2.5.1). 
 
6.2.5.3 Ammonia analysis 
 
Samples of both reactors were centrifuged, for 5 min at 10 000 rpm and the ammonia concentrations 
was measured by an ammonia selective electrode (Orion model 720A), where 20 µL of ionic strength 
adjustor (ISA) solution (951211 ISA, Orion ISE series) was added to 1 mL of sample. Standard 
solutions of ammonia in the range of 0-20 mg L
-1
 NH4
+
-N have been prepared to obtain the respective 
calibration curve. 
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6.2.6 Fluorescence in situ hybridisation (FISH) 
 
Fluorescence in situ hybridization (FISH) was carried out according to Amann et al., (1995) in 
samples of the SBR B for characterization of the autotrophic bacteria. The probes, NSO1225 (Mobarry 
et al., 1996) for ammonia oxidizing bacteria and Ntspa662 (Daims et al., 2001) for nitrite oxidizing 
bacteria were tested against the probes for all bacteria, EUBmix (EU338, Amann et al., 1990; 
EUB338-II and EUB338-III, Daims et al., 1999). FISH samples were observed using an Olympus 
BX51 epifluorescence microscope. 
 
6.2.7 Determination of the proposed biodegradation mechanism 
The biocatalysis and biodegradation database (BBD) software developed by the University of 
Minnesota (UM) was used to simulate and predict the biodegradation pathway of CLF (Helbling et al., 
2010; Gao et al., 2010).  
The pathway prediction system (PPS) predicts microbial catabolic reactions using substructure 
searching by atom-to-atom mapping (Gao et al., 2010). The system is able to recognize organic 
functional groups found in a compound and predict transformations based on biotransformation rules. 
The biotransformation rules are based on reactions found in the UM-BBD database or in the scientific 
literature. Thus, the PPS predicts plausible pathways for microbial degradation of chemical 
compounds. PPS predictions are most accurate for compounds that are (Gao et al., 2010):  
 similar to compounds whose biodegradation pathways are reported in the scientific literature;  
 in environments exposed to air, in moist soil or water, at moderate temperatures and pH, with 
no competing chemicals or toxins; and  
 the sole source of energy, carbon, nitrogen, or other essential element for the microbes in these 
environments, rather than present in trace amounts. 
The simulation of the reaction was carried out under aerobic conditions, exposed to air, soil (moderate 
moisture) or water, at neutral pH, 25 °C, with no competing or other toxic compounds.  
6.3 Results and Discussion  
 
6.3.1 Clofibric acid biotransformation 
 
Initially, activated sludge from a WWTP was used as the inoculum for a sequencing batch reactor 
(SBR) fed with 300 µg L
-1
 CLF and glucose as a supplemental carbon source to facilitate biomass 
growth and potentially co-metabolism of CLF. This system was operated for more than 2 months, 
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where minimal CLF removal was observed (data not shown). At this time the CLF concentration in 
the feed was increased to 1200 µg L
-1
 in order to confirm that the CLF concentration was not limiting. 
However, CLF removal was still not observed after another 2 months of SBR operation (data not 
shown).   
Thereafter, a microbial enrichment obtained from an agricultural soil exposed to the herbicide 
propanil, a compound that is structurally similar to CLF, was tested. This culture was shown to be able 
to degrade propanil as the only carbon source (Carvalho et al., 2010) 
Two sequencing batch reactors (SBRs) were inoculated with this enriched culture. In one SBR, 
clofibric acid was added as the sole carbon source (SBR A) and in the other, propanil and clofibric 
acid (SBR B) were added together to facilitate biomass growth and potentially co-metabolism. The 
initial CLF and propanil concentrations were 2 mg L
-1
 and 6 mg L
-1
, respectively, Figure 6.1a) and 
6.1b).  
 
a) 
 
b) 
 
Figure 6.1 -  Clofibric acid (CLF) degradation in SBR A (without propanil) (a) and SBR B (with 
propanil) (b). Arrows indicate pH adjustments. 
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SBR A showed lower CLF removal (15%) as compared to SBR B (51%), suggesting that the addition 
of propanil to the SBR increased the CLF degradation capacity. In separate sets of tests, the abiotic 
transformation of CLF (using the same conditions but no microbial culture added) was found to be 
negligible, as was the quantity of CLF adsorbed to the biomass (data not shown), suggesting that the 
removal observed in Figure 6.1 could be attributed to CLF biodegradation. In previous work, Tran et 
al. (2009) showed that the presence of acetate (100 mg L
-1
), as an additional carbon source to the 
biotransformation study of CLF, increased its removal from almost 10% in the absence of acetate to 
35% in its presence (Tran et al., 2009). Similarly to our study, the addition of another carbon source 
likely induced biomass growth, leading to higher CLF removal. The biomass concentration of SBR B 
was more than double that of SBR A (1026 mg VSS L
-1
 vs 472 mg VSS L
-1
, respectively). Despite this 
difference in biomass concentration, SBR B had a superior specific CLF removal as compared to SBR 
A. In SBR B, propanil biodegradation led to the temporary accumulation of its well known metabolite, 
3,4-dichloroaniline (DCA), where the DCA was completely removed after one day.   
Since substantial CLF biotransformation occurred in SBR B, further analysis was performed to 
investigate the mechanism responsible for this biotransformation. Biodegradation was observed until 
all of the ammonia was consumed in this reactor, suggesting that the nitrifiers may have been 
responsible for this biodegradation. Many previous studies have suggested a co-metabolic action of 
ammonia and aromatic compounds in nitrifying bacteria (Perkins et al., 1994; Batt et al., 2006; Yi et 
al., 2007). Yi et al. (2007) proposed that the dioxygenase enzymes are capable of mediating the co-
metabolic biotransformation of aromatic compounds (for biotransformation of 17α-ethinylestradiol), 
which was not only associated to nitrifiers but also to heterotrophic bacteria.  The co-metabolism of 
PhACs (such as CLF) may be important because AMO (ammonium monooxygenase) has a relatively 
wide spectrum for the degradation of substrates (Tran et al., 2009). 
 
Since nitrification to nitrite and nitrate occurred in both reactors, FISH analysis was performed to 
study the autotrophic microbial community. FISH confirmed that both reactors were dominated by 
ammonia-oxidizing bacteria (AOB), which were targeted by FISH probe Nso1225. Each SBR also 
contained some nitrite oxidizing bacteria (NOB) as detected by the Ntspa662 probe, for the 
determination of the presence of Nitrospira and Nit3 for Nitrobacter. The high level of autotrophic 
nitrifiers is not surprising considering the low quantity of organic matter fed to each SBR and the 
relatively high content of ammonia.  
In order to study whether or not nitrifiers were really responsible for CLF biodegradation, an 
additional batch test was performed on SBR B with a higher and non-limiting ammonia concentration 
(initially 20 mg L
-1
NH4
+
-N, followed by two additional spikes of 5 mg L
-1
 each). The performance of 
SBR B without ammonia limitation is shown in Figure 6.2. Results revealed that a similar amount of 
CLF biodegradation could be observed (41%) in SBR B as compared to Figure 6.1b, suggesting that 
CLF biotransformation was not linked directly with the abundance of ammonia.  
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Further, the accumulation of nitrite was observed in both experiments (Figures 6.1 and 6.2). Nitrite has 
been frequently shown to be an inhibitor to many different types of bacteria (Zhou et al., 2011). Thus, 
it was investigated if nitrite inhibition represented the limiting factor towards achieving CLF 
biodegradation. 
 
 
Figure 6.2 -  Clofibric acid degradation in SBR B (with propanil) with no NH4
+ limitation. Arrows indicate 
5 mg L-1 NH4
+-N spikes. 
 
6.3.2 Nitrification inhibition 
 
Figure 6.3 shows a batch test carried out in SBR B where nitrification was inhibited by ATU. In this 
test, negligible ammonia was consumed and nitrite and nitrate were not produced. Nevertheless, CLF 
biodegradation decreased only slightly (from 41% to 28%), suggesting that CLF removal was not 
mainly carried out by nitrifiers, but more likely by heterotrophs. Furthermore, since nitrite was not 
produced in this assay, the hypothesis of nitrite inhibition leading to the stop of CLF biodegradation 
was also discarded.  
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Figure 6.3 - SBR B operated with 1 mg L-1 ATU. 
 
It is not clear why CLF biodegradation proceeded until a certain value and then did not continue 
(Figures 6.1-6.3). One possibility is that CLF removal is limited by an unknown nutrient present in the 
media or to the accumulation of an inhibitory metabolite in the culture medium. Analysis of spectra 
obtained by GC-MS along the reactor cycle showed that some metabolites (see section 6.3.3) 
temporarily accumulated in the culture media, but were later eliminated. Accumulation of these 
metabolites did not cause inhibition of CLF biodegradation, since even after being eliminated, the CLF 
concentration did not decrease further. 
To the best of our knowledge, the percentage of CLF biodegradation obtained in this study is higher 
than those previously reported in the literature. While Evangelista et al., (2010) found that >90% of a 
100 mg L
-1
 CLF solution was transformed by Rhodococcus rhodochrous in 20 days after 
acclimatization, it was mainly transformed into its parent compound ethyl clofibrate, which 
accumulated in the solution. Winkler et al., (2001) found that CLF was not removed at an initial 
concentration of 90 g L
-1
 (over ~400 h)  and  only 27%  removal  was obtained at  11 g L
-1
 (over 
~95 h) in a biofilm reactor fed with river water. The  elimination of CLF  was less than  30% (200-500 
g L
-1
) even with a high HRT of 48 h (Kosjek et al., 2009). Similarly a maximum removal of ~25% 
was obtained for CLF with 200 mg L
-1
 N-NH4
+
 addition and an initial CLF concentration of 100 g L
-1
 
after 6 days of cultivation (Tran et al., 2009). 
 
6.3.3 Products of microbial clofibric acid transformation 
 
Identification of the metabolites produced from clofibric acid degradation was done by GC-MS 
analysis of the bioreactor effluent samples. Table 6.2 shows the chemical structures of the 4 identified 
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compounds by GC-MS with their respective matches for the mass spectra comparison between the 
NIST and Wiley databases and the reactor samples. 
 
Table 6.2 - Metabolite characteristics of chromatograms of GC-MS and HPLC-DAD analysis. 
 
 
        GC-MS  HPLC-DAD 
Metabolite MW Formula Chemical structure 
tr 
(min) 
m/z (%)* 
 
Match/R.Match/
Probability with 
spectra (%) 
tr  
(min) 
λ 
(nm) 
 
α-hydroxyisobutyric 
acid  
(AHIBA) 
 
104 
C4H8O3 
 
 
7.98 
45(12), 
73(100), 
117(80),  
131(100), 
147(60),  
205(20), 
233(12) 
91.1/97.1/60.4 3.28 
211, 
250 
 
lactic acid  
(LA) 
 
90 
C3H6O3 
 
 
8.14 
45 (20), 
73(100), 
117(75), 
147(75),  
162 (3), 
191(12), 
219(6) 
94.9/97.1/78.8 3.48 258 
4-chlorophenol  
(4-CP) 
129 
C6H5ClO 
 
 
 
 
12.47 
 
 
 
65 (30), 
 73 (18),  
100 (12),  
128 (100), 
202 (3) 
81.4/86.4/62.6 8.24 
209, 
281 
cis-3-hexenyllactate 172 C9H16O3 
 
7,01 
45(100), 
67(69) 
73(12), 
82(90), 
99(12), 
115(10), 
172(10) 
 
65.9/72.3/40.6 7.11 
197, 
277 
*m/z obtained by derivatization with MSTFA, trimethylsilyl ethers; TMSi (-Si(CH3)3) m/z 73 
 
GC-MS analysis was able to identify 4 metabolites generated in the reactors as well as the remaining 
CLF in solution. The match (similarities) between the sample and the MS database spectra during GC-
MS analysis were higher than 81% with the exception of the metabolite, cis-3-hexenyllactate, which 
was only 66%. 
The metabolite cis-3-hexenyllactate did not appear in the HPLC-DAD chromatograms of the 
monitored reactor samples, suggesting that this compound was unstable and/or an intermediary 
metabolite present at concentrations below the level of quantification. The absence of cis-3-
hexenyllactate was also in agreement with the GC-MS results, where low confidence was obtained in 
the identification of this compound.  
The main metabolites detected were α-hydroxyisobutyric acid (AHIBA), followed by lactic acid (LA) 
and, in lower concentrations, 4-chlorophenol (4-CP). The quantification of the three main metabolites 
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by HPLC-DAD from the biotransformation of CLF in SBR B: AHIBA, LA and 4-CP, is plotted in 
Figure 6.4a and 6.4b. 
4-chlorophenol was generated by the cleavage of the ether bond of CLF, and has previously been 
recognized as a metabolite of CLF by Kosjek et al., (2009). 4-CP is known to have higher toxicity 
than the parent compound, CLF. In our experiments, 4-chlorophenol was temporarily detected in very 
low concentrations (low µg L
-1
) throughout the SBR cycle (Figure 6.4a and 6.4b). Pérez et al., (1997) 
found that chlorophenol was biodegraded, in their tests with Phanerochaete chrysosporium. 
Biodegradation was enhanced from 25% to 50% for an initial concentration of 100 mg L
-1
 of 4-
chlorophenol with the addition of glucose (10 g L
-1
) in that study. Similar results have been obtained 
by Buitrón et al., (2011), where after 1 h of reactor operation, 18 mg L
-1
 of 4-chlorophenol was 
biodegraded.  
 
a) 
 
b) 
 
Figure 6.4 - Metabolites generated from CLF degradation in SBR B (with propanil) at 20 mg L-1 NH4
+-N (a) 
and with 1 mg L-1 of ATU (b). 
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During the biodegradation of CLF, AHIBA was the most important metabolite formed initially, and 
appeared almost immediately after inoculation (Figure 6.4a and 6.4b). All of the metabolites were 
biodegraded in the SBR and a conversion of AHIBA into LA seemed to begin after 30 h when 
nitrification was not inhibited (Figure 6.4a). After 72 h, the CLF and metabolites biodegradation 
seemed to slow down and LA was the metabolite produced in the highest abundance overall when 
nitrification was not inhibited, but even this metabolite was mostly consumed by the end of the cycle 
(after 107 h). The metabolite 4-CP was produced in only low concentrations and was immediately 
consumed thereafter. 
 
When the nitrification was inhibited with ATU (Figure 6.4b), there was a lower accumulation of 
metabolites detected during the experiment, only a small quantity of AHIBA was formed, whivh was 
then quickly consumed. The nitrification inhibition experiment showed that the generated metabolites 
were removed from the process at a higher rate, or that they were not generated in the first place. This 
could suggest that some of the metabolites result from partial CLF degradation concomitant to 
autotrophic activity, or that the nitrite produced when nitrification was uninhibited (Figure 6.2) caused 
inhibition to the metabolite degradation, but not the degradation of the parent compound (CLF).  
 
Figure 6.5 shows the simulation of the biodegradation pathway for clofibric acid under aerobic 
conditions, using the UM-BBD software as described in section 6.2.7. Three of the metabolites 
suggested by the software are in agreement with the results obtained by GC-MS and HPLC-DAD: 
specifically AHIBA, LA and 4-CP. Two other metabolites proposed, the acetone, and an opening of 
the aromatic ring, (Z)-4-chloro-5-oxohex-2-enedioic acid, are hypothesized to be major compounds in 
the second step of the biotransformation of CLF. The acetone was not detected neither in the HPLC-
DAD nor the GC-MS, likely because it is a structure that is very easy to biodegrade. The (Z)-4-chloro-
5-oxohex-2-enedioic acid compound was also not detected, but could have been a limiting 
intermediate in the reaction with AHIBA that yields lactic acid, which was detected. 
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Figure 6.5 - Mechanism of biotransformation of clofibric acid proposed by the biocatalysis and 
biotransformation database of the University of Minnesota. 
 
 
This proposal for the biotransformation of CLF under aerobic conditions, suggests that the formation 
of AHIBA and LA occurs at a faster rate than 4-CP, which was confirmed by HPLC-DAD results 
showing that greater AHIBA and LA accumulation was observed. This work, thus contributed towards 
understanding in mechanism of CLF biodegradation, where the main degradation pathway for CLF 
appeard to be the AHIBA – LA pathways. 
 
6.4 Conclusions  
 
In this study, CLF biodegradation was observed to a greater extent in a SBR fed with CLF and 
propanil as compared to CLF as the sole carbon source. Nevertheless, the presence of propanil was 
confirmed not to be essential towards co-metabolism of the clofibric acid. The heterotrophic 
populations within the bioreactor were likely more responsible for CLF biodegradation than the 
autotrophic populations, after testing without ammonia limitation and with inhibition of nitrification. 
Combining the information from GC-MS and HPLC-DAD, it was possible to identify and quantify 
three main metabolites produced in the reactors, including α-hydroxyisobutyric acid, lactic acid and 4-
chlorophenol. The α-hydroxyisobutyric acid was the first important metabolite produced, and 
accumulated in the reactor, getting transformed into LA over time. The 4-chlorophenol was detected 
only in small concentrations, due either to fast biodegradation when compared to the other metabolites 
or due to only a small amount of CLF being channeled through the 4-CP pathway. It is unclear why 
122 
 
the biotransformation of CLF slows down before it is fully consumed, but could perhaps be due to the 
limitation of a specific nutrient in the media that regulates the biodegradation reaction. 
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CHAPTER 7 
 
 
 
PHOTODEGRADATION KINETICS AND INTERMEDIATES OF KETOPROFEN, 
DICLOFENAC AND ATENOLOL IN PURE WATER AND TREATED 
WASTEWATER 
 
 
 
7.1 Introduction 
7.2 Materials and Methods 
7.3 Results and discussion 
7.4 Conclusions 
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7 Photodegradation kinetics and intermediates of ketoprofen, diclofenac 
and atenolol in pure water and treated wastewater 
 
Pharmaceutical compounds such as ketoprofen, diclofenac and atenolol are frequently detected at 
relatively high concentrations in secondary effluents from wastewater treatment plants. Therefore, it is 
important to assess their transformation kinetics and intermediates in subsequent disinfection 
processes, such as direct ultraviolet (UV) irradiation. The photodegradation kinetics of these 
compounds using a medium pressure (MP) lamp was assessed in pure water, as well as in filtered and 
unfiltered treated wastewater. Ketoprofen had the highest time- and fluence-based rate constants in all 
experiments, whereas atenolol had the lowest values, which is consistent with the corresponding 
decadic molar absorption coefficient and quantum yield. Not surprisingly, the fluence-based rate 
constants of all compounds were lower in a wastewater matrix than in pure water. However, 
particulated organic matter had an enhancement effect on photolysis, probably due to the stronger 
indirect action of free radicals generated in this matrix due to the higher concentration of organic 
matter. Finally, the transformation products of ketoprofen, diclofenac and atenolol were identified and 
monitored throughout the irradiation experiments. This enabled the identification of persistent 
transformation products, which can be discharged from WWTP disinfection works using UV 
photolysis. 
 
7.1 Introduction  
 
In the past decade, there has been a growing concern about the discharge of pharmaceutical active 
compounds (PhACs) from wastewater treatment plants (WWTP) (Fatta-Kassinos et al., 2011; Kolpin 
et al., 2002). These compounds are designed to have an impact on life and are often resistant to 
biological degradation in the treatment systems. Therefore, it is important to assess the fate of PhACs 
in the tertiary treatment of WWTPs where physical/chemical methods are often used. UV irradiation is 
often employed for disinfection of drinking water and municipal WWTP (Oppenländer, 2003), and it 
has also been demonstrated to effectively reduce the concentration of recalcitrant organic compounds 
(Canonica et al., 2008; Rosario-Ortiz et al., 2010). However, this process can also generate 
photodegradation intermediates that are more recalcitrant or toxic than the parent compounds. The 
compounds selected for this study were widely used pharmaceutical compounds with different 
chemical structures: ketoprofen, diclofenac (non-steroidal anti-inflammatory drugs), and atenolol (a β-
blocker). These compounds were found in relatively high concentrations (up to 21.6 µg L
-1
, Salgado et 
al., 2010 and Salgado et al., submitted) in the effluent of the secondary settler of municipal WWTPs, 
thus reaching a subsequent disinfection process. The photolysis of ketoprofen, diclofenac and atenolol 
has been previously investigated, mostly in distilled water and surface water matrices (e.g. Pereira et 
a.l, 2007a and b, Szabo et al., 2011, Canonica et al., 2008). Baeza and Knappe (2011) recently studied 
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the kinetics of diclofenac using low pressure (LP) direct and indirect UV photolysis in ultrapure water, 
lake water and also in wastewater effluent and found that the degradation rate was similar across all 
matrices. Good LP/UV photodegradation of ketoprofen and diclofenac in treated wastewater was 
demonstrated by Kim et al. (2009, JHM), although atenolol only showed medium removal. Also 
Rosario-Ortiz et al. (2010) reported low atenolol removal in WWTP effluent through LP/UV 
photolysis. Nevertheless, very few studies reported the effect of treated wastewater on 
photodegradation using medium pressure (MP) lamps. LP systems are known by their high 
disinfection efficiency since they irradiate at a wavelength close to the maximum absorption of DNA. 
However, MP lamps may be preferred in compact treatment systems, since the UV intensity per lamp 
is higher than in LP systems (Oppenländer, 2003). 
The motivation for this study was to investigate the degradation kinetics and extent of transformation 
of selected PhACs by UV radiation used for wastewater disinfection purposes (i.e. direct photolysis). 
UV photolysis can be strongly affected by the presence of other organic compounds (other PhACs or 
dissolved organic matter), or particulated matter. In the present study, the photodegradation kinetics of 
ketoprofen, diclofenac and atenolol were assessed in a reactor equipped with a MP lamp, in filtered 
and unfiltered treatment wastewater, and compared to the results obtained in pure water. Moreover, 
the photodegradation products of each compound were identified and monitored along irradiation 
time. To the best of our knowledge, this is the first study identifying the transformation products of 
ketoprofen, diclofenac and atenolol with direct photolysis.  
  
7.2 Materials and Methods  
 
7.2.1 Reagents 
 
The PhACs used in this study were atenolol, diclofenac and ketoprofen (Discovery CPR, Sigma-
Aldrich, Portugal). Atrazine (Discovery CPR, Sigma-Aldrich, Portugal) was used for actinometry of 
the UV medium pressure lamp. For each compound was prepared a solution standard 1.0 mg mL
-1
 in 
methanol and stored at 4 °C. The mobile phases used in HPLC were acetonitrile (HPLC grade, 
Panreac, Portugal) and ultra pure water obtained from MilliQ50 system water purification (Millipore, 
Bedford, USA), acidified with formic acid (analytical grade, Merck, Portugal). The derivatization 
reagent used for GC analysis was MSTFA (N-Methyl-N-(trimethylsilyl)trifluoroacetamide) (GC grade, 
Sigma-Aldrich, Portugal). 
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7.2.2 UV irradiation experiments 
 
7.2.2.1 Photolysis with UV mercury vapour lamp, low pressure (LP) 
 
LP/UV photolysis experiments were conducted in a collimated beam bench-scale reactor (Trojan 
Technologies Inc., Canada) using a low pressure Hg lamp that emits mainly monochromatic light at 
254 nm.  
100 mL of laboratory grade water were spiked with the appropriate volume of each pharmaceutical's 
stock solutions to achieve concentrations of 1 mg L
-1
. 50 mL of sample were placed in a Petri dish and 
continuously stirred underneath the LP/UV lamp. The remaining 50 mL were used as control and kept 
in the dark under identical experimental conditions in order to determine possible PhACs losses due to 
evaporation or adsorption to the Petri dish walls. All experiments were conducted at room temperature 
(21 2 ºC). The lamp irradiance was measured using a calibrated radiometer (IL1700, International 
Light, Newburyport, MA) which was placed at the same height of the water level in the Petri dish and 
the solution transmittance was measured by a UV photometer (P254C, Trojan Technologies Inc.). UV 
fluences of approximately 0, 100, 500, 750, 1000 and 1500 mJ cm
-2
 were selected (taking into account 
the radiometer meter reading as well as Petri, reflection, water, and divergence factors) to establish the 
corresponding exposure times at which 200 L of sample were taken to quantify the concentration of 
the compounds by HPLC-UV and LC-MS/MS analysis.  
 
7.2.2.2 Photolysis with UV mercury vapour lamp, medium pressure (MP) 
 
The photodegradation tests were carried out in a pear-shaped glass reactor with a maximum volume of 
300 mL, using a medium pressure (MP) Hg lamp, Heraeus Noblelight model TQ 150 (nominal power 
150 W) which emits radiation between 200 and 450 nm. The lamp was covered with a quartz cooling 
jacket, where pure water (with negligible light adsorption in the wavelength range of emitted 
radiation) was used as optical filter and to maintain a temperature of 25 1 ºC. 
300 mL of pure water was added to the reactor and it was spiked with atenolol, ketoprofen or 
diclofenac to get a concentration of 1 mg L
-1
, or a mixture of the three compounds with the same 
concentration of each. The homogenization of the mixture of the PhAC and the pure water was 
obtained by bubbling air in the UV reactor. In order to calibrate the MP/UV lamp emission 
spectrum of the lamp, and the irradiation parameters, atrazine was added in the experiments. The 
photolysis of a mixture of the three PhACs was also carried out in 300 mL of filtered and unfiltered 
secondary effluent of a biological WWTP (Fernão Ferro, Portugal).   
2 mL samples were taken throughout the experiments to assess the photolysis of the PhACs in the 
different experimental conditions through HPLC analysis. Samples were also taken for identification 
of photolysis transformation products at critical points of the photodegradation experiments 
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(ketoprofen, LP - 2.5 h; ketoprofen, MP - 7.5 min; diclofenac - 1.5 min; atenolol - 17.5 min), where 
the highest relative area of new chromatographic peaks was detected.  
 
Fluence rates under MP Hg lamp irradiation were determined by chemical actinometry at low optical 
density (Canonica et al., 2008) using 4.6 µM aqueous atrazine as an actinometer, following the 
procedure described in Canonica et al., (2008), i.e. assuming a wavelength-independent quantum yield 
and using the emission spectrum of the MP Hg lamp. 
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where Ep
0
(200 – 450 nm) (einstein m-2 s-1) is the photon fluence rate determine through atrazine 
actinometry in the wavelength interval of 200 to 450 nm, katr (s
-1
)is the pseudo-first-order rate constant 
of atrazine depletion, atr is the quantum yield of atrazine depletion (= 0.046 mol einstein
-1
, Canonica 
et al., 2008), fp,λ is the emission spectrum of the lamp based on the photon flux and normalized to the 
chosen wavelength interval, i.e., nm
nm f
f
450
200 ,
1)( and εatr,λ (M
-1
 cm
-1
) is the molar absorption 
coefficient of atrazine at wavelength λ (=3860M-1 cm-1, Canonica et al., 2008). 
 
7.2.3 Analytical procedures 
 
7.2.3.1 HPLC-DAD-MS analysis 
 
HPLC analyses with a diode array detector (DAD) were used to monitor diclofenac, ketoprofen, 
atenolol and atrazine degradation kinetics. HPLC-DAD was carried out in a HPLC system (Waters) 
coupled with a pump and controller (Waters 600), an in-line degasser (X-Act-4 channels, Jour 
Research), an autosampler (Waters 717 plus), a photodiode array detector (DAD, Waters 996). 
Reverse-phase chromatography (LiChroCART 250-4 Purospher Star RP18 endcapped, 5 μm, column, 
Merck) of the samples (injection volume of 50 μL) was performed using a degassed mobile phase 
with 70 % water with 0.01% formic acid and 30% acetonitrile with a 0.6 mL min
-1
 flow rate, with 
DAD detection from 200 to 400 nm. The chromatograms were acquired with a MassLinx
TM
 software 
data acquisition system. The (ESI+)MS was carried out a quadropole VG Platform (Micromass, UK 
Ltd) spectrometer equipped with an electrospray ionisation (ESI) source operating in positive mode. 
An accurate splitter (split ratio of 1:10) was used between the
 
HPLC column and the mass 
spectrometer. Capillary temperature was kept between 100 ºC and 120 ºC, using a scanning cone 
voltage from 35 to 100 V and capillary voltage of 3.5 kV. Nitrogen was used as drying and nebulising 
gas at 300 mL min
-1
 and 10 mL min
-1
, respectively. The mass/charge spectrum range used was 100-
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450 amu with a MassLynx
TM
 software data acquisition system. Limits of detection of ketoprofen, 
diclofenac and atenolol were 23, 129 and 78 µg L
-1
, respectively. 
 
7.2.3.2 LC-MS/MS Analysis  
 
Two LC-MS/MS systems were used for identification of the photolysis intermediates. The LC-MS/MS 
(BfG Lab, Koblenz, Germany) analysis of ketoprofen and diclofenac metabolites generated in LP UV 
lamp was carried out using an Agilent 1200 HPLC system. The reverse-phase chromatography 
(Zorbac XDB/C8 column, 4.62 x 150 mm, 5 μm) was operated at an oven temperature of 30 ºC. The 
samples (10 μL) were injected into the LC system (including degasser, quaternary pump and 
autosampler, Agilent Technologies, Waldbronn, Germany) using water/formic acid 0.2% (A) and 
acetonitrile/formic acid 0.1% (B), as the mobile phases. The following binary gradient was used: start 
with 100% A, kept isocratic for 1 min, linearly increased to 100% B in 15 min. It was maintained at 
100% B for 5.5 min, and then linearly decreased back to 100 % A in 5 min, which was maintained for 
an additional 1 min. The mobile phase flow rate was kept constant at 400 μL min-1 during the analysis. 
The tandem mass spectrometer (API 4000 QTrap with turbo/electrospray ionization and nitrogen as 
the collision gas; Applied Biosystem, Foster city, CA) was operated with atmospheric-pressure 
chemical ionization (APCI) in positive ionic mode using multiple reaction monitoring for all 
measurements. The source temperature was 450 ºC and the entrance potential, 10 V. The ionspray 
voltage was adjusted to 5 kV. The MS analysis was carried out in a hybrid triple quadrupole/linear ion 
trap mass spectrometer LC-MS/MS system.  The spectra mass/charge range used was 120 to 500 amu, 
with Q-MS (Q1). Data acquisition was carried out by Analyst 1.4 Software. 
The LC-MS/MS (EPAL, Lisbon, Portugal) analysis of atenolol, ketoprofen and diclofenac metabolites 
generated in MP UV lamp was performed using a Waters UPLC Acquity system from Waters 
equipped with a binary pump, an automatic injector and a thermostatic column compartment coupled 
to a Mass Spectrometer Quattro micro API triple quadrupole and Acquity TDQ equipped with a Z-
spray electrospray interface (Micromass). Chromatographic separation was achieved with an Acquity 
BEH C18 (2.1 x 50 mm, 1.7 m) from Waters. The tandem mass spectrometer was operated with 
electrospray ionization (ESI) in positive and negative ionization modes using Full Scan, Product Ion 
Scan and Multiple Reaction Monitoring modes with the same mobile phase of the other LC-MS/MS 
system.  
 
7.2.3.3 GC-MS analysis 
 
Derivatization was used to achieve a chemical modification of the acid compounds that would 
not otherwise be suitable for GC analysis. The fragmentation pattern characteristic of the 
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chemical derivatives formed can then be used as a mass spectral fingerprint to confirm the 
identity of the original compounds. 
Derivatization reaction: 200 μL of sample was evaporated in an N2 stream to remove all the water. 20 
μL of the derivatization reagent N-methyl-N-trimethylsilyltrifluoroacetamide (MSTFA) was added to 
the vial and the mixture was incubated at 60 ºC for 60 min. 
 
GC-MS analysis: the gas chromatograph was an Agilent 6850 fitted with a 5975 VL MSD (Triple 
Axis Detector) mass spectrometric detector (Agilent Technologies, Waldbronn, Germany). The 
injection port was operated in splitless mode, during 5 min. A DB-5MS, 5% phenyl and 95% 
dimethylpolysiloxane capillary column (30 m x 0.25 mm i.d., 0.25 µm film thickness) from Agilent 
was used, with helium as carrier gas at a flow rate of 1 mL min
-1
. The injection port temperature was 
250 ºC. The ion source, the quadrupole and the transference line were kept at 230, 150 and 280 ºC, 
respectively. The oven temperature was maintained at 60 ºC for 3 min, programmed to 250 ºC at 10 ºC 
min
-1
, then programmed to 310 ºC at 20 ºC min
-1
, and held 13 min. The MS spectrum was obtained 
with electron energy 70 eV, mass range m/z 40-650 amu and using MSD ChemStation software. The 
identification of the photolysis intermediates was possible through a mass spectra database library of 
NIST (2005) and Wiley (2005) that suggest possible chemical structures, followed by the injection of 
standards derivatized with the same procedure as the samples.  
 
7.3 Results and Discussion 
 
7.3.1 Low pressure and medium pressure UV photoliability 
 
Direct photolysis can only take place when a compound is able to absorb light at the wavelengths to 
which it is exposed. A measure of this absorption capacity, or photoliability, is given by the decadic 
molar absorption coefficient (ε), defined as the probability that a compound will absorb light at a 
certain wavelength (λ). In this study, the decadic molar absorption coefficient determined for the 
LP/UV lamp (λ=254 nm) for ketoprofen was in the same order of magnitude than the value obtained 
by Pereira et al. (2007), and was 1 or 2 orders of magnitude higher than for diclofenac and atenolol, 
respectively (Table 7.1), showing that ketoprofen has a higher probability to absorb monochromatic 
light at λ=254 nm than the other compounds. Therefore, LP/UV photolysis was only assessed for 
ketoprofen in this study, while MP/UV photolysis efficiency was investigated for the three target 
compounds. 
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Table 7.1 - Decadic molar absorption coefficient at 254 nm of the studied PhACs, and specific rate of light 
absorption and quantum yield for the interval 200-450 nm. 
 
 
 
 
 
The decadic molar absorption coefficient was also determined for a wavelength range including that 
covered by the MP/UV lamp (200-450 nm). The profile obtained for ketoprofen was overall higher 
than the other two compounds (Figure 7.1), which shows the stronger photoliability of ketoprofen for 
MP/UV irradiation, followed by diclofenac and finally, atenolol. The latter displayed low ε values for 
wavelengths >200nm, thus it was expected to be degraded to a lesser extent than the other compounds 
in the conditions investigated in this study. 
 
Figure 7.1 - Decadic molar absorption coefficient ( ) for atenolol, diclofenac and ketoprofen. MP/UV lamp used 
in this study covered λ=200-450 nm. 
 
Another important parameter to assess the direct photolysis of a compound is the quantum yield ( ), 
which gives the number of molecules degraded per photon absorbed by the solution due to the 
compound‘s presence. This implies that the degradation rate of a compound is proportional to the 
compound‘s quantum yield (Pereira et al., 2007a). Thus, the quantum yield (mol einstein-1) for each 
compound in the wavelength interval used in this study (200-450 nm) was obtained from: 
nm
nm s
k
k
450
200
                                     (Eq. 7.2) 
Compound 
254 nm) 
(M
-1
 cm
-1
) 
 
Σ ks (200-450 nm) 
(einstein mol
-1
 s
-1
) 
 
 
(mol einstein
-1
) 
 
Ketoprofen 37155 0.00231 0.759 
Atenolol 527 0.00372 0.036 
Diclofenac 5929 0.07121 0.066 
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where ks(λ) is the specific rate of light absorption by the compound, determined by equation 7.3 
(Pereira et al., 2007a). 
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where Ep
0
 (einstein cm
-2
 s
-1
) is the photon fluence rate at 200-450 nm determined according to 
equation 7.1, ε (M-1 cm-1) is the decadic molar absorption coefficient, Abs(λ) is the compound 
absorbance at wavelength λ, and z is the solution depth (2.75 cm for the reactor used in this study).  
 
The quantum yield obtained for ketoprofen (Table 7.1) was substantially higher than the two other 
compounds. This result, combined with the higher decadic molar absorption coefficient profile (Figure 
7.1) shows that light absorbed by ketoprofen results in high degradation of this compound. Despite the 
intermediate ε profile observed for diclofenac, its quantum yield value had the same order of 
magnitude as atenolol. The low quantum yield observed for the atenolol is consistent with its low 
decadic molar absorption coefficient and indicates its low photodegradation by direct photolysis. 
 
7.3.2. Photolysis kinetics in pure water 
 
The photodegradation of the three studied PhACs in pure water followed a pseudo-first-order kinetics 
(Figure 7.2), and the time-based pseudo-first-order rate constants (k) were determined according to 
equation 7.5 (Lopez et al., 2003, Kim et al., 2009): 
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C
C
o
.ln                 (Eq. 7.4) 
 
where C is the concentration of the PhAC and C0 is the initial concentration of the PhAC. 
The time-based rate constants, k (s
-1
), were converted to photon fluence-based rate constants, o
pE
k     
(m
2 
einstein
-1
), using the following equation: 
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where the photon fluence rates (Ep
0
) were determined through actinometry (equation 7.1). The o
pE
k  is a 
measure of the sensitivity of the photochemical transformation, it is independent of the photon fluence 
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rate variations and allows to directly compare constant rates obtained with different equipments 
(Canonica et al., 2008). 
 
 
Figure 7.2 - Degradation kinetics of ketoprofen (LP and MP), diclofenac and atenolol in pure 
water as single compound (a) or combined in a mixture with the three PhACs (b). 
 
MP/UV phtolysis of ketoprofen and diclofenac had comparable time-based degradation rate constants 
and one order of magnitude higher than atenolol (Table 7.2). Both compounds were removed below 
detection levels in only a few minutes, whereas atenolol took over 40 minutes of irradiation. The time-
based degradation rate constant for LP/UV photolysis of ketoprofen was 0.000143 s
-1
, and it took 150 
minutes for 78% removal when subjected to a dose of 1500 mJ cm
-2
. Thus, ketoprofen was degraded at 
a higher rate with a MP lamp than a LP lamp under the conditions used in this study (Figure 7.1). 
The low photon fluence-based rate constant obtained for atenolol (Table 7.2) confirmed the low 
photoliability of this compound for MP direct photolysis, which was expected from its low decadic 
molar absorption coefficient and quantum yield values (Table 7.1). Overall, these parameters reflect 
the probability of a compound to be degraded at the wavelength range used, and in this study indicated 
a higher degradation potential for ketoprofen, followed by diclofenac and atenolol (Table 7.1 and 
Figure 7.1), which was confirmed by the fluence-based rate constants obtained (Table 7.2). 
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Table 7.2 - Time- and fluence-based degradation rate constants of the studied PhACs under MP/UV 
irradiation in pure water as single compounds and combined in a mixture; photon fluence rate in 
the 200-450 nm interval for each experiment, and irradiation time to total removal for each 
condition. 
 
 Single compound Multiple compounds 
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Ketoprofen 0.000070 0.01753 250.2 
0.00069 
0.04669 67.4 
Atenolol 0.000513 0.00132 2.6 0.00134 1.9 
Diclofenac 0.002602 0.04721 18.1 0.00824 11.9 
 
 
When the three compounds were combined in a mixture and subjected to MP/UV photolysis, the 
pseudo-first-order photon fluence-based rate constants decreased, as can be expected from higher 
competition for light absorption in the presence of other substances. The degradation kinetics followed 
the same order (higher for ketoprofen, then diclofenac and finally atenolol), but ketoprofen seemed to 
be substantially slower than the other two compounds despite its larger absorbance spectrum (Figure 
7.1), suggesting that its photoliability is dependent on light absorption at wavelengths where the other 
two compounds also have strong absorbance.  
 
7.3.3 Wastewater matrix effect 
 
The MP/UV photolysis of ketoprofen, atenolol and diclofenac was investigated in a real matrix, i.e., 
the secondary effluent of a biological WWTP. The treated effluent was characterised by 37 mg COD 
L
-1
, 218 NTU turbidity, pH 6.91, 28 mg T-N L
-1
, 5 mg N-NO2
- 
L
-1
, 15 mg N- NO3
- 
L
-1
, 2.1 mg P L
-1
 
(total P) and 13 mg SS L
-1
 before filtration.  
 
Table 7.3 - Time- and fluence-based degradation rate constants of a mixture of the studied PhACs under 
MP/UV irradiation in filtered and unfiltered wastewater; photon fluence rate in the 200-450 nm 
interval for each experiment, and irradiation time to total removal for each compound. 
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Ketoprofen 
0.00072 
0.00801 11.1 
0.00041 
0.01347 33.1 
Atenolol 0.00017 0.2 0.00342 8.4 
Diclofenac 0.01284 17.8 0.00829 20.4 
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The time- and fluence-based degradation rate constants obtained for ketoprofen in a treated 
wastewater matrix (Table 7.3) were lower than in a pure water matrix (Table 7.2). This result is not 
surprising since the wastewater effluent likely comprised many compounds that competed for light 
absorption within the broad absorption spectrum of ketoprofen. The fluence-based degradation rate 
constant of atenolol also decreased in filtered effluent as compared to pure water, but it increased in 
unfiltered effluent. An increase was also observed in both cases for diclofenac.  
 
The higher fluence-based degradation rate constants in unfiltered effluent for all compounds as 
compared to filtered effluent could be explained by indirect photolysis arising from free radicals 
generated from the incidence of UV radiation on the dissolved organic matter present in the effluent. 
This effect was stronger for unfiltered effluent since the particles present in secondary effluent of a 
WWTP are mostly comprised of biomass, thus the difference between the two matrices is a higher 
content of organic matter in the unfiltered effluent, which probably increased the amount of free 
radicals generated from UV irradiation.  
 
Overall, longer irradiation times were necessary to degrade the PhACs in a wastewater matrix than in 
pure water. The degradation of atenolol was particularly inefficient in a real matrix and it was not 
possible to remove the compound beyond 53% and 85% in filtered and unfiltered effluent, 
respectively, within the 75 min experiments. This result could be anticipated from the low decadic 
molar absorption coefficient profile for atenolol in the wavelength range used in this study (Figure 
7.1), suggesting that MP/UV irradiation is not an appropriate methodology for polishing atenolol in 
WWTP tertiary treatment. Advanced oxidation processes, such as indirect photolysis, may improve 
atenolol degradation, as suggested by the enhanced removal obtained in unfiltered wastewater. 
 
7.3.4 Phototransformation products of diclofenac, ketoprofen and atenolol  
 
7.3.4.1 Phototransformation products identification 
 
UV irradiation of the target compounds resulted in the formation of new chromatographic peaks 
corresponding to transformation products generated during the photolysis process. Most of these 
products (Table 7.4) were identified through LC-MS/MS and/or GC-MS after derivatization. 
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Table 7.4 - Identification of the transformation products generated by MP/UV photolysis (unless indicated) of 
ketoprofen, diclofenac and atenolol. 
 
Compound Structure 
Formula and 
MW 
tr 
 (min) 
m/z 
(relative 
abundance) 
Analytical
Mode 
Ketoprofen 
2-(3-benzoylphenyl) 
propanoic acid 
 
 
C16H14O3 
(MW 254) 
 
 
16.4 
105(100), 
124(16), 
 131(30),  
147(6), 
209(12), 
255(1) 
LC-MS/MS 
(APCI+) 
 
Product K1* 
2-(3-(carboxy(hydroxy)-
methyl)-?-oxocyclohexa-
1,3-dien-1-yl)propanoic 
acid
a
 
  
 
C11H12O6 
(MW 240) 
 
15.3 
105(90),  
124(52), 
147(79),  
225(44) 
241(52) 
LC-MS/MS 
(APCI+)  
 
Product K2 
2-(3-(carboxy(hydroxy)-
methyl)phenyl)propanoic 
acid 
 
C11H12O5 
(MW 224) 
 
17.5 
 
105 (61),  
119 (19),  
124 (60), 
147(96),  
183 (10), 
225(53) 
LC-MS/MS 
(APCI+)  
 
Product K3 
2-(3-(carboxyoxomethyl)-
phenyl)propanoic acid 
 
  
C11H10O5 
(MW 222) 
 
16.6 
 
105(16), 
124(60), 
147(96), 
223(39) 
LC-MS/MS 
(APCI+)  
 
Diclofenac 
2-[2-(2,6-dichlorophenyl 
amino)phenyl]acetic acid 
 
 
C14H11Cl2NO2 
(MW 296) 
 
 
18.1 
 
107(25), 
124(64), 
214(10), 
278(82), 
297(1) 
LC-MS/MS 
(APCI+) 
Product D1 
2-(8-hydroxy-3-oxo-3H-
carbazol-1-yl)acetic acid 
 
C14H9NO4 
(MW 255) 
14.2 
124(19),  
170(9),  
210(93),  
226(8),  
238(11),  
256(8) 
LC-MS/MS 
(APCI+)  
 
Product D2 
(E)-6-[2,6-
dichlorophenyl)-imino]-3-
oxocyclohexa-1,4- 
dienecarbaldehyde  
C13H7 Cl2NO2 
(MW 279) 
16.4 
124(19), 
149(5), 
168(18), 
180(86), 
279(1) 
LC-MS/MS 
(APCI+)  
 
Diclofenac 
2-[2-(2,6-dichlorophenyl 
amino)phenyl]acetic acid 
 
 
C14H11Cl2NO2 
(MW 296) 
 
 
17.4 
 
297(100) 
LC-DAD-MS 
(ESI+) 
Product D3 
2-(8-hydroxy-3-oxo-9,9a-
dihydro-3H-carbazol-1-
yl)acetic acid  
 
C14H10NO4 
(MW 256) 
7.8 
 
257(100) 
LC-DAD-MS 
(ESI+) 
Product D4 
(E)-2-[3-(2,6-dichloro-?- 
hydroxyphenylimino)-6- 
oxocyclohexa-1,4-dienyl] 
acetic acid
b  
C14H9Cl2NO4 
(MW 325) 
15.5 
 
326(100) LC-DAD-MS 
(ESI+) 
*Generated by LP/UV photolysis; a - the carbonyl position in the cyclic ring can be C5 or C6; ** The m/z 73 correspond to the fragment 
generated by derivatizing reagent (MSTFA) but the group trimethylsilyl, TMSi (-Si(CH3)3) is not shown in the chemical structure presented 
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Table 7.4 - (cont.) Identification of the transformation products generated by MP/UV photolysis (unless 
indicated) of ketoprofen, diclofenac and atenolol. 
 
Compound Structure 
Formula and 
MW 
tr 
 (min) 
m/z 
(relative 
abundance) 
Analytical
Mode 
Diclofenac 
2-[2-(2,6-dichlorophenyl 
amino)phenyl]acetic 
acid** 
 
 
 
C14H11Cl2NO2 
(MW 296) 
 
 
22.3 
73(75), 
179(25), 
214(100), 
242(50), 
277(25) 
367(30) 
GC-MS  
(EI+) 
Product D5 
2-[2-(phenylamino]phenyl)  
acetic acid** 
 
C14H13NO2 
(MW 227) 
21.7  
 
 
73(100), 
152(25), 
179(75), 
207(20), 
300(75) 
GC-MS  
(EI+) 
Product D6 
2-(8-chloro-9H-carbazol-1-
yl)acetic acid** 
 
C14H10ClNO2 
(MW 260) 
22.7 
 
73(100), 
151(18) 
178(20), 
213(40), 
241(15) 
333(10) 
GC-MS 
 (EI+) 
Atenolol 
2-[4-[2-hydroxy-3-
(isopropylamino)propoxy] 
phenyl]acetamide  
C14H22N2O3 
(MW 266) 
13.3 
 
116(2), 
145(100), 
190 (60), 
208(12), 
225 (2), 
267(35) 
LC-MS/MS 
(ESI+) 
Product A1 
2-(?-hydroxy-4-(2-
hydroxy-3-
isopropylamino)propoxy) 
phenyl)acetamide
c  
C14H22N2O4 
(MW 283) 
10.0 
 
61(5) 
118(20), 
197(8), 
215(5), 
283(100) 
LC-MS/MS 
(ESI+) 
Product A2 
?-hydroxy-4-[2-hydroxy-3-
(isopropylamino)propoxy] 
benzaldehyde
c  
C13H19NO4 
(MW 254) 
15.6 
 
61(5), 
118(15), 
197(5), 
254(100) 
 
LC-MS/MS 
(ESI+) 
Product A3 
4-[2-hydroxy-3-
(isopropylamino)propoxy] 
benzaldehyde  
C14H19NO3 
(MW 238) 
16.2 
 
61(5), 
87(3), 
118(5), 
238(100) 
LC-MS/MS 
(ESI+) 
Product A4 
3-(isopropylamino)- 
propane-1,2-diol  
C6H15NO2 
(MW 134) 
0.93 
92 (10), 
118 (12),  
134(100) 
LC-MS/MS 
(ESI+) 
Product A5 
4-[(2-amino-2-
oxoethyl)phenyl- 2-hydroxy-3-
(isopropylamino)] propanoate 
  
C14H20N2O4 
(MW 281) 
4.68 
61(15), 
118(15), 
197(3), 
281(100) 
LC-MS/MS 
(ESI+) 
*Generated by LP/UV photolysis;
 b
 - the phenolic hydroxyl group position can be C3, C4 or C5; 
c 
- the phenolic hydroxyl group position can 
be C2 or C3;** The m/z 73 correspond to the fragment generated by derivatizing reagent (MSTFA) but the group trimethylsilyl, TMSi (-
Si(CH3)3) is not shown in the chemical structure presented 
 
 
Two products were generated from MP/UV photolysis of ketoprofen (K2 and K3, Table 7.4), which 
were also the principal products obtained from LP/UV photolysis. Intermediate K1 was identified 
from LP/UV photolysis, but only with low peak area and it was not detected from MP/UV photolysis. 
The chemical structures of K2 and K3 were identified through LC-MS/MS(APCI+) as 2-(3-
(carboxycarbonyl)phenyl) propanoic acid and 2-(3-(carboxy(hydroxy)methyl) phenyl) propanoic acid, 
respectively. These transformation products involved the oxidation of one of the rings of ketoprofen, 
which had not been observed by Kosjek et al. (2010) in a study reporting 22 ketoprofen transformation 
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products using LP and MP photolysis. Interestingly, these structures had previously been identified as 
ketoprofen biodegradation metabolites using activated sludge (Quintana et al., 2005), suggesting that 
both photolysis and biodegradation of ketoprofen can proceed through a similar pathway involving 
oxidative ring opening.  
 
The diclofenac photoproducts were analysed through liquid and gas chromatography coupled to mass 
spectrometry. The target compound appears in the chromatogram at 18.1 min. In the mass spectrum, it 
is possible to identify the protonated molecular ion [M+H]
+
 of diclofenac, and the fragment ions could 
confirm the structure of the compound. The base peak corresponds to the fragment ion m/z 278 [M-
18]
+
. The ion fragment with m/z 214 corresponds to decarboxylation of the compound followed by the 
loss of one chlorine atom, [Cl-M-COOH]
+
. All of the photoproducts detected by HPLC (D1, D2, D3 
and D4) have lower retention times than diclofenac, suggesting that these transformation products are 
more polar than the parent compound. Pérez-Estrada et al. (2005) studied the photo-Fenton 
degradation of diclofenac and determined the intermediates as well as the mechanistic pathway of 
transformation. Two of the compounds identified in that study had the same chemical structure as 
products D2 and D4 proposed in the present work. 
The identification of transformation products obtained in the photodegradation of diclofenac was 
complemented with GC-MS analysis of the irradiated sample after derivatisation with the reagent 
MSTFA. The chromatogram obtained for the standard of diclofenac has a peak at 22.3 min 
corresponding to the target compound. The identification of the peak of diclofenac was performed by 
the interpretation of mass spectra obtained by GC-MS. The base peak at m/z 214(100%) corresponds 
to the fragment ion [M-COOTMSi-Cl]
+
. The molecular ion of the silylated compound [M]
+ 
is present 
in the mass spectrum m/z 367(30%). The chromatogram obtained with the irradiated sample showed 
two products with retention times of 21.7 and 22.7 min. The first photoproduct identified by GC/MS 
(D5, Table 7.4) presents a molecular ion [M]
+
 m/z 298, compatible with the formula C14H13NO2 after 
silylation. This metabolite corresponds to the loss of the two chlorine atoms and does not match any of 
the previously proposed structures in literature. In the mass spectrum of the second photoproduct, 
product D6, it is possible to identify the silylated form of the molecular ion [M]
+
 at m/z 333, which 
corresponds to a molecular formula of C14H10ClNO2. The formation of this photoproduct could be due 
to the loss of a chlorine atom followed by cyclisation and formation of carbazole (2-(8-chloro-9H-
carbazol-2-yl) acetic acid). This structure was previously proposed to occur in solar photodegradation 
of diclofenac by Agüera et al. (2005), who detected its acetone form. 
 
The analysis of an atenolol standard by LC-MS/MS(ESI+) gave a peak at the retention time of 13.3 
min, with a MS base peak with m/z 145 corresponding to [M+H-NH2CH(CH3)2-H2O-CO-NH3]
+
, and 
molecular ion peak with m/z 265. Analysis of the irradiated atenolol sample allowed the identification 
of five photoproducts with base peaks in the mass spectra of m/z  283, m/z 254, m/z 238, m/z 134 and 
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m/z 281 (A1-A5, Table 7.4). The chemical structure of product A3 resulted from the loss of the 
formamide group (-NH2CO), followed by an oxidation reaction, while product A2 may have resulted 
from the hydroxylation of the structure of A3, probably at the benzene ring. Product A4, resulting 
from the loss of the aromatic ring of atenolol, lost the chromophore capacity to be detected by HPLC-
DAD and could only be measured in association to a MS system. All atenolol UV photolysis products 
identified in this work, except for A4, are consistent with those obtained by Radjenovic et al. (2009) 
with TiO2 and photon-Fenton solar photocatalysis. 
 
7.3.4.2 Dynamics of the transformation products generated by UV photolysis 
 
The phototransformation of ketoprofen in the LP/UV photolysis experiment in pure water by HPLC-
DAD-MS resulted in two main products (K2 and K3, Table 7.4). Product K1 was also identified but 
only with very low HPLC peak areas.  
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Figure 7.3 - Relative peak area of the PhACs and corresponding transformation products in the UV 
photolysis experiments carried out in pure water: dynamics of LP/UV photolysis of 
ketoprofen (a) and MP/UV photolysis of ketoprofen (b), diclofenac (c) and atenolol (d). 
 
 
UV photolysis of ketoprofen with MP lamp irradiation produced the same two main products. Product 
K2 (2-(3-(carboxy(hydroxy)methyl) phenyl) propanoic acid) was the most persistent in both cases 
(Figure 3). In the MP photolysis experiment, products K3 was unstable and it seemed to be converted 
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into product K2 and back to K3 during the first 30 minutes of irradiation, until it was totally converted 
into K2, which accumulated in the reactor.  
MP/UV photolysis of diclofenac generated the persistent product D2 or (E)-6-[2,6-dichlorophenyl)-
imino]-3-oxocyclohexa-1,4-dienecarbaldehyde).  Some other intermediates were also detected, most 
of which disappeared after 10 minutes of irradiation (D1, D4 and D5, see Table 7.3), and one of which 
prevailed for approx. 20 minutes (D3), but none of them were detected after that irradiation time. 
 Photolysis of atenolol generated three main products. Product A1, which consisted of the addition of a 
hydroxyl group to the aromatic ring, was observed immediately after the beginning of the irradiation. 
Shortly after, this product gave place to products A2 and A3, where product A2 (3-hydroxy-4-(2-
hydroxy-3-(isopropylamino)propoxy) benzaldehyde) was the most persistent, remaining unaltered 
after approx. 50 min of irradiation when the other intermediates were no longer detected. Medana et 
al. (2008) also observed the appearance and disappearance of product A1 within 30 minutes of solar 
irradiation with TiO2 photocatalysis, although products A2 and A3 were not identified as possible 
subsequent intermediates. Furthermore, all products seemed to be fully mineralized in that study, 
which suggests that the use of a catalyst could be a solution to enhance the extension of atenolol 
photolysis. 
Several persistent transformation products from the MP/UV photolysis of ketoprofen, diclofenac and 
atenolol were identified in this study. This work suggests that it is important to assess the occurrence 
of these intermediates in effluents of WWTP using direct photolysis for disinfection purposes. 
Furthermore, future research should be conducted to evaluate their ecotoxicity potential. 
 
7.4 Conclusions 
 
The UV photolysis of ketoprofen, diclofenac and atenolol was investigated and the following 
conclusions are taken from this study: 
 Decadic molar absorption coefficient and quantum yield values indicated high 
photodegradation for ketoprofen, followed by diclofenac, and low photolysis for atenolol; 
 Time- and fluence-based rate constants determined in pure water confirmed these kinetics, 
suggesting that ketoprofen, and to a certain extent diclofenac, can be adequately removed in 
MP/UV disinfection systems. LP/UV photolysis of ketoprofen at 1500 mJ cm
-2
 showed a 
lower extent of degradation. 
 The presence of other PhACs in pure water or of other organic compounds in filtered treated 
wastewater seemed to reduce the photodegradation kinetics of the studied PhACs. However, 
photodegradation was higher in unfiltered than in filtered wastewater, suggesting increased 
indirect photolysis from free radicals arising from particulate organic matter. 
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 MP/UV photolysis products of ketoprofen, diclofenac and atenolol were identified and 
monitored throughout the irradiation time. This enabled the identification of the most 
persistent transformation products, which are possibly discharged from WWTP using direct 
photolysis for disinfection. In the future, it is important to assess the toxicity and 
environmental persistence of these intermediates, and if necessary, investigate complementary 
solutions for their mitigation. 
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CONCLUSIONS  
 
 
8.1 Main Achievements 
8.2 Contributions to the advancement of PPCP monitoring and removal studies in 
WWTPs  
8.3 Future work 
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8. Conclusions  
8.1 Main Achievements 
Five important conclusions were obtained with this work: 
1) It was possible to identify many of the pharmaceutical active compounds and musks as target 
compounds of this work in the five different WWTP in Portugal at the influent, effluent and sludges in 
different periods of the year. With these results it was possible to conclude that some compounds are 
very frequently detected but no seasonal pattern was observed.  
The total PhACs and musks concentrations found in this work were in a similar range as previously 
reported studies. The most abundant PhACs were the NSAIDs (particularly ibuprofen), while the 
antihypertensives (particularly enalapril), caffeine, and clofibric acid were also present in relatively 
high concentrations in the influent and effluent. Clofibric acid represented one of the few compounds 
present at a similar range of concentrations in the influent and effluent of the plants. The analytical 
methodology employed in this work was effective for monitoring pharmaceutical and personal care 
products in wastewater treatment plants. This method reduced the analytical effort necessary to cover 
a wide range of compounds with different natures, and still achieved good LOD and LOQ levels (with 
the exception of the estrogens), with high recoveries in influent wastewater.  
2) The dynamics of PPCPs in a WWTP was evaluated through an intensive sampling campaign 
covering a large number of pharmaceuticals and musks. It was found that the PhACs concentrations in 
the influent were subject to a wider variability than the musks, which were more repeatable. The 
typical diurnal pattern for macropollutants (i.e. higher loading during the day as compared to the 
night) was observed for the musks and some PhACs, while other frequently detected PhACs (e.g. 
ketoprofen) displayed the opposite trend or no trend. In general, the mean PhAC loadings varied 
between 1-3 orders of magnitude from one sampling day or week to the next, whereas the mean musk 
loadings were far less than one order of magnitude apart. This information is relevant to the design of 
sampling campaigns for modelling purposes. 
3) The combination of biodegradation, adsorption and removal by UV are each important mechanism 
that lead to the transformation of PPCPs in WWTPs. Biodegradation was found to be the principal 
degradation mechanism, followed by adsorption and UV, which was found to be an effective effluent 
polishing step for PhAC removal. More than 75% removal was usually found for 17 of the 18 most 
commonly detected PPCPs, with the sole exception being diclofenac, which often showed negative 
removal rates and was mostly degraded by UV.  
4) Clofibric acid (CLF) which is considered to be environmentally persistent and refractory was 
biotransformed by microbial consortia in two sequencing batch reactors (SBR). CLF biodegradation 
was observed to a greater extent in a SBR fed with CLF and propanil as compared to CLF feeding 
alone. Nevertheless, the presence of propanil was confirmed not to be essential towards co-metabolism 
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of the clofibric acid. The heterotrophic populations within the bioreactor were likely more responsible 
for CLF biodegradation than the autotrophic populations, after testing with and without inhibition of 
nitrification. Combining the information from GC-MS and HPLC-DAD, it was possible to identify 
and quantify three main metabolites produced in the reactors, including α-hydroxyisobutyric acid, 
lactic acid (LA) and 4-chlorophenol (4-CP). The α-hydroxyisobutyric acid was the first important 
metabolite produced, and accumulates in the reactor, getting transformed into LA over time. The 4-
chlorophenol was detected only in small concentrations, due either to fast biodegradation when 
compared to the other metabolites or due to only a small amount of CLF being channeled through the 
4-CP pathway. Based on the identification of CLF metabolites, a metabolic pathway for its 
biodegradation was proposed  
5) The UV photolysis of ketoprofen, diclofenac and atenolol was investigated. Decadic molar 
absorption coefficient and quantum yield values indicated high photodegradation for ketoprofen, 
followed by diclofenac, and low photolysis for atenolol; Ketoprofen, and to a certain extent 
diclofenac, were quite efficiently removed in MP/UV, while LP/UV photolysis of ketoprofen showed 
lower degradation extent. The presence of particulate organic matter present in unfiltered wastewater 
had a negative impact in the photodegradation of PhACs. The most persistent transformation products 
from MP/UV photolysis of ketoprofen, diclofenac and atenolol were identified and monitored 
throughout irradiation time.  
 
8.2 Contributions to the advancement of PPCP monitoring and removal studies 
in WWTPs 
This work gives an important contribution to the knowledge of the occurrence and fate of PhAC and 
musks in WWTPs as well as to the best available analytical techniques for monitoring this kind of 
compounds by the WWTP operators and engineers. The simplified analytical methodology should 
facilitate PPCP monitoring, which is needed throughout the year because seasonal patterns were not 
observed. The influent variability and repeatability was also another important contribution of this 
study, since it was determined that PhAC loading is indeed highly variable, while musks can be 
monitored much more reliably. The WWTP study of biotransformation, adsorption and UV 
highlighted the importance of each individual mechanism and illustrated that a WWTP has the 
potential to be operated successfully for efficient removal of PPCPs (>75%). Nevertheless, it was also 
shown that the removal of PPCP compounds via biotransformation or UV radiation can produce by-
products that have the potential to be highly toxic to aquatic organisms. The biodegradation of the 
reported refractory compound, clofibric acid was studied in a SBR reactor and the biotransformation 
mechanism that was observed was characterized through a metabolic pathway by analyzing the 
metabolites generated.. It is of high importance to understand the biodegradation pathway and the 
side-products generated in order to evaluate effects on ecotoxicity. This was of likewise importance 
for the UV radiation studies, where the most persistent by-products were identified and monitored, in 
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combination with the study of the degradation kinetics of atenolol, ketoprofen and diclofenac by this 
disinfection technology. 
 
8.3 Future work 
Recommendations for future work in this field are outlined below: 
(1) Investigate new strategies for the biological removal of musks and other PhACs that are not 
very easily biodegradable. The study of other PhAC and musk compounds in lab scale 
reactors should be performed in order to understand the best operational conditions that 
achieve the maximum removal of these specific compounds with the purpose of helping 
environmental engineers in the operation of WWTPs. Identification of the microbial 
communities responsible for this removal would be highly beneficial.  
 
(2) Test new technologies for sludge treatment and measure the potential impact of the treatment 
on the application of the sludges in agriculture. Some PhACs and musks can be removed by 
adsorption to the sludges and additional studies should be done to investigate the ultimate fate 
of PPCPs in different sludge treatment technologies (e.g. stabilization, aerobic and anaerobic 
digestion, composting). The sludge application in agriculture can produce problems of soil, 
surface and groundwater contamination by desorption of the PhACs and musks from the 
sludges. 
  
(3) Comparing advanced oxidation technologies (e.g. ozone, hydrogen peroxide) with UV 
radiation and combining these technologies with the biological wastewater treatment process 
through recycling the effluent from the tertiary treatment stage back to the secondary stage. 
Other oxidation technologies should be tested in the future (e.g. sonolysis) in order to compare 
efficiencies and treatment costs for the removal of PhACs and musks.  
 
(4) Study the ecotoxicological effects of the final wastewater discharges on fish and other living 
organisms. The effect of the discharges of PhAC and musks is not well studied with and 
without the use of tertiary treatment technologies (e.g. UV radiation used for disinfection). 
The effect of UV radiation on atenolol, ketoprofen and diclofenac and their by-products are 
already being carried out with fish (Zebra fish) for testing the biochemical reactions in the 
liver and other organs.   
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APPENDIX I OF CHAPTER 4 
 
The probability that the frequency of occurrence of each compound was due to chance was 
determined through chi-square tests, as follows: 
 
 
 
where θ is the observed number of samples where the compound was detected and ξ is the 
expected (average) value; i and j are the entries of a contingency matrix where the rows (i) are 
the analysed days and the columns (j) are the number of samples per day where the compound 
was either detected or not detected (see table S.1 for example). 
Table S1. Example of contingency table for etofenamate: number of samples per day (a total 
of 12 samples were analysed per day) where the compound was detected or not-detected. 
Day Detected 
Not 
detected Total 
1 0 12 12 
2 8 4 12 
3 11 1 12 
4 10 2 12 
Total 29 19  
 
The chi-square values obtained for each compound were used to determine the p-values, or 
probability that the observed frequency of occurrence was due to chance alone. The number 
of degrees of freedom (df) was calculated as: 
df = (i - 1)·(j - 1) 
P-values <0.05 were considered significant, p<0.01 was considered very significant and 
p<0.001 was considered highly significant. 
 
161 
 
APPENDIX II OF CHAPTER 5 
 
Daily influent, effluents loads before and after UV and secondary sludge loads for the 6 days of the campaign 
 
 Influent load (g d
-1
) Effluent load before UV (g d
-1
) Effluent load after UV (g d
-1
) Secondary sludge load (gd
-1
) 
Compound Day 0 Day 1 Day 2 Day 7 Day 8 Day 10 Day 1 Day 2 Day 3 Day 8 Day 9 Day 10 Day 1 Day 2 Day 3 Day 8 Day 9 Day 10 Day 1 Day 3 Day 9 Day 10 
Diclofenac 35.05 131.61 1.29 12.98 13.56 14.19 55.41 13.19 3.25 0.00 28.23 10.33 45.24 4.31 2.22 0.00 0.00 3.78 1.41 1.11 17.89 15.29 
Etofenamate 0.00 25.33 1.69 4.82 3.74 18.01 0.00 0.00 0.88 0.00 0.00 0.00 0.00 0.00 0.65 0.00 0.00 0.00 0.16 1.03 3.44 3.09 
Ibuprofen 46.00 15.23 2.96 3.03 1.40 2.48 0.78 1.81 1.97 0.00 0.62 0.30 0.00 0.55 0.88 0.00 0.44 0.19 0.04 0.28 0.20 1.35 
Ketoprofen 83.34 31.50 0.20 0.20 0.21 0.00 0.00 2.67 0.40 0.00 0.09 0.00 0.00 0.41 0.33 0.00 0.00 0.00 0.02 0.00 0.04 0.14 
Fluoxetine 0.00 3.67 0.00 0.63 2.35 0.00 0.00 2.66 0.00 0.00 0.24 0.00 0.00 0.70 0.00 0.00 0.23 0.00 0.03 0.03 0.00 0.00 
Clorazepate 0.00 1.42 0.82 0.71 0.79 1.83 0.00 1.62 0.61 0.00 0.62 0.69 0.00 0.38 0.00 0.00 0.00 0.52 0.00 0.00 0.78 0.12 
Hydroxazine 0.00 0.00 0.00 1.35 0.54 7.38 0.00 0.00 0.00 0.00 0.19 0.00 0.00 0.00 0.00 0.00 0.13 0.00 1.20 0.79 0.00 3.25 
Indapamide 0.00 0.00 0.00 7.64 8.64 3.81 0.00 0.00 0.00 0.00 15.87 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.45 0.03 8.50 3.70 
Enalapril 0.00 0.00 0.73 1.99 3.81 1.16 0.00 0.00 0.87 0.00 0.75 0.44 0.00 0.00 0.00 0.00 0.00 0.38 0.01 0.08 0.00 0.36 
Captopril 2.88 1.31 0.36 2.25 2.52 2.83 0.00 0.00 0.00 0.00 0.12 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.40 0.50 0.42 0.79 
Atenolol 12.80 1.45 3.53 1.36 2.03 0.85 0.00 0.00 0.70 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0,00 
Clofibric acid 49.88 2.05 0.23 0.79 1.10 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.77 0.00 
Ampicillin 0.00 0.43 0.00 0.45 0.25 0.52 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.07 0.00 0.00 0.00 
Paroxetine 0.00 32.93 0.00 0.72 0.00 0.00 15.82 0.00 0.00 0.00 0.00 0.00 22.84 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 
Galaxolide 1.41 1.35 0.15 1.33 0.51 0.40 0.03 0.05 0.05 0.08 0.08 0.08 0.04 0.00 0.00 0.05 0.07 0.06 0.95 2.02 17.73 16.12 
Tonalide 0.37 0.61 0.05 0.40 0.18 0.13 0.03 0.02 0.03 0.05 0.02 0.02 0.03 0.00 0.00 0.05 0.02 0.02 0.08 0.17 2.15 2.20 
Cashmeran 1.77 4.63 0.06 4.14 1.73 0.39 0.07 0.02 0.03 0.32 0.06 0.04 0.00 0.00 0,02 0.18 0.03 0.03 1.34 2.04 36.05 22.98 
Celestolide 0.64 1.60 0.09 0.43 0.25 0.14 0.02 0.04 0.06 0.25 0.04 0.04 0.02 0.00 0.00 0.16 0.03 0.04 0.08 0.19 2.22 0.18 
Traseolide 0.26 0.71 0.04 0.15 0.09 0.06 0.01 0.02 0.02 0.08 0.02 0.03 0.01 0.00 0.00 0.07 0.02 0.02 0.00 0.06 0.64 0.07 
 
